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ABSTRACT 
The synthesis of a series of peptides spanning the entire sequence of the protein 
nerve growth factor (NGF) has been carried out using solid-phase peptide synthesis 
(SPPS). A twenty-two residue peptide sequence from the carboxyl-terminal region 
of NOF was found to inhibit the binding of native NGF to its known receptor, in a 
cell-free assay. This fragment may define an area in the native NGF molecule which 
is important for receptor interactions. 
The optimisation of this initial fragment found that the inhibitory effect was retained 
when the fragment was reduced to a fifteen residue, disulphide-linked peptide. 
Further attempts at optimising this smaller fragment have been carried out by 
substituting unnatural amino-acids into the sequence, as well as altering the 
conformation around the disulphide bond. 
Several of the smaller NGF peptides have been investigated by high-field nuclear 
magnetic resonance (N.M.R.). The complete assignment of several analogues of the 
fifteen residue, disulphide-linked peptide has been achieved. Analysis of the 
'through-space' interactions indicated that these peptides adopt only random 
conformations in solution. 
As a prelude to a total NGF synthesis, the assembly of the well-characterised protein, 
hen egg white lysozyme (HL) has been attempted in order to test the current methods 
for approaching the synthesis of large, multi-cysteine peptides. Some evidence that 
the peptide chain was successfully assembled has been presented and the difficulties 
encountered in attempts to purify and fold the protein are discussed. 
ABBREVIATIONS 
Ac acetyl HFIP 1,1,1,3,3,3-hexafluoro-2-propanol 
ACh acetylcholine HL hen egg white lysozyme 
AChE acetyicholinesterase HPLC high-performance liquid 
chromatography 
Acm acetarnidomethyl HOBt 1-hydroxybenzotriazole 
AcOH acetic acid hrms high-resolution mass spectrometry 
AD Alzheimer's disease IC concentration producing 50% 
inhibition 
AE active ester IR infrared 
BDNF brain-derived neurotrophic 
factor 
LHRH luteinising hormone releasing 
 hormone 
Boc :ert-butyloxycarbonyl MS mass spectroscopy 
BSA bovine serum albumin NGF nerve growth factor 
Bum err-butoxycarbonyl N.M.R. nuclear magnetic resonance 
But terr-butyl NOESY nuclear Overhauser enhancement 
spectroscopy 
BzI benzyl NTB 2-nitro-5-thiobenzoate 
CAT choline acetyltransferase NT-3 (or 4) neurotrophin-3 (or -4) 
CHO Chinese hamster ovary NTF neurotrophic factor 
CNS central nervous system p140 protein receptor product of irk 
gene 
COSY correlated spectroscopy P75 NGFR  low-affinity NGF receptor 
DBU 1 ,8-diazabicyclo-[5. 4 .0.]- 
undec-7-ene  
PG protecting group 
DCC 1 ,3-dicyclohexylcarbodiimide Pmc 2,2,5,7,8-pentamethylchroman-6-
sulphonyl 
DCM dichioromethane PNS peripheral nervous system 
DIC 1,3-diisopropylcarbodiimide ROESY rotating frame NOESY 
DKP 2,5-diketopiperazine SA symmetrical anhydride 
DMAP 4-dimethylaminopyridine SBut ter:-butylsulphenyl 
DMF N,N-dimethylformanüde SPPS solid-phase peptide synthesis 
DMSO dimethylsulphoxide TBNS 2,4,6-Irinitrobenzenesulphonic acid 




DTT dithiothreitol TFA tnfluoroacetic acid 
EDT 1,2-ethanedithiol TFE 2,2,2-trifluoroethanol 
EMS ethyl methyl sulphide TFMSA trifluoromethanesulphonic acid 
FAB fast-atom bombardment (cF3c02)3T1 thallium (III) trifluoroacetate 
FID free induction decay TOCSY total correlation spectroscopy 
Fmoc 9-fluorenylmethoxycarbonyl irk tropomyosin receptor kinase 
HBr hydrogen bromide Trt triphenylmethyl 
HF hydrogen fluoride UV I ultraviolet 




All amino acids used were of the L-configuration unless otherwise stated 
AMINO ACID I 	SIDE-CHAIN (R) I 3-LErrEp, CODE I 1-LEFIER CODE 
Alanine CH3 Ala A 
Arginine (CH2)3NHC(NH)NH2 Arg R 
Asparagine CH2CONH2 Asn N 
Aspartic acid CH2COOH Asp D 
Cysteine CH2SH Cys C 
Glutamic acid (CH2)2COOH Glu E 
Glutamine (CH2)2CONH2 Gin 
Giycine H Giy 0 
Histidine RN 	N His H 
Isoleucine CH(CH3)C2H5 lie I 
Leucine CH2CH(CH3)2 Leu L 
Lysine (CH2)4NH2 Lys K 
Methionine (CH2)2SCH3 Met M 




Serine CH20H Ser S 




Tyrosine CH2C6H40H Tyr Y 
Valine CH(CH3)2 Val V 
GLOSSARY OF BIOLOGICAL TERMS 
axons the long process arising from a nerve cell or neuron, which transmits 
an impulse or action potential away from the cell body 
bacteriophage a virus containing DNA (sometimes RNA) which infects bacteria 
central nervous main ganglia of nervous system 	with associated nerve cords, 
system (CNS) consisting usually of a brain and a dorsal or ventral nerve cord 
cholinergic nerve fibre secreting acetylcholine at its ends when nerve impulses 
arrive there 
Down's syndrome congenital 	condition 	caused 	by 	presence 	of 	extra 	copy 	of 
chromosome 21, characterised by mental retardation, mongoloid 
facial features and reduced life expectancy 
endocytosis process by which a cell engulfs material by the infolding of the 
plasma membrane 
ganglia mass of nervous tissue, encapsulated in connective tissue and 
containing many synapses and cell bodies. They generally act as 
integrative centres for areas of high sensory input/motor output 
gene cloning process of isolating a gene DNA sequence, inserting it into a plasmid 
(also recombinant (a piece of circular DNA) and the subsequent large scale growth of 
DNA the plasmid in a suitable bacterial host. The appropriate gene (or its 
protein product) may then be recovered from bulk bacterial cultures 
G.proteins guanyl-nucleotide-binding 	proteins 	which 	act 	as 	intermediaries 
between receptors and secondary messengers (e.g. adenylate cyclase) 
in signal transduction mechanisms 
hippocampus tract of nervous tissue running back from olfactory lobe to posterior 
end of the cerebrum 
kinase an enzyme which catalyses the phosphorylation of its substrate by 
ATP. Act as molecular 'switches' in signal transduction 
lysosomes single-membraned 	organelle 	containing 	hydrolytic 	enzymes, 
generally involved in degradative processes 
microtubules minute tubules which occur in groups in cells and involved in cell 
integrity and orientating the movements of cytoplasm 
monoclonal antibody produced by a cell clone thus comprising only a single 
antibody species of immunoglobulin molecule 
niuscarinic receptor in cholinergic synapses, sensitive to plant poison muscarine 
receptors 
neurons principal cell types of nervous system, specialised for transmission of 
information 
oncogenes genetic locus originally identified in RNA tumour viruses, which is 
capable of the transformation of the host cell. Implicated as the cause 
of certain cancers 
peripheral N.S. rest of nervous system not including CNS. Consists of nerves that 
serve 	as 	relay 	channels 	between 	receptors/effectors 	and 	the 
integrative parts of the CNS 
proto-oncogenes gene required for normal function in an organism, but which has 
mutated to become an oncogene 
tyrosine kinase kinase present in intracellular domains of several receptors e.g. EGF, 
insulin. Binding of ligand stimulates autophosphorylation onto certain 
tyrosine residues, which activates the kinase to phosphorylate tyrosine 
residues on its target proteins to initiate signal transduction 
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Introduction 
CHAFFER ONE: INTRODUCTION 
1.1. ALZHEIMER'S DISEASE 
1.1.1. General 
Neurological disorders have amongst them some of the most distressing of all human 
illnesses, such as Alzheimer's Disease (AD) and Huntingdon's Chorea. Typically, 
the signs and symptoms appear slowly over a period of years, usually in middle or 
late life, and lead inexorably to dementia (the severe impairment of cognitive 
function) and eventually death, in a gravely debilitated state, within five to ten years 
after onset. In the case of AD, the dementia is often heralded by impairments in 
recent memory. From this point, the higher cognitive functions deteriorate; sufferers 
lose the ability to read, write or use language properly and their emotional state is 
commonly affected. Eventually, sufferers will unfortunately die of some 
complication that afflicts bedridden patients. 
The magnitude of AD occurrence was not appreciated until the early 1970's. In the 
U.S.A. (for which figures are available), it is estimated that 100,000 people die each 
year of AD-related illnesses. The cost, apart from the human suffering, is reckoned 
to be $80 billion/annum, primarily in custodial care. The incidence is linked to 
aging, with a ten or twenty-fold increase between the ages of 60-80; the prevalence 
may exceed 50% in those aged 95 or more. As the geriatric segment of the 
population, in the Western World in general, is predicted to grow over the next fifty 
years or so, it can be expected that the incidence of AD will similarly increase. 
1.1.2. Diagnosis and Study of AD 
There are certain substantial obstacles which hinder the study of potential AD 
therapies. These are summarised below in Table 1.1. 
Table 1.1 Hurdles to the investigation of AD 
 No diagnostic tests exist to detect the early onset of the disease 
 Aetiology unknown, but AD possibly has multiple causes 
 Not known if AD is a homogeneous or heterogeneous disease 1 
 No truly effective therapeutics exist at present 
 No suitable animal models exist for testing therapeutic strategies 
0 
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AD is currently diagnosed by the exclusion of other possible causes e.g. drug 
intoxication,, vitamin B 12 deficiency, for the observed clinical manifestations. 
Neuropsychological tests may be used to assess the degree of dementia. While 
diagnosis of the condition is problematical, post-mortem examination of the brain 
tissue of AD sufferers has clearly shown that substantial changes to the brain's 
architecture, which typify the disease, have occurred during the course of the 
disease. The most common changes are; 
A large number of neuritic plaques appear: these consist of abnormal neurites, 
associated with a core of an insoluble protein fragment called 3-amyloid. In 
addition, altered glial cells (involved in neuron function and protection) are 
present in the plaques 2. 
Neurofibrillary tangles, dense bundles of abnormal fibres, can be observed in 
the cytoplasm of certain neurons. These fibres are composed of a naturally-
occurring neuronal protein called tau. These tangles (as well as the plaques) 
are found mainly in the hippocampus and neocortex regions 3 (ref. Fig. 1.2). 
There is extensive degeneration of specific neuronal systems, which use 
acetylcholine (cholinergic neurons) and noradrenaline (adrenergic neurons) as 
their transmitters. 
Some of these observations have helped in the formulation of models which try to 
account for the observed biochemical and pathological changes that occur during the 
course of the disease. Below are listed possible factors involved in the aetiology and 
pathogenesis of AD; 
a.) Genetic defects e.g. AD is linked to Down's syndrome. 
b.)Abnormal proteins e.g. 3-amyloid. 
c.) Infectious agents e.g. prions. 
d.)Toxins e.g. aluminium. 
e.) Changes in cerebral blood flow e.g. 'hardening of the arteries' observed in AD. 
Q Neurotransmitter deficits e.g. cholinergic hypothesis. 
These factors are considered in more detail below. 
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1.1.3. Possible Models to Explain the Cause(s) and Effects of AD 
Each of the above factors has been considered as a basis for working models to aid in 
the understanding of how AD may be caused, and how the disease causes its effects 
in sufferers. Each model is supported by some observational or experimental 
evidence, although each is contradicted by other evidence and none seems to, so far, 
account for all of the symptoms and pathological findings. 
The genetic model for AD has received much attention recently 4. While AD has 
generally been considered to be a sporadic disorder, increased risk has been reported 
in the relatives of AD patients 5. Individuals with Down's syndrome, who reach the 
age of forty or more, almost always develop AD-type symptoms. These individuals 
have three copies of chromosome 21, which also contains the gene coding for the 
amyloid precursor protein (APP) 2. The -amyloid fragment, which is present in the 
neuritic plaques, is erroneously formed from this APP by abnormal enzymic 
processing6. The resultant amyloid fragment, which is released from APP, becomes 
deposited in the brain cortex and also around blood vessels. The theory has been 
forwarded that APP is over-produced in Down's syndrome, leading to the 
adventitious processing of the protein by inappropriate enzymes (in an attempt to 
reduce the APP level), which then release the 3-amyloid protein. Recently, it has 
been found that mutations in the APP gene are linked with early-onset, familial AD 
(FAD)7'8. These mutations cause a Val to Ile, Gly or Phe change in APP, which 
may be the site at which the incorrect processing occurs. Although this mechanism 
may be involved in FAD, it is unclear if this would encompass all AD cases, and 
whether or not the amyloid deposition is a primary event in the initiation of the 
illness. Nevertheless, this remains a very active area of research in the search for 
AD causation and treatments. 
There is some support for the theory that AD may be caused by an infectious agent, 
perhaps a virus. This derives from certain clinical and neuropathological similarities 
to Creutzfeldt-Jakob disease. This is a rare brain disorder, usually affecting 
individuals between 55-75 years old. It leads to a progressive dementia, disturbances 
in movement and causes death within one to two years of onset. The infective agent 
was considered to be a 'slow' virus, in that several years were required between 
exposure to the agent and the onset of symptoms: this was discovered as 
experimental animals could be infected by brain extracts of infected tissue. 






prion9 , which forms rod-like aggregates. Attempts to transmit AD in a similar 
fashion have been unsuccessful, although it could be argued that other predisposing 
conditions may be required for such an infection to occur. 
The presence of elevated aluminium (Al) levels in the brain of AD patients as a 
causative factor, has often been put forward: aluminium is present in 
aluminosilicates in the neuritic plaques and it has been suggested that Al is involved 
in the early stages of plaque formation. While this continues to be a controversial 
area, again whether Al is implicated in the onset of AD or simply the result of, for 
example, an increased affinity of the neurofibrillary tangles for Al, remains to be 
seen. Similarly, the decreased cerebral blood-flow associated with AD may simply 
reflect the reduction in the neurons responsible for controlling blood delivery, rather 
than being a causative factor itself. 
1.1.4. The Cholinergic Hypothesis for AD 
The most widely accepted hypothesis for the cognitive deficits seen in AD involves 
the cholinergic system, although this is unlikely to account for some of the other 
deficits caused by the disease. The cholinergic neurons, which degenerate in the 
brains of AD sufferers, are those forming the ascending cholinergic pathways of the 
basal forebrain. The cell bodies of these neurons are located in the septal area and 
basal nucleus areas of the brain. The axons of these neurons innervate the 
hippocampus and parts of the neocortex 1 ° (Fig. 1.2). 
CORTEX 
Fig. 1.2 Major cholinergic pathways implicated in AD 
(arrows indicate areas into which the neurons extend) 
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The loss of these neurons is evidenced by the associated decrease in the levels of 
certain cholinergic marker enzymes e.g. choline acetyhransferase (CAT) and 
acetyicholinesterase (AChE). Figure 1.3 shows how the cholinergic neurons use 
these enzymes, and the neurotransmitter acetylcholine (ACh), to carry out their 
normal functions. As well as the above, there is reduced acetylcholine synthesis in 
the target areas and the loss of the previously mentioned cholinergic cell bodies. The 
decrease in general cholinergic factors correlates with the increase in the number of 
plaques and with the degree of dementia 3 . It is the loss of these specific neurons 
which is generally regarded as the principal reason for the memory deficits 
characteristic of AD 11 . In support of this view, is the fact that many researchers 
have previously shown that disrupting cholinergic transmission affects proper 










PKF.SYNAPTIC 	 SYNAPTIC 
TERMINAL CIEFI 
Fig. 1.3 Function and metabolism of acetylcholine in the cholinergic system 
Choline (I, grey) passes into the synaptic clefs from blood vessels and is taken into the presynaptic 
cholinergic terminal via transport systems. Here, acetylcholine (ACh, 3, black) is synthesised from 
choline and acetyl-coenzyme A (2, white) by the enzyme CAT. ACh is stored in vesicles and 
released into the synaptic cleft (4) upon neuron depolarisation (caused by an incoming nerve 
impulse). ACh crosses the cleft to activate mainly muscarinic receptors (5) and hence propagate the 
signal. ACh release is also self-modulating, by affecting receptors on the presynapsic terminal (6). 
The action of ACh is rapidly terminated by hydrolysis by AChE, which is located on both pre- and 
post-synaptic membranes (7). The choline released from this hydrolysis (7) re-enters the pre-
synaptic terminal (8) or enters blood vessels (9). The breakdown of phosphatidylcholine (lecithin), a 
cell membrane constituent, also contributes to choline supply (10). 
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These findings led to the hypothesis that drugs to stimulate the cholinergic system 
might revive at least some of the lost mental faculties of AD patients. The simplest 
approach would be to use replacement drugs which may increase nerve 
communication by elevating the acetylcholine levels. Unfortunately, cholinergic 
precursors e.g. choline, lecithin (ref. Fig. 1.3), do not readily cross the blood-brain 
barrier thus would not be useful as drugs. Alternative approaches have been 
considered: 
NH 2 
Inhibiting cholinesterase: this may raise the levels 
of acetylcholine in cholinergic neurons and 	
!C 
hopefully enhance cholinergic function. Several CCN _ Tacrine 
pharmaceutical companies have produced 	 CM3  
acetyicholinesterase inhibitors e.g. Tacrine 
N - N 
(Parke-Davis), Physostigmine derivatives [Merck, 	Physostigmine 	 ci- 
Sharp and Dohme, (MSD)], (Fig. 1.4). 
Fig. 1.4 AChE inhibitors 
Increasing acetylcholine release from intraneuronal stores: some compounds 
e.g. 4-arninopyridine appear to alter ACh metabolism to elevate normal levels. 
c.) Using acetylcholine mimics: these may interact 
with ACh (muscarinic) receptors in the post-
synaptic membrane and hence perhaps emulate 
signal transmission 13 . However, three subtypes 
exist; the M 1 muscarinic receptor sub-type is the 
one involved in cholinergic function and would 
make an ideal target for drug development, but the 
M2 sub-type is involved in cardiovascular 
function, while M3 is associated with the digestive 
tract, thus finding a M,-specific drug may prove to 





Fig. 1.5 Muscarinic 
receptor agonists 
be difficult. Some muscarinic drug agonists are currently in clinical trials e.g. 
a thiopilocarpine derivative (Sandoz), and others are being examined e.g. 
quinuclidine (MSD), (Fig. 1.5). 
Unfortunately, all of these strategies have failed to produce significant improvements 
in AD patients; furthermore such therapies may only limit the symptoms rather than 
prevent the disease. A better therapy may be one which promotes the survival of 
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these cholinergic neurons that degenerate during AD. Such a treatment may be able 
to prevent the onset of AD or stop further deterioration of mildly afflicted patients. 
1.1.5. Neurotrophic Factors and AD 
In recent years, evidence has accumulated which shows that the survival (during 
development), and maintenance of specific groups of neurons is influenced by 
certain proteins, termed neurotrophic factors (NTFs). The best studied of these is 
nerve growth factor (NGF), which was known to affect the survival and function of 
peripheral sympathetic and sensory neurons 14"5. Other NTFs have subsequently 
been discovered which act on different neuronal groups. The discovery of these 
proteins led to the concept that a specific group of neurons may have an absolute 
requirement for a certain NTFs. 
Surprisingly, in the early 1980's, NGF was shown to act as a neurotrophic factor in 
the central nervous system (CNS), as well as the peripheral nervous system 3 . 
Significantly, NGF was seen to be required by the exact same neurons which are 
involved in memory functioning and which degenerate in AD. In 1983, Hefti 16 
suggested that the lack of NOF may be a direct cause of the pathogenesis of AD. 
Since then, no evidence to support this view has been uncovered, and it appears that 
NGF levels are not, in fact, reduced in AD 17. Nevertheless, NGF and related 
proteins may potentially represent a new avenue for research into the aetiology and 
treatment of AD and other neurological disorders, as will be outlined in the 
following section. 
1.1.6. Possible Role for NGF in the Treatment of AD 
Several studies have shown that NOF can help in the survival of injured neurons, and 
even help in the regeneration of damaged axons. Neurons in the medial septal 
nucleus (and part of the diagonal band nucleus) project into the hippocampus (ref. 
Fig. 1.2) in a dense bundle of fibres, through a region called the fimbria/fornix: 
about half of the neurons sending axons through this narrow region are cholinergic. 
When this pathway is surgically transected in experimental animals e.g. adult rats, 
many of the septal/diagonal band neurons gradually degenerate and die 18. An 
explanation for this could be that the neurons became deprived of their supply of a 
NTF (e.g. NGF) supplied by the target areas of the hippocampus, which the axons of 
these neurons innervate. It was hoped that the administration of exogenous NGF to 
7 
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these axotomised neurons in,- kprevent their degeneration; also NGF rnhi also allow 
these neurons to regenerate their transected axons and connect back to the 
hippocampus 18. Several studies have indeed shown that direct infusion of NOF into 
the brains of axotomised rats will prevent the loss of these cholinergic neurons 19. 
More recently, it has also be demonstrated that the continuous infusion of murine or 
recombinant human NGF into similarly axotomised monkeys can also protect these 
neurons from degenerafion 222. It may be the case, therefore, that treating AD 
patients with NGF could prevent the deterioration of these same cholinergic neurons, 
and hence ameliorate the memory loss associated with the disease 23. 
If such a treatment is to be successful, a major problem would be in how to 
administer the NGF protein to the required areas of the brain. Proteins do not 
normally cross the blood-brain barrier (BBB), thus alternative strategies to possibly 
increase the normal concentrations of NGF available have been suggested; 
Direct injection/infusion of exogenous NGF (perhaps via a small pump 
mechanism)23 . 
Transplantation of a cell-line which secretes genetically recombinant 
human NGF1824. 
Augmentation of the endogenous NGF levels 25. 
Methods 1 and 2 will obviously provide problems due to the invasiveness of the 
procedures, although they have had some success in animal models. The evolving 
understanding of the regulation of NGF synthesis may eventually help with the 
realisation of a strategy like method 3. 
Perhaps a more realistic approach may be to try to develop a drug which could act as 
an NGF agonist. A small molecule could more easily cross the BBB, although it 
would presumably have to be directed to the appropriate areas of the brain to 
promote the survival of the cholinergic neurons there, without influencing those in 
the PNS. To design such a drug will require a full understanding of the structure of 
NGF and on how it produces its biological effects. At the commencement of the 
work described here, only limited information had available on both of these matters. 
8 
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1.2. NERVE GROWTH FACTOR (NGF) 
1.2.1. The Structure of NGF 
NGF was first discovered as a factor from mouse sarcoma cells that caused extensive 
growth in chick embryo neurons 26'27. Since then, NGF activity has been found in 
many tissues, although few mammalian sources are rich enough to allow the 
purification and biochemical characterisation of their NGF. The major exception to 
this is the mouse submaxillary gland was found to contain unusually large quantities 
of NGF30, the isolation of which has permitted the complete structural elucidation of 
the molecule from that source. NGF from several other species e.g. human 28, 
chicken29, rat29, has also been produced by recombinant DNA technology, which 
has enabled their subsequent characterisation. It appears that most NGF molecules 
from different sources have significant homology with the murine structure, and may 
have similar three-dimensional structures. 
Murine NGF (mNGF) actually exists as a complex of three types of subunit: a, 3 
and y31 . The p-subunit represents the active NGF molecule (which exists as a 
dimer). There is considerable homology between the a and y  forms; y is a trypsin-
like protease and may be involved in the processing of the mNGF complex, thus 
releasing the active 0 form. The a-subunit is thought to protect NGF from 
proteolysis and may regulate its activity. 13-NGF is present in the complex as a 
noncovalently-linked dimer with a M.W. of 26.5 kDal. This dimer is quite stable 
and remains intact at biologically relevant concentrations 32. Strong denaturants can 
separate the dimer into two identical chains, each 118 residues long (120 in human 
NGF). Both monomers and the dimer are biologically aótive 33. The primary 
sequence for the murine chain was elucidated in 1971 34 and since then, many NGFs 
from various species have been predicted by molecular cloning 35 (Fig. 1.6). There is 
a high degree of sequence homology between all NGFs so far discovered; all contain 
three intrachain disulphides, at conserved positions, and reduction of these bonds 
causes the complete loss of biological activity 36. Murine [3-NGF is transcribed from 
a single gene copy, localised on chromosome 3 (1 in humans). From this the -NGF 
is synthesised as a large precursor (prepro-NGF), which is processed to form a 
further precursor (33.8 kDal). This itself is then processed into the mature 13.2 kDal 
protein. The processing occurs at both ends, with cleavage between two basic 
residues in each case. The y-subunit is thought to be responsible for these actions37. 
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Introduction 
somewhere along the pathway taken by the complex inside the neurons, intracellular 
signals responsible for the function of NOF, must be generated. It seems likely that 
the actual binding of NGF to its receptor must initiate the signal transduction effects 
that are the key to the mechanism; however, whether the signal transduction is 
restricted to the nerve terminal membrane, or also occurs during the transport of the 




cut. Itt)DY 	 ' V 
r.4K(;t.T CELLS 
I. NGF is released from target cells 
NGF binds to receptors and is internalised at nerve terminals 
NGFreceptor complex is retrogradely transported to the cell 
body e.g. of forebrain cholinergic neurons 
Signal transduction occurs on route to cell body, triggering 
trophic actions of NGF 
Fig. 1.7 Retrograde transport in cholinergic neurons 
Certain biological changes have been observed on the initial binding of NGF to the 
receptor. These are varied and numerous, but fall into two main classes; 
1. Early responses, which occur within seconds to hours, for example, 
regulation of the uptake of nutrients and precursors, such as 
amino acids and sugars 47 , 
the induction of protooncogenes c-myc and c-fos48, 
the phosphorylation of ribosomal proteins S6 (increases protein 
synthesis) and tyrosine hydroxylase (increases catecholamine synthesis) 49. 
2. Delayed responses, which occur within hours to days, for example, 
the initiation of neurite outgrowth 50, 
the activation of enzymes required for neuronal function, such as tyrosine 
hydroxylase51 and ornithine decarboxylase52. 
These changes act to promote the survival and maintenance of the cholinergic 
neurons in the CNS. There is considerable evidence that NGF is also important in 
II 
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the survival of the cholinergic cell bodies of the basal forebrain during 
development1 8• 
1.2.3. NGF Receptors 
The first step in the transduction of the extracellular message of NOF into the 
required intracellular responses, occurs by its initial association with its receptor 15 . 
For many years it was observed that two forms of this receptor appeared to exist: a 
low-affinity form (which had a K, for NGF of 10 -9M) and a lesser-populated high-
affinity form (K d  for NGF of lOnhIM). The primary structure of the low-affinity 
form, named p75NGk,  has been elucidated by gene cloning53.54. This showed the 
receptor to be 427 a.a.'s long, consisting of a twenty-eight a.a. signal sequence; an 
extracellular domain containing four, forty-a.a. repeats, followed by a region rich in 
serine and threonine residues; connected to this is a single transmembrane domain, 
made up of mainly hydrophobic a.a.'s, then a 155 a.a. cytoplasmic domain 55. The 
M.W. of the fully processed receptor protein is approximately 70-80 kDal (hence 
named p75). The difference between this and the predicted size of the receptor 
protein (399 a.a.) is due to the extensive 0- and N-linked glycosylation in the 




Fig. 1.8 Representation of proposed structure of p75R. 
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The predicted human, rat and chicken sequences show that while there is 92% 
homology between the rat and human forms, the chicken sequence is less well 
conserved, although importantly, almost every cysteine residue and the 
transmembrane region are conserved between the three species. Of the twenty-eight 
cysteine residues, twenty-four are found within the first 160 residues. Aligning these 
shows that they are contained within four, forty residue repeats (Fig. 1.9), which 
may be evolutionarily related. Similar cysteine-rich repeats have been found in the 
extracellular domains of several proteins e.g. tumour necrosis factor receptor 56. The 
cysteine-rich sequences have recently been shown to contain the NGF binding 
domain(s)57 . 
KEftTGLY THSGEC CKACgLGEGVAQPC3AN QTVft i 
PDSVTFSDLVSATEPPftE4TGLQSMSAP/EADDAVft n 
YGYYQDE 	TTGRftAftVftAGSGLVF S DKQNTVI*E m 
DGTYSDE IV 
Fig. 1.9 Four internal repeats in p75' 
(spaced to allow maximum alignment) 
This extracellular region also contains many negatively charged residues (aspartic 
and glutarnic acids), giving a net negative charge of -24. It has been suggested that 
the folding of the extracellular domain may arrange these charges so that they 
provide a binding pocket for a corresponding basic (hence positively charged) region 
on the NGF molecule itselP 3 . 
The deduced a.a. sequence of p75NG,  whilst having some structural features in 
common with known receptors, nevertheless lacks significant similarities with any 
other known receptor or protein. The intracellular domain also bears no similarity to 
other known growth factors, oncogenes or tyrosine kinases. In fact the p75NO 
appears to have no tyrosine kinase activity 58 '59. This was taken to suggest that the 
mechanism of action of NGF must differ substantially from that of other peptide 
growth factors, such as platelet-derived growth factor, epidermal growth factor 
(EGF) and insulin, which all have tyrosine kinase activity in their receptors. The 
intracellular domain does however contain a single mastoparan-like domain (a 
consensus sequence for the binding of G-pmteins), which might provide a possible 
signal transduction route. 
13 
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In the mid-1980's, it was observed that a second protein species, as well as the 
p75NR, could be obtained, bound to radiolabelled NGF, from cells which expressed 
both high- and low-affinity receptors 61 . This protein had an approximate M.W. of 
140 kDal. Further studies showed that both it and the p75 were required to elicit 
the nerve's responses to NGF. At the time, it was thought that the p75NOFR was part of 
this larger receptor, along with a smaller 'accessory' protein, perhaps a 60 kDal 
tyrosine kinase protein; together these would constitute the high affinity form. In 
early 1991, it was shown that the 140 kDal protein itself contained phospho-
tyrosine62, implying that this may participate in a tyrosine kinase signalling pathway. 
Subsequently, it has been shown that the 140 kDal protein was the product of the irk 
protooncogene, named pl4Ok,  and this was required to provide the high-affinity 
binding observed for NGF635. 
The irk protein had been identified some years earlier, when the irk oncogene was 
found in a human colon carcinoma 66, and subsequent gene cloning enabled the 
protein sequence to be predicted. This sequence indicated a tyrosine kinase-like 
domain fused to a tropomyosin sequence (thus irk - tropomyosin receptor kinase). 
There appear also to be several forms of the irk protein67 , all of which have a M.W. 
of 140-145 kDal, as well as containing an extracellular domain, a single 
transmembrane domain and an intracellular tyrosine kinase domain. The 
extracellular domain has cysteine- and leucine-rich regions, as well as several 
regions characteristic of cell adhesion molecules. When the irk proteins were found 
to be localised in tissues of neural origin 68, the search for its natural ligand was 
similarly focussed on nervous tissues, which led ultimately to the identification of 
NGF as its ligand. 
What is not clear, at present, is how the p75 Nm and the pl40' receptor are involved 
in generating the high-affinity binding required to cause the biological effects of 
NGF. Two theories have been proposed to explain the observed experimental 
results, and define the component(s) of the high-affinity receptor; 
The p1401k  protein alone mediates all of NGFs biological actions 65 . 
Both p75NGFR and the p14017k  receptor are required for high-affinity binding 64 . 
The second theory suggests that the two receptors interact in some way, perhaps to 
form a heterodimer, and thus generate the high-affinity binding site 64  (Fig. 1.10). 
By analogy to some other receptor tyrosine kinases, whose dimerisation is thought to 
14 
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be required for phosphorylation and activation e.g. EGF receptor, such dimer 
formation maybe required here for the signal transduction of NGF. Conversely, a 
dimer of the pi4O" protein may be the active species 65 . The overall picture of what 
actually constitutes the high-affinity binding species, and the role that both receptors 
play in it, is still not complete and represents a very active area of on-going research. 
Recent evidence has suggested that the p75 NGM  may play only a modulating role in 
the high-affinity binding of NGF69. 
Fig. 1.10 'Two-protein' model of the NGF high-affinity receptor 
Both receptors interact with the NGF dimer. The pl4Q1  may additionally 
interact with the intracellular domain of the p75  R. 
1.2.4. Other Neurotrophins 
NGF is actually part of a family of related neurotrophins, whose other members are 
now beginning to be characterised. The best defined are brain-derived neurotrophic 
factor (BDNF)70 and neurotrophin-3 (NT-3) 71 , although recently neurotrophin-4 
(NT-4)72 and neurotrophin-5 (NT-5) have been discovered. As yet the physiological 
roles of these molecules in vivo are unknown, but in vitro, they appear to promote 
the survival of similar neuronal populations as NGF 73. All of these proteins are 
structurally related (Fig. 1.11), with about 50% of their sequences conserved 
between the three molecules. All six cysteines are conserved in similar positions to 
those in NGF, so perhaps the same disulphide formation also exists. Four variable 
domains can be seen, which presumably contain residues defining the neuronal 
specificities of the proteins. 
15 
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NOF, BDNF, NT-3 and NT-4 all bind to the p75NQPR with roughly equal affinities 74 . 
They have also been found to bind to other members of the rrk receptor family. The 
p140 receptor, involved in the high-affinity binding of NGF, is coded for by the 
trkA gene, thus has been renamed p140'; trkB and trkC genes have also been found 
and these code for the slightly-higher M.W. receptor proteins, pl450 75 and 
p145" 76. All of the trk receptors share considerable homology, especially in their 
tyrosine kinase domains. 
NT-3 	_YAEHKSHRGEYSVcDSESLWVT* *DXSSAIDIRGHQJJT 
NGF SSTHPVFHMGEFSVSVSVWV* *KTTAIKGKEWI7J 
BDNF 	--HSDPARRGELSVSI SEWVTADKKTAVDMSGGTVTVL 





BDNF 	RTTQSYVRALTMD SKKRIGWRFIRIDTSCVCTLT IKRGR-- 
Fig. 1.11 Sequence comparisons of mouse NT-3, NGF and BDNF. 
Bold letters show identical a.a.'s at conserved positions; asterisks indicate gaps which allow optimal alignment. 
The four main variable regions are indicated by lines above the sequences. 
It was originally postulated that the p75N1t,  along with one of these trk proteins, may 
form a specific high-affinity receptor for an individual neuroirophin e.g. BDNF was, 
at first, found to bind to pl45, thus p75Nm plus pi45 may form an analogous 
high-affinity receptor to that proposed for NGF. However, current evidence 
indicates a more complex picture: it has been shown that pl40tM will bind NT-3 as 
well as NGF77 , pl45&0 will bind BDNF and NT-3, but not NGF78 and pl45&w binds 
only NT-376 . The structural determinants in these neurotrophins, and in the trk 
receptors, which account for these subtle differences have yet to be characterised. 
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1.3. THE CHEMICAL SYNTHESIS OF PEPTIDES 
1.3.1. General 
Amino acids can be covalently linked by the formation of an amide bond between 
their respective a—amino and a—carboxyl functions. The resultant molecules are 
termed peptides when the polyamide chain formed is less than 100 a.a. units, thus 
distinguished from proteins which are generally of much higher molecular weights. 
The amide or peptide bond (Fig. 1.12) is formed in 
Nature by a specific enzyme complex, peptidyl- 	+ R1 Hi 
transferase, in the ribosome, elongation of the peptide H3Njf)4 H 
or protein occurring in the N-to-C-terminal direction. 
Whilst we are unable to directly mimic-this process in 
vitro, peptides (and maybe proteins) are nevertheless 
accessible by chemical synthesis due to the ingenuity 	Fig. 1.12 The peptide bond 
of many synthetic organic chemists throughout this (in a dipeptide) 
century. 
The interest in peptides and in advancing peptide chemistry has been spurred largely 
by the discovery of a myriad of naturally-occurring, complex biologically active 
peptides over the last twenty to thirty years, especially neuropeptide hormones and 
neurotransmitters 79. In fact, peptides play key structural and functional roles in 
many areas of biochemistry, pharmacology and neurobiology 80-83 as demonstrated 
by the vast literature in these fields. The chemical synthesis of peptides thus has 
important applications in many areas of research, some of which are outlined below 
(Table 1.13) 
Table 1.13 Some important applications of Synthetic Peptides 
Structure determination 
Epitope mapping of proteins 
Structure-function studies 
Protease substrates/inhibitors 
Synthetic vaccine production 
Peptide hormone agonists/antagonists 
Investigation of protein folding 
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The peptide bond was first recognised as a feature of peptide/protein structure early 
this century8 '85 . It has about 40% double bond character due to resonance 
stabilisation - this fact has two important consequences: 
-NH- (imide) has no significant tendency to ionise or protonate, 
-C-N- bond is relatively rigid and cannot freely rotate hence peptide bonds 
usually have a trans-conformation. 
These factors have significant consequences in defining peptide and protein 
structure. The first small steps to chemically forming this bond were taken by 
Curtius86 (benzoylglycyl-glycine) in 1881 and later, around the turn of the century, 
by Fischer87  (ethoxycarbonylglycyl-glycine ethyl ester). From here, the field has 
gradually evolved, punctuated by advances in methodology, which have led 
ultimately to the development of peptide synthesis on solid supports 88-90 and even 
the approach to protein synthesis 91 '92. Despite the undoubted complexity of many 
peptide and protein systems, the underlying basis behind the chemical synthesis of 
such molecules is the formation of the peptide bond. Before considering the various 
chemical means of forming these bonds, the subject of protecting groups (POs) will 
be discussed as this is most vital to the success of any of the chemical strategies. 
1.3.2. Na.protecting Groups in Peptide Synthesis 
Consider the formation of the theoretical dipeptide AB (Fig. 1.14). We require that 
the carboxyl of A couples with the amine of B, via the activation of the carboxyl of 
a.a. A by chemical means (see section 1.3.3). If we simply mix activated A with B, 
we will form some of the required dipeptide AB but also some cyclic A—B and many 
other undesired products. Additionally, due to the functionality of some a.a. side-
chains e.g. Asp, Glu, Lys, we may also get branching and other side-reactions. The 
solution to these problems has been through the extensive use of PGs which allow 
only the desired reactions to occur. 
E1 
Eim 	CO2H + }12N '1! CO2FXI 
A 	i 	B  
I XNPG 
A B 
I YcarbonyI PG 
(polymer in SPPS) 
PIQ=sani-paTTanat, 
A-B , AB, AA, BB, ABA, AAA ... etc° 	ProteCted AB 
H2N CO2H + H2N 	CO2H 
Fig. 1.14 The use of PGs enables the formation of dipeptide AB 
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The foundation of chemical synthesis of peptides is the NczPG. This can be 
selectively removed to allow the coupling of subsequent a.a.'s whereas the other 
functionalities i.e. C-terminus and side-chains, have 'permanent' PGs which remain 
intact during chain elongation and are removed at the end of the assembly. 
Ideally a useful (x-amino PG: 
should be introduced into the a.a. in high yield, 
should have a chemical procedure for its introduction that will not cause 
racemisation, 
should preserve the chiral integrity of the a.a. during coupling, 
should be capable of being removed without damaging the peptide or other 
PGs. 
Most of the currently used groups are based on urethane-type structures, the majority 
of which may be easily removed by acid or base under mild conditions. The 
urethane sub-unit appears to especially prevent the formation of azlactones, which 
have been shown to be involved in racemisation (conversion of normal L-a.a. to D-
isomer, see section 1.4.4). Paradoxically, the first urethane PG used by Fischer 93, 
ethyloxycarbonyl, was unsuccessful as it was difficult to remove and caused side-
reactions. In 1932, the benzyloxycarbonyl (Cbz or Z) 94 group was introduced. This 
could be removed by catalytic hydrogenation or by acidolysis (Fig. 1. 15)95,96. 
Br - 0 R 	 0 R 
llBr 0A N 
H 0 	 + H 0 
1 
R 	 0 R 
CO2 + BrH3N-1-0 HBr 	 + HOAN _ f(1 
0 	 H 0 
Fig. 1.15 Acidolysis of Z group with HBr/glacial acetic acid 
The basis of its deprotection by strong acids was the formation of a stable 
carbocation. Developing this strategy, groups with greater acid-lability were 
introduced, the most important being the Natertbutyloxycarbonyl (Boc) 97 '98 
group, which can be removed by HC1/acetic acid or trifluoroacetic acid (TFA) [SN 1 
mechanism], and the even more labile biphenylisopropyloxycarbonyl (Bpoc) 99 
group. Many other acid-labile PGs have been suggested and reviewed 80 . 
19 
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Urethane protection founded on deprotection by base 	 9 
has gradually assumed greater importance over the 
past decade. Originally, it had been shown that 	- 	o 
urethanes containing suitably activated hydrogen 9 
atoms e.g. arylsuiphonylethoxycarbonyl derivatives 	CH3 - 	o 
could be cleaved by base-catalysed kliminationlOO, 
although strong alkaline conditions were required. 
Alkyl derivatives 101 of similar compounds found Fig. 1.16 Two base-labile 
greater application (Fig. 1.16). 	
Na.protecting  groups 
In the early 1970's, Carpino showed that 9-fluorenylmethoxycarbonyl (Fmoc)102-104  
derivatives could be deprotected, again using weak bases e.g. piperidine. The 
-: 	 fluorene ring system renders the lone hydrogen on the 
carbon especially s ecia ly acidic. If removed by a base, the carbanion intermediate which is 







R 	 0 	0 R 
+ c02 + H2N 
	[Hi 	 + 	NH 
ON 	 R 	 0 	OR 
Fig. 1.17 Base deprotection of the Fmoc group 
This species is additionally scavenged by the excess base used, resulting in an adduct 
whose UV detection may be used in monitoring systems 106 (see section 2.2.3). This 
group is now widely used and has become the basis of an orthogonal scheme for 
Solid-Phase Peptide Synthesis (SPPS) 10709. Other base-labile groups have been 
suggested, some with certain special properties e.g. 2,2-[bis-(4-nitrophenyl)]-
ethoxycarbonyl (Bnpeoc) 0 group, whose deprotection with base leads to a colour 
change. 
While other PGs and methods of deprotection have been suggested and may have 
uses in special cases, the use of Boc (acid-labile) and Fmoc (base-labile) are most 
prevalent. The choice of a.a. side-chain protection is dependent on the type of Ne-. 
20 
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protection used and will be considered later in the context of SPPS. With suitably 
- 	protected a.a. residues, their chemical coupling to form peptide chains can be 
undertaken. 
1.3.3. Formation of the Peptide Bond 
PRA-9j"IMAM 13 M-767, 
Under normal circumstances, carboxylic acids will not react with amines I i to orn 
q Ilce 6 thus it is usually necessary to augment the electrophilic 
character of the carboxyl group of the acylating molecule. This can be achieved by 
replacing its hydroxyl function with a variety of electron-withdrawing groups, whose 
inductive effect can greatly enhance the carbonyl's susceptibility to nucleophilic 









Y 	IR-C-Y I I 
H — N — H 	 I H--N—H 1 
I 	 I 	I 
R' L R' 	] 
 
11 
R — C 
N — H 
R' (+HY- ) 
Fig. 1.18 Generalised activation and coupling reactions in Peptide Synthesis 
The original method of Fischer 111 used acid chlorides. In combination with his 
urethane protection at that time, this led to the formation of N-carboxyanhydrides 112 
with the subsequent loss of his Naprotection, as well as the formation of oxazolones 
when using acyl-protected a.a.'s. Thus, although acid chlorides are very reactive, 
they are not routinely used in peptide synthesis. Recently however, Fmoc-a.a. 
chlorides have been formed and used in the synthesis of short peptide segments 113 . 
Stable derivatives bearing the tert-butyl moiety were not able to be formed, hence 
this limited the approach. This problem appears to have been overcome by the use 
of Fmoc-a.a. fluorides 114,  which have subsequently enabled both solution and solid-
phase syntheses to be carried out. 
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The azide method1 15,  discovered by Curtius (Fig. 1.19) a contemporary of Fischer, 









01 1 L I . Oil HO 	 HO 
Fig. 1.19 Curtius's original synthesis of benzoylglycyl glycine via azide method 
Improvements in strategy 7 and the activation of the hydrazide to the acid azide via 
alkyl nitrites  1 18 , has led to reagents which may directly form the azide from the free 
acid e.g. diphenylphosphoryl azide (DPPA) 119 (Fig. 1.20). The major drawback 
with azides is however their propensity for rearrangement to isocyanates (Curtius 
rearrangement) (Fig. 1.21). 
R —CO —NNN 	R—CO— N—NN 
0- o_—o_0 
	




Fig. 1.20 DPPA 
	
Fig. 1.21 Curtius rearrangement 
The isocyanates formed may react with the free amine function to yield ureas. To 
overcome this problem, azide couplings have to be carried out at low temperatures 
(at or below 0°C) and with high concentrations of reactants to speed an otherwise 
slow reaction. The yields obtained are generally low/moderate (30-70%) but an 
advantage is the low level of racemisation said to be associated with this coupling 
procedure. 
The acid chloride and azide methods were the only two coupling methods available 
until the early 1950's when mixed anhydrides were introduced 120' 121 . The use of 
these reagents has been reviewed122. This procedure was developed and refined, 
exemplified by the use of isobutylcarbonic acid mixed anhydrides, which provided 
steric and electronic effects to ensure that nucleophilic attack occurred at the correct 
22 
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carbonyl (Fig. 1.22). Despite the attractive feature of using only one equivalent of 
a.a. per coupling (c.f. symmetrical anhydrides), their use has almost exclusively been 
confined to solution-phase synthesis. Mixed anhydrides formed from substituted 
phosphonic chlorides e.g. diphenyiphosphinyl (DPP) chloride, in the presence of 




RA  R, J—NHCH—' + H
2N-R' - 
0 	 7 
J—NHCH—CrX —NHcH 
oo 	
+CO2 	 d o 
Fig. 1.22 Mixed anhydride coupling 	 Fig. 1.23 A Dpp 
anhydride 
The above methods of peptide bond formation have found extensive use in solution 
phase synthesis, although they are not usually applied to SPPS. The two major 
methods which follow have been applied to both. 
1.3.3.2. Symmetrical Anhydrides 
With symmetrical anhydrides (SA), acylation of a.a.'s can occur by attack at either 
carbonyl group. The disadvantage of losing half of the reacting material is largely 
offset by their high reactivity. Formation of S.A. by the use of carbodiimides was 
conceived in 1955124,  with dicyclohexylcarbodiimide (DCC) being suggested by 
Sheehan and Hess 125 that same year. The mechanism of its formation and its use in 
coupling is shown in Figsi.2415. 
The dicyclohexylurea (DCU), which forms, is insoluble in most of the solvents used 
for synthesis e.g. dichloromethane (DCM), dimethylformamide (DMF), thus other 
carbocliimides which form soluble ureas e.g. diisopropylcarbodiimide (DIC) 126 ' 127 
are often used for SPPS to prevent the build-up of insoluble material. The 0-
acylurea formed in the reaction provides activation leading to: 
direct attack by an amine to form a peptide bond. 
attack by another carboxyl function to form the S.A. 
bond formation via a reactive species, which may be formed by the addition 



















Fig. 1.24 Activation and coupling by carbodiimides 
RCO2H+RNH2 +DIC +HOBt 
OyR 
0 
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HOBt addition significantly reduces the side-
reactions associated with the coupling 
method, principally the formation of N-
acylureas and some racemisation, by 
reducing the concentration of 0-acyl ureas. 
Thus for in situ activation, where all of the 
components are simply mixed together in the 
reaction vessel, multiple pathways probably 
exist (Fig. 1.25). The reactive species 
formed by HOBt is typical of another class of 
compounds used for peptide bond formation: 
active esters. 
Fig. 1.25 (right) Probable multiple pathways in 
carbodiimide-mediated couplings. 
1.3.3.3. Active esters 
Aminolysis of esters has been widely studied as a method of peptide bond formation. 
Here the alcohol component provides the inductive effect on the carbonyl, leaving it 
more electrophilic. The most widely used alcoholic function is still HOBt 129, which 
may form an active ester (AE) in situ when added to carbodiimide-mediated 
couplings, or be preformed outside the reaction vessel. In any case, these esters are 
unstable and are not usually isolated. Whilst the formation of AE by DICIHOBt is 
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well established, many new coupling reagents for the in situ formation of HOBt 
active esters have been suggested and are claimed to produce faster couplings. These 
are generally based on the hexafluorophosphate or tetrafluoroborate salts of 
carbonium or phosphonium species (Fig. 1.26) e.g. B0P 130' 131 , PyBOP 132, 
H13TU 133134 ,13130 35; all require a tertiary base for activation. 
PF6 Y 
o—X--Y 
X Y Z Abbrev. 
N None BBC 
C 
-ci', 
N.. None HBTU 
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Fig. 1.26 Reagents for in situ Active Ester formation 
Other types of AE can be obtained in stable, crystalline forms and have gained 
popularity as they can more easily be used in automatic synthesizers. Representative 
of these compounds are nitrophenyl esters 136, superseded by trichiorophenyl 
esters 13738 and more recently pentafluorophenyl esters 13941 . All of these react 
slowly in the absence of HOBt as an additive. Lately, other AE, which may enable 
the spectroscopic determination of the acylation reaction, have been used e.g. 
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Fig. 1.27 Alcoholic functions useful for AE formation 
It is clear, therefore, that many different types of reagent are available to the peptide 
chemist for the formation of the amide bond. The choice is sometimes dictated by 
the particular protection group strategy that is chosen but more often by what can be 
accommodated in an automatic synthesizer. For reasons which are not entirely clear, 
often one type of activation method will succeed in a particular coupling reaction 
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where another fails, thus it is prudent to consider all the above mentioned methods as 
potentially useful. 
Although great advances had been made in peptide chemistry in the first half of the 
century, it remained a specialised and difficult area. The need to couple a.a.'s, wash, 
recrystallise, etc. in the solution phase, made the assembly of even quite small 
peptides a major feat. In the early 1960's, an advance was made which has greatly 
changed the nature of peptide synthesis and made it into the major field that it is 
today: the assembly of peptides on solid supports. 
1.4. SOLID-PHASE PEFrIDE SYNTHESIS (SPPS) 
1.4.1. General: Boc and Fmoc Strategies 
The concept of SPPS is straightforward but nevertheless elegant in how it overcomes 
the problems associated with solution synthesis, especially in the manipulation and 
solvation of the large, protected peptides formed. A generalised scheme is outlined 
in Fig. 1.28. An Naprotected a.a. (usually bearing a compatible PG on the side-
chain) destined to become the C-terminus of the peptide, is covalently anchored to 
an insoluble polymeric support, often via a linker. The blocking group is then 
selectively removed and the peptide chain lengthened by the addition of another  Na-
protected a.a., using one of the previously mentioned methods, to yield a protected 
dipeptide. After each of the deprotection and coupling steps, the growing 
peptide/resin can be thoroughly washed with suitable solvents, simple filtration 
removing the excess reagents. Subsequent cycles of washing, deprotection, washing, 
coupling and so on, can extend the peptide chain to the desired length. The coupling 
cycles may be stepwise with individual a.a.'s or with protected segments (see below). 
The overriding advantage compared to solution work, is that the substantial excesses 
of protected a.a.'s used to drive each coupling reaction to completion, can simply be 
removed by washing/filtration. Additionally, the fact that the growing chain is 
immobilised largely avoids solubility problems, lengthy purification of intermediate 
stages and reduces the mechanical loss of material. When the desired peptide length 
is reached, the peptide is released from the support, usually by mild or strong acid. 
Strategies are chosen so that the side-chain protection, which has remained intact 
during chain assembly, can be simultaneously removed to yield the free peptide. 
Introduction 
Peptides with acid or amide functions at their C-termini may be formed depending 
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SP = 'semi-permanent' I'I-protecting group e.g. Boc, Fmoc 
P ='permanent' side-chain PG 
X = carboxyl activating group (via SA or AE methods) 
Fig. 1.28 Generalised scheme for SPPS 
Such a scheme was first put forward by Merrifield 88' 148  in 1963. The solid support 
that he chose is still widely used today: a copolymer of polystyrene with 1% m- 
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divinylbenzene 149 ' 150, which provides cross-links, enabling the resin to swell in 
DCM and DMF. His initial use of the benzyloxycarbonyl (Z) group required 
HBr/AcOH for deprotection, then triethylamine (TEA) as a base to liberate the free 
amine before coupling could occur. Unfortunately, this strong acid treatment also 
removed some of the peptide chains from the resin, requiring nitration of resin to 
overcome this. In an improved method 151 , the Z group was replaced by the Boc 
group, which could be more easily removed by HCl/AcOH or TFAIDCM. These 
residues were activated for coupling using DCC. The final cleavage of the peptide 
from the resin and removal of the side-chain protection called for the use of very 
strong acids. At first HBr/TFA was used but this has been superseded by anhydrous 
hydrogen fluoride (HF) 152 ' 153 and trifluoromethanesulphonic acid (TFMSA) 154 . 
The concern about the detrimental effects of the peptide's repeated exposure to 
acidolysis 155 , with many reports of acid-catalysed side-reactions, led to 
investigations into orthogonal approaches. Here, instead of graded acid-lability 
being the foundation to link the protecting strategy of resin/peptide bond, side-chain 
and Nablocking groups, instead PGs which theoretically can be removed in any 
order and in the presence of all other protecting classes, are envisaged. The most 
successful realisation of this approach was suggested by two research groups in 
1978 107,109  using the Fmoc group for Nablocking (base-labile) and having side-
chain functionalities protected by PGs which were labile to mild acid such as TFA, 
as well as TFA-labile resin linkers. The many improvements made to this basic 
scheme, primarily in side-chain protection, have been reviewed 156-158.  The Fmoc 
group is removed quite rapidly by nucleophilic bases e.g. 20% piperidine in DMF, 
with subsequent coupling by the previously stated methods (SA and AE are 
generally used). A brief comparison of both Boc and Fmoc strategies is shown in 
Table 1.29a and b. As the Fmoc strategy was used in this work, only this will be 
considered in the following sections. 
NaBoc Na.Fmoc 
Nalability TFA (S N 1) Piperidine (f3-elimination) 
Side-chain PGs Benzyl-based tert-Butyl-based 
Side-chain lability BF, RS03H TFA 
Solubilties I 	High Moderate 
Fig. 1.29a Comparison of Boc and Fmoc strategies 
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A.A. residue NaBoc NaFmoC 
Asp, Glu OBzl ; OcHxl O-reri-butyl 
Lys 2-CI-Z Boc 
Arg Tos;Mts Mtr;Pmc 
His Tos;Dnp;Bom Trt;Boc;Bum 
Ser, Thr Bzl tert-butyl 
Tyr Br-Z tert-butyl 
Cys pMeBzI ; MeOBzl Acm ; SBu1 ; Tn 
Met None; Suiphoxide None 
Trp Formyl None;Boc 
Asn, Gin None; Xan None; Mbh ; Tnt 
Ala, Giy, lie, Leu, 
Phe, Pro, Val  
None None 
OcHxl. 0-cyclohexyl; Tos, 4-toluenesuiphonyl; MLS, mesitylene-2-sulphonyl; Dop. 2,4-dinhtrophenol; Born, benzyloxymethyl; 
Xan. 9-xanthenyl; Mir, 4-methoxy-2,3.6-tnmethyl-benzenesulphonyl; Prnc, 2,2.5.7,8,-pentamethyl-chrornan-6-sulphonyl; Bunt, 
lert-butoxymethyl; Acm, acetamidornethyl; SHut,  ierl-butylsuphenyl; Tn, tnphenylmethyl; Mbh. 4.4.dimethoxybenzhydry1 
Fig. 1.29b Comparison of PGs used in each strategy 
1.4.2. Side-Chain PGs 
PGs are mandatory for many of the functional side-chains of certain a.a.'s to: 
prevent them from reacting during the course of chain assembly e.g. they 
could be acylated, especially as excess a.a.'s are used during coupling. 
prevent modifications to the a.a. during synthesis. 
prevent specific side-reactions associated with certain of these side-chains. 
The Fmoc strategy enables the design of mild acid-labile protection for the side-
chains, thus most have been devised so that they may be removed in TFA solutions 
in reasonable time (2-4 hr). Several a.a.'s are protected as their tert-butyl esters 
(Asp, Glu) 159 or ethers (Ser, Thr, Tyr) 159 . These may be prepared by the initial 
attachment of the But  group via isobutylene 160, then the Fmoc added using 9-
fluorenylmethylsuccinimidyl carbonate (FmocONSu) 161 ' 162. The c-amino function 
of lysine is primarily blocked by the Boc group, introduced by Boc-azide to a 
copper-complexed lysine residue 163 . The aliphatic a.a.'s (Ala, Val, Leu, lie, Phe) are 
unreactive thus do not require protection. Of the rest, Asn and Gin, Arg and His 
deserve closer consideration (Cys and Trp protection is discussed later). 
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1.4-2. 1. Asparagine and Glutamine 
These are often left unprotected. However, the Fmoc derivatives have poor 
solubilities and the amide side-chain can undergo dehydration during DIC activation, 
resulting in nitrile formation 164,165  (Fig. 1.30). This may largely be prevented in 
carbodiimide couplings by the addition of HOB0 6J67, probably due to the 
acylation reaction occurring more rapidly. Various PGs have been suggested to try 
to overcome the solubility problems e.g. 4,4'-dimethoxybenzhydryl (Mbh/Dod) 168 , 
trityl (Trt) 169 and dibenzosuberyl (Dbs) 170 . 
0 	 NH 	 N 
Fmo 	
DIC 	 o 
Fmoc- 
N 
o 	 0 	 0 
Fig. 1.30 Intramolecular dehydration of Asn during DIC activation 
1.4.2.2. Arginine 
The guanidino group of Arg is a strong nucleophile and may be acylated during 
SPPS, hence chosen PGs must be strongly electron-withdrawing to reduce its 
basicity. The most common side-reactions are, when activated, ö—lactam 
formation 171.172  and acylation of the guanidino function (during coupling) followed 
by base-catalysed ornithine formation (during the following deprotection of the 
Fmoc group) 173 . Many groups have been forwarded to suppress these reactions, the 
most successful being based on aryl sulphonyl derivatives. The best of these is the 4 
-methoxy-2,3,6-trimethylbenzene-sulphonyl (Mtr) 174 group; its 
Fmoc derivative however couples slowly and requires extended 
TFA/thioanisole treatment for its removal 175 . Leading on 
from these derivatives, the much more labile 2,2,5,7,8-
pentamethylchroman-6-sulphonyl (Pmc) group 176479 (Fig. 
1.31) has solved many of the problems associated with Mtr and 
has rapidly become the choice group for Arg protection, 









Two major side-reactions occur when using histidine: 
acylation of the imidazole side-chain if left unprotected during coupling 180 , 
and 
racemisation due to intramolecular base catalysis by the it-nitrogen 181 
(Fig. 1.32). 
Racemisation can be suppressed by 	
N i. 	 .N 
01 
blocking the ic-nitrogen, although most Fmoc 7. LH\X Fmoc 	X 
PGs are derivatised onto the t-nitrogen. 	1% 
Effective protection of the latter can still Nw 
operate through electronic and steric 
effects to reduce the basicity of the more 	Fig. 1.32 Racemisation of activated 
critical it-nitrogen e.g. via Trt 182. Groups His derivatives 
which actually protect this it-nitrogen are the most effective e.g. rert-butoxymethyl 
(Bum) 183 , but are expensive and require several steps to synthesise. 
After the chain assembly has been completed, these side-chain PGs must be 
removed, as well as the peptide being released from the resin. This may be achieved 
most conveniently by acidolysis. 
1.4.3. Removal of the Protecting Groups (PGs) 
Fmoc SPPS is designed such that relatively weak acids can be used in the 
deprotection of the side-chains (Fig. 1.33) and release of the peptide from the resin 
(Fig. 1.34). The ease of side-chain removal is largely governed by the stability of 
the carbocation formed 
W 





















Fig. 134 Cleavage of a peptide from the Wang linker using TFA 
PGs may thus be designed so that all are removable simultaneously or some can be 
made to be acid-stable for the purposes of post-synthesis modifications to certain 
a.a.'s (especially cysteine). The task of removing so many different PGs is 
problematical and the various stable carbocations formed can attack areas of high 
electron-density e.g. the indole group of Trp, the rings of Phe and Tyr, the sulphur 
atoms in Cys and Met, causing modifications if left unchecked. These deleterious 
side-reactions can however be suppressed to a great extent by the addition of 
scavengers to the cleavage mixture. When added in excess, these sacrificial 
compounds are selectively attacked by the released carbocations in preference to the 
a.a. side-chains, hence minimising these unwanted modifications. The role of 
scavengers and the classes used will be considered later. 
1.4.4. Problems in SPPS 
Although many of the original problems in SPPS have been solved by improved 
strategies, PGs, protocols etc., various others 80,184 are still a cause for concern and 
require brief consideration. 
All a.a.'s (except Gly) have a chiral a-carbon. In Nature, a.a.'s mostly exist as the L- 
isomer but partial conversion to the D-isomer may occur during chain assembly and 
much of SPPS strategy has been designed to counter racemisation by the control of 
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coupling conditions, PG strategies, etc. - control in DICIHOBt couplings and His 
protection have previously been mentioned. The mechanism of racemisation may be 
due to the formation of 4,5-dihydro-oxazole-5-ones (azlactones) 185 in activated a.a.'s 
(Fig. 1.35). In the presence of base, abstraction of the a—proton from the chiral 
centre gives a resonance-stabilised carbanion. Reprotonation can occur on either 
face to give either the L- or D-forms. To begin with, it was thought that urethane-
type NaPG's e.g. Z, Boc, Fmoc, did not form azlactones. 
- 0 	 0 H H 	
- 
R.I—(X 	R-\ 1 —X R..-r"%0 
Ny—H 	N/ 








Nj/ 	 N/ 	 N/ 
PG 	 PG 	 PG] 
Fig. 1.35 5(4H)Oxazolone formation leading to loss of chirality 
However, as such species have now been isolated 186, it may be that electron-
donation from these groups can suppress anion formation thus affording protection 
against racemisation. In the absence of base therefore, amide bond formation usually 
proceeds with very low levels of racemisation 187. One potential problem is loading 
the first a.a. onto the resin. This often requires the creation of an ester bond, 
catalysed by a base, usually 4-dimethylaminopyridine (DMJiP) 188. When loading 
with DICIDMAP, the levels of the base must be kept low (0.1 equiv. or less) 189 and 
reaction times short to avoid racemisation 190. Higher concentrations of DMAP may 
also cause partial removal of the Fmoc group191. 
1.4.4.2. Problems with chain assembly 
When a dipeptide on the resin is deprotected, the 
freed amino group may attack the peptide-resin ester 
bond. The resulting cyclic dipeptide (a 2,5-diketo-
piperazine, DKP) is released from the resin (Fig. 
1.36). This side-reaction is sequence-dependent 
(facilitated by Gly, Pro or D-a.a. residues) but may 
lessened by increasing the level of piperidine in the 
deprotection mixture in susceptible sequences 192. 
R i A H_ 
OR2 
+ HO4J 
Fig. 1.36 DKP formation 
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Difficulties with sequences of 'Asn/Gln-X' or 'Asp-X' where X=Gly, Ala, Ser or Thr, 
are well-known. Base-catalysed imide formation of Asn/Gln-X, especially where 
X=G1y 193 , results in either chain termination or the formation of a- or 3-aspartyl (or 
(x/y-glutamyl) peptides 193 . These reactions may occur when coupling using 
powerful activation methods. They may however largely be overcome by the choice 
of an appropriate PG. The situation for 'Asp-X' sequences is even more serious. 
Attack of the backbone nitrogen onto the side-chain carboxyl, promoted by base e.g. 
pipericline, results results in the formation of aspartimides 194 ' 195 (Fig. 1.37), with the 
subsequent loss of any PG that is present ¶) (:BUC H 
on the side-chain. This imide can open to 
give either the correct a- or incorrect J3-
aspartyl peptides. This reaction is further 
considered later in section 2.2.2. 
N çI - - 
	IN 
Fig. 1.37 Aspartimide formation 
1.4.4.3. Deletions 
Not all coupling reactions can be driven to completion, for a variety of reasons e.g. 
unavailability of the amine on the resin, solvation factors, steric factors. To combat 
this, covalent blocking of the free, unreacted amino termini of unacylated peptides is 
carried out, often via acetylation using acetic anhydride. The capped deletion 
peptides can usually be separated from the required sequence as they often have 
different physical characteristics. Apart from this 'deliberate' chain termination, 
some side reactions are known which act to prematurely halt or interrupt chain 
elongation: 
cyclisation of N-terminal Glu residues (when side-chains are left unprotected) 
to pyroglutamine. This can be catalysed by weak acids, e.g. a.a.'s or 
HOBt 196 , 
solvent or resin-bound aldehydes may form Schiffs bases with deprotected 
amine groups, thus preventing acylation 197, and 
in some long sequences, it has been reported that the Fmoc group may not be 
completely removed in some cases 198, even in the presence of high 
concentrations of pipendine hence may lead to deletions. 
Additionally, the sequence Asp-Pro is often acid-labile and can be cleaved by weak 
acids in the work-up 199 . 
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Overall, although most problems with SPPS have been more or less solved, some or 
all of the above may combine in certain circumstances to thwart even the best 
planned and executed synthesis. 
1.5. CYSTEINE AND DISULPHLDES IN PEFTIDES AND SPPS 
1.5.1. General 
The thiol group of cysteine is probably the most reactive of any a.a. side-chain. At 
slightly alkaline pH, it ionises to form the strongly nucleophilic thiolate anion. It can 
react with a wide variety of species e.g. alkyl halides and metal ions, to give stable 
compounds. Complexes with metals ions like mercury and silver are common and 
can be used to titrate the number of thiols present in a peptide/protein 200. The 
sulphur atom may exist in a number of oxidation states and thiols are easily oxidised 
by air, a reaction catalysed by the presence of trace amounts of certain metal ions, 
e.g. CU2 , Fe3 . A disulphide is the usual product of such oxidation processes (Fig. 
1.38). 
+ ' 2 02 	 + 
H II 	0 	H 	0 
DISULPRDE [ 	] 2 
[Cyteine)2 
Fig. 138 Cysteine may form a disulphide in the presence 
of an appropriate electron acceptor 
Disulphide bonds often occur between cysteine residues in peptides and proteins, 
being introduced in vivo as a post-translational modification. The bond is greatly 
affected by the particular conformation of the protein backbone: cysteines must have 
their aC-atoms within 4-9A. for a disulphide to form between them 201 . Disulphides 
appear almost exclusively in extracellular proteins, where their role is probably in 
providing additional stability. Moreover, in some proteins e.g. insulin, disulphides 
act to stabilise a relatively unstable folded conformation. Disulphides can be 
converted back to their original thiols groups under strongly reducing conditions and 
at alkaline pH, where thiol/disuiphide interchange is greatest 202. 
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1.5.2. Cysteine Protecting Groups 
In SPPS, protection of Cys is obviously required to prevent: 
oxidation to thiols during assembly. 
acylation (as thiol function is nucleophilic). 
The fact that some peptides/proteins require the presence of a disulphide bond 
whereas others need only the free thiol, adds another dimension to cysteine 
protection strategies. Many groups and oxidation methods have been suggested, 
although few have found common usage in Fmoc SPPS. The following Table 1.39 
summarises most of the Cys PG's used. Methods of preparation (for a general 
review of these, see ref. 203) and removal procedures are included. Codes for the 
removal strategies are given below. Some of these procedures lead directly to the 
formation of disulphide bonds from protected species. The PG's and various 
methods for forming disulphides as they relate to this work will be discussed in more 
detail later 
Protecting 
STRUCTURE PREPARATION REMOVAL 
Prep 
Group  Ref.  of Use  
BF 
pMe.BzI (}CH3 pMeBzlBr S/S[FFA 204 80  
11713+  
HE D[FA 
80 pMeOBzI OC}13 pMeOBzICl S/S/TFA 205 
AgfHgfFl  217 
Fcm.OH 
+ Fan TFA 206 206 
TFA 




BF 3.OEt2 AgJHg/T1  216 
0 Ag/Hg[Fl 212 
Acm 
Acm.OH 
+ S/S[FA 208 214 
TFA 12  215 
—C f- 3] TFMSA 212 Rut I sobutylene Hg/Ti 209 3 
S/S/TFA  215 
SBu t  b—S—C fCH3] Bu'SH 
RSH 
210 213- Phosphines 215 
RSH 218 Npys s..5) Npys-Cl 211 
Phosphines 219 NO2  
Table 1.39 Various cysteine PGs useful in the Fmoc strategy 
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S/S/TFA 	Various silyl chloride/sulphoxide/TFA systems 220 '221 . 
DITFA DMSO/TFA system222 . 
Ag/Hg/Ti 	Silver (Ag)223 '224 , Mercury (Hg24 )208.209, and Thallium ('fl3+)225 
or Hg/TI salts/various solvents. 
4 	Iodine in various solvents 216. 
RSH Various reducing agents e.g. tri-n-butyl-phosphine 213 , f3- 
mercaptoethan01 214, (for Npys, this may be the thiol group of 
another cysteine residue) 219 . 
1.6. PROTEIN SYNTHESIS: LYSOZYME 
1.6.1. General: Protein Synthesis 
Stepwise SPPS has been successfully applied to the preparation of some small 
proteins in the region of 50-100 a.a.'s. e.g. HIV-1 protease (99 residues - using Boc 
strategy)226  and ubiquitin (76 a.a.'s - Fmoc strategy) 227 . The fact that both synthetic 
proteins were able to be crystallised and the X-ray structures determined 228 '229, 
indicates that products of the highest purity had been obtained. To realise such 
syntheses requires much initial investigation into optimising coupling steps, 
protection strategies, deprotection and cleavage protocols and extensive purification. 
Additionally, actually determining whether or not synthesis of the target protein has 
been achieved, necessitates using a battery of techniques e.g. sequencing, mass 
spectrometry, isoelectric focussing etc., few of which can distinguish whether or not 
minor changes to the synthetic protein had occurred, for instance, a side-chain PG 
may still be present or may have modified another residue. Despite these hurdles, 
the assembly of even larger, more complex proteins has been attempted. Several 
workers have used a convergent strategy, in which protected segments of the protein 
are first assembled either in solution 230 or by SPPS (then released as the protected 
segment231). These are then subsequently coupled in the solution phase or on a 
solid-phase support 232 . Whilst theoretically this should result in a purer final 
product (if the intermediate stages can be purified), in practice the frequent poor 
solubility of these protected fragments, and problems of C-terminal racemisation 
during coupling, often limit this approach. More successful may be couplings using 
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minimal side-chain protection 233 or perhaps using enzymes 91 . Examples of large 
peptides/proteins made by chemical methods are shown in Table 1.40. 
Protein NO. A.A. Strategy Comments Ref. 
Interleukin-3 140 SWIBoc 
Purification problems 234  
unresolved  
Bovine 124 Frag/Boc 
Four disulphides. Full enzymic 235 
Pancreatic RNase  activity claimed 
Apocytochrome 
104 Frag/Boc 
Coupled three frag. with C- 
236 
C  terminal Gly-thiocarboxyls  
BP Trypsin 
58 FragfBoc 
Three disulphides. Solid-phase 237 Inhibitor  frag. syn., frag. linked in soin.  
Human TGFa 53 SW/Fmoc Three disulphides 238 
Human 3CG 74 SW/Fmoc 
9.5% yield. Continuous flow 239 
methodologyused  
RET 79 SW/Fmoc Continuous flow methodology 240 
used  
(Notes; SW = stepwise Frag. = fragment) 
Table 1.40 Examples of chemical syntheses of proteins 
Multi-cysteine proteins with more than 100 residues have provided targets which 
presently set the upper limits for chemical synthesis. Perhaps prompted by the 
display that the reduced forms of the proteins can refold into biologically active 
species241 '242, several attempts have been made to chemically produce the enzymes 
Bovine Pancreatic Ribonuclease 235 '243 and Hen Egg White Lysozyme (HL). 
Although synthesis of the ribonuclease appears to have been accomplished 235 , two 
attempts at lysozyme analogues have not produced successful outcomes 24 '245 . 
1.6.2. Structure of Lysozyme 
HL is one of the most widely studied enzymes. It was the first to have its structure 
determined by X-ray crystallography 246 . This structure, in fact, along with those of 
complexes with various small saccharides, enabled a theory of its catalysis to be 
forwarded247 . The residues G1u35 and Asp52 appear to be directly involved but 
several others, like the Trp's at 62,63 and 108, are important in substrate binding. 
This mechanism appears as the standard example of enzyme catalysis in most 
biochemistry texts 248 . Lysozyme derives its name from its capacity to destroy 
certain bacteria by cleaving the polysaccharide components of their cell walls, 




The enzyme is relatively small, 129 a.a.'s long (14.6 kDal.) with four disulphides, 
linking 6/127, 30/115, 64/80 and 76/94249,  and is not greatly conserved between 
species (some have only two or three disulphides). The structure has become the 
model for extensive work on protein folding, with the classic hydrophobic core and 
disulphides whose interchanging during the folding process has enabled intermediate 
stages to be trapped 250'251 . The study of the renaturation of reduced, denatured 
lysozyme using differing concentrations of oxidised/reduced glutathione (see section 
2.7.6.1) to yield up to 85% of the original activity, has given us a general method for 
disulphide formation in peptides/proteins 242. It may also provide a way to fold a 
chemically synthesised lysozyme. The enzymic activity regained can easily be 
quantified by a sensitive spectroscopic assay, where the regenerated protein can 
clarify a suspension of Micrococcus lysodeikricus cells252, the transmittance increase 
being directly proportional to the enzyme activity present. 
How the initial stages of an attempt at a total HL synthesis were carried out, and 
their potential importance in aiding work towards the total synthesis of a protein like 
NGF, will be discussed in detail later (see section 2.10). 
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CHAPTER TWO: DISCUSSION 
2.1. RATIONALE AND APPROACH TO THE INVESTIGATION 
2.1.1. General 
It is clear that NGF exerts its biological effects through binding to various cell 
surface receptors 253-255 , in common with all other growth factors. What was not 
apparent at the commencement of this study, was which areas on the NGF molecule 
were actually responsible for triggering these effects. Knowledge of which a.a.'s are 
important for binding tothe NGF receptor, and essential for this biological activity, 
should provide clues to NGF's mechanism of action. Perhaps more importantly, 
agonists or antagonists could be discovered from such facts. These would be 
potentially useful in clinical/research studies as mentioned earlier. For example, 
agonists which imitated NGF's actions could be useful as potential drugs for treating 
neuropathies such as AD, by enabling the damaged cholinergic neurons in the CNS 
to survive or perhaps even regenerate. This could ameliorate the chronic memory 
losses associated with such conditions. Alternatively, as one study has suggested 
that NGF may actually potentiate the toxic -effects of amyloid (the major constituent 
of the neural plaques seen in AD patients) 256 , it may turn out that antagonists may 
also be helpful. No major systematic study of the protein has been undertaken and 
little conclusive structure-activity relationship (SAR) data has appeared previously in 
the literature. 
The few studies that had been reported relied on altering murine NGF by the specific 
chemical modification of certain residues. The results are summarised in Table 2.1. 
Residue(s) Chemical 
modification 




Lys 25,3Z34.57.74.89.95.115 Dimethylsuberimidate None/None 257 
Lys .3Zl.l4$8..'S Acetylation None/None 258 
Lys.3Z3 l.l4$S.95." 5 Succinylation None/None 258 
Arg50'59 •'°°•'°3114 "8 1 ,2-cyclohexanedione Inactivates* 258 
Tyr52-79 Nitration/lodination None/None 259 
Trp2' N-bromosuccinimide Large reduction/LR 259,260 
Trp21'9 N-bromosuccinimide Small reduction/SR 259,260 
Disuiphides Reduction I 	Inactivates 261 
*evidence suggests that this is due to structural changes rather than specific modifications. 
Table 2.1 Effects of chemical modifications on mouse NGF 
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These may be difficult to interpret as certain modified residues, which are not 
themselves necessary for binding or biological activity, may nevertheless disrupt the 
secondary/tertiary 262 structure hence will alter NGF's properties. More sophisticated 
approaches had to be utilised if sensible results were to be obtained and progress 
made. 
2.1.2. Method of Investigation 
It was decided to probe the biologically relevant areas in NGF by synthesising 
fragments from across the entire protein and testing these in several assays against 
authentic NGF, in the hope that potential 'active-site' sequences would be discovered 
which would give receptor binding/biological activity similar to the native protein. 
At the commencement of this study, the relationship between receptor binding (to 
the p75N)  and the biological effects caused by this binding, were still unclear. 
Hence assays were to be carried out which would determine the degree of binding to 
p75NGFR alone: it was thought that searching for agonist activity (i.e. receptor binding 
with the elicitation of a biological response) would be too complex at the early stages 
of our work. There is some precedence for this approach; it has been shown that, at 
relatively high concentrations (.tM or mM), peptide fragments containing an active 
region blocked the biological activity of the protein fibronectin 263 and mimicked the 
activity of basic fibroblast growth factor 264. In fact shortly after our study had 
commenced, a group published results on NGF based on a similar plan 265 . 
The potential value of using synthetic peptides can also be assessed by considering 
earlier published work in the NGF field. It was claimed that a fragment from a 
tryptic digest of murine NGF showed activity (as judged by neurite outgrowth from 
a chick sensory ganglia assay) which was about one hundred times more effective 
than intact NGF on a molar basis 266. This fragment was found to consist of residues 
10-25175-88 linked by the disulphide between 15-80, which is present in the native 
protein. Later this same research group also alleged that the sequence 58-59/60- 
69/104-114,  again joined by disulphides, could partially prevent native NGF from 
binding to an antibody (raised to NGF) in a competitive assay 7. To clarify the 
situation, the earlier peptide was chemically synthesised and shown to have none of 
the said activity 268. The original assertion has since been further refuted, being 
found to be due to trace amounts of incompletely digested NGF 269. Thus the 
dangers of obtaining peptides from digests are clear, as is the value of synthetic 
peptides whose purity can be assured. 
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The next step was to decide exactly which sequences should be made. Several 
avenues had previously been investigated. Some work had been carried out on 
raising antibodies (ABs) to hydrophilic regions of NGF 35 . Highly hydrophilic areas 
(determined via Hopp and Woods plots 270) often lie on the surface of proteins 
(hence represent antigenic epitopes) and may be involved in protein:receptor 
interactions. Interestingly, none of the NGF peptides (residues 23-35, 58-67, 87-97 
and 111-120 in rat; 23-35, 55-70 and 109-118 in chicken) 35 used in that study to 
raise the ABs, mimicked NGF activity nor did the ABs themselves block NOF 
binding. Alternatively, other investigators had begun to look at the effect of site-
directed mutagenesis on the protein 271 . Here, molecular biology techniques were 
used to change individual a.a.'s in the protein to see what effects (if any) these had 
on activity or receptor binding. The limitation of this approach may be in initially 
choosing the appropriate target residues to alter and that, like the chemical 
modifications, a change in an a.a. which is not essential for binding may still cause 
destabilisation of the protein structure, often meaning that the mutant protein cannot 
even be isolated. Having considered what had already been done, we decided to 
adopt a more general and fundamental approach. 
As previously stated, NGF is highly conserved over all of the species so far 
sequenced. It has been shown that the N-terminal octapeptide is not required for 
activity272 , thus comparing the remainder of the sequences for human 273, bovine274 , 
mouse34275 and chicken276  NGF's, several areas containing long stretches of 
completely conserved residues can be identified. Presumably, these should be 
structurally and/or functionally significant. Accordingly the conserved sequences of 
five residues or more were considered as initial synthetic targets, as summarised in 
Fig. 2.2. Several peptides containing non-conserved residues were also synthesised 
to overlap peptides from these areas as will be discussed later. 
NGF sequence 1 - -----10------20----- -30----- -40------50----- -60 
Conserved regions 	 10 	 17 	21 	 36 	41 46 	50 	 60 
NGF sequence 61 ------ -70 ------ -80 ------ 90------100-----jiO ------ 120 
Conserved regions 	
66 	 7274 	 91 	95 	 116 
Fig. 2.2 Conserved regions across human, bovine, mouse 
and chicken NGFs, which were to be synthesised 
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2.1.3. Potential Agonist/Antagonist Molecules from Peptide Leads 
There are few examples of peptide analogues of peptide/protein fragments being 
used directly as drugs: LHRH has been modified to produce anti-cancer compounds 
e.g. Zoladex (Id)277 , and gastrin analogues (e.g. Pentagastrin) are used for the 
diagnostic stimulation of gastric acid secretion 278 . Increasingly however, synthetic 
peptides are being used as a method of producing 'leads' in drug discovery 
programmes. This is witnessed by the explosion in methods for producing multiple 
peptides in the minimum time as a way of speeding an initial screening process e.g. 
simultaneous multiple syntheses on polystyrene pms 279 , on beads 80, on cover-
slips281 , and even presented on the surface of recombinant bacteriophage 2. 
Central to these schemes is, of course, the hope that some linear sequence can be 
found which will give receptor binding and there are many successful examples of 
this approach. 
One important difference, between a native protein and a peptide binder, which must 
be borne in mind, is how they interact with their receptor. Peptides below around 
forty residues tend to have a large number of conformers in dynamic equilibrium 
when in solution. However, these peptides tend to adopt more defined 
conformations when they bind to their receptors, which themselves often have pre-
defined structures: their fit to the receptor is thus 'induced' so that they form 
complementary conformations to those of their respective receptors. On the other 
hand, proteins tend to have inherently stable three-dimensional structures. In the 
interaction with its receptor therefore, the native protein has the advantage, over a 
peptide, of having a sufficiently large area to enable intramolecular, noncovalent 
interactions to occur and hence to overcome the unfavourable conformational 
entropy associated with adopting a defined three-dimensional structure. A 
consequence of this is that a linear fragment (from a native protein) which binds to 
the receptor, is unlikely to have any innate structure itself (with some exceptions 283). 
Thus if any structural information is to be obtained, it will be necessary to make 
analogues of this peptide binder which may lock the molecule into its biologically 
active conformation, and, in restricting the population of conformers in solution, 
may enable its structural elucidation by, for example, nuclear magnetic resonance 
(N.M.R.). Several illustrations of this approach have been reported 284 '285 . 
Before a conformationally restricted analogue of a peptide can be made, it is 
important to first delineate which side-chains may be crucial for activity. This can 
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be done by making progressively shorter analogues of the original parent peptide 
until the minimum sequence, that still retains the degree of receptor binding or 
biological activity, is reached. From here, the side-chains can be varied to determine 
the significance of charge, steric size, hydrophobicity, chirality etc., at each (or at a 
specific) position. The arrangement of side-chains involved in receptor binding can 
be envisioned on the basis of these results and conformationally restrained analogues 
could be made to test these theories. Such analogues could consist of 
macrocyclisations of the peptide chain (N-to-C-terminus) or between side-chains 
(e.g. Asp/Glu to Lys) or further by the introduction of alkyl groups to restrict the 
movement of the peptide backbone. Often these constrictions may improve the 
degree of receptor binding due to the smaller decrease in entropy associated with its 
binding compared to the unstrained parent peptide. An outline for the approach to 





Antibody binding studies 
F synthesise peptide fragments 
Determine minimum sequence 
Analogues to investigatee I Constrain conformation via II Determine structure 
I chirality,hydrophobicity,  J 	Aib substitutions, cyclisations 	by N. R. charge. etc.  
\/ 
i Concensus sequence as template I 
for possible non-peptide binders 
Fig. 2.3 Generalised protein 'active-sequence' investigation strategy 
2.2. THE CHEMICAL SYNTHESIS OF NGF FRAGMENTS 
2.2.1. Types of Resin used in the Syntheses 
The standard resin used for most of the syntheses was the Wang resin 286'287. This is 
a 4-(hydroxymethyl)phenoxymethyl derivative of a copolymer of styrene cross- 
linked with 1% DVB (Fig. 2.4). The C-terminal Fmoc-a.a. was coupled to this, with 
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SA activation, to form an ester bond in a reaction catalysed by a small amount of 
DMAP (<0.1 equiv.) (Fig. 2.4). Alternatively, a type of resin developed in this 









Fig. 2.4 Catalytic action of DMAP in loading the Wang resin 
The 2-copoly(styrene- 1 %-divinylbenzene)methoxy-5-aminodibenzocycloheptadiene 
resin288 (referred to as the dibenzosuberyl resin) (Fig.  2.5) could be derivatised 
using the standard SA/AE couplings to form an amide linkage. An intermediate in 
the preparation of this resin was modified to enable the formation of a heptylamide 
peptide (NGF 100-1 15-NH-heptyl). The heptadiene- 
5-one (1) had previously been prepared289 (Fig. 2.6). 	
NH2 
This was reacted with heptylamine in the presence of cc 0 	H] titanium (IV) chloridelDCM to yield the imine (2). 
Monitoring the reaction by IR showed the gradual 	Fig. 2.5 Dibenzosuberyl 
disappearance of the ketone band at 1640 cm -1 over a resin 
2.5 h. period. corporation of the heptylamine was confirmed by nitrogen analysis. 
The imine structure on the resin was assigned on the basis of previously reported 
analogous reactions 290. 







N - (CH2)6 - CH, 











Fig. 2.6 Scheme for synthesis of the heptylamine resin 
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The imine/resin was reduced to the secondary amine (3), characterised by the 
appearance of a broad band in the IR at around 3400 cm -1 . The coupling of the first 
residue, Fmoc-Lys(Boc)-OH, required extended reaction times and large excesses of 
SA. Presumably, steric factors made this reaction unfavourable: previously, only 
glycine had been coupled to the resin using acid chloride activation 289; The 
derivatised resin (4) was used in the assembly of the required peptide with no further 
difficulties. 
Whichever resin was used, the amount of derivatisation (loading) was assessed by 
measuring the amount of dibenzofulvene adduct released during a sample 20% 
piperidine/DMF deprotection under standard conditions 291 (see section 2.2.3). 
Loadings were generally between 0.5-0.6 mmol/g resin. For longer syntheses (>25 
a.a.'s), a lower loading was used (effected by decreasing the derivatisation reaction 
time from two to one h.) as recommended by Kent 91 , to lessen possible steric effects 
(which may interfere with coupling reactions) between the growing chains. 
2.2.2. Manual and Automatic Methods of Peptide Assembly 
The NGF peptides were assembled by one of two methods; manual or automatic, 
both employing the same principles. The apparatus for manual assembly and its 
operation are described in Appendix A. Basically, the resin was suspended in DMF 
inside a cylindrical glass vessel fitted with a fine sintered-glass frit. Mixing of the 
resin/reagents was by nitrogen, introduced through a three-way tap. Reagents were 
added via wash-bottles or pipettes and could be drained from the vessel into a lower 
waste reservoir under slight vacuum. The cycles for Fmoc-deprotection and 
coupling are given in sections 3.2.3 and 3.2.4. Each coupling was by a single SA, 
which was usually sufficient; however if the monitoring tests (section 2.2.3) showed 
that acylation was incomplete, a further AE acylation was carried out, sometimes 
using in situ activation by BOP or HBTU in difficult cases. Changing the coupling 
method often produced complete acylations, perhaps due to AE being less sterically 
hindered (although also less reactive) than SA. If a coupling was incomplete after 
three attempts, the peptide/resin was acetylated with acetic anhydride. Usually the 
resulting truncated, acetylated peptides could be easily separated from the target 
peptides. 
Automatic assembly was carried out on an Applied Biosystems 430A peptide 
synthesizer. The cycles of washing, deprotection, coupling and capping were similar 
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to those used in manual assembly. 	Here, deprotection was with batches of 20% 
piperidine/DMF for a total of twelve minutes (5, 3, 3 and 1 mm.). It was later found 
that this could be reduced to four minutes (3 and 1 mm.) without any adverse effects. 
This was prudent as extended exposure to piperidine 
may lead to the formation of 3-aspartyl peptides 195 . H 	0 :Buc 
This is usually not considered to be a significant 
problem when using the Asp(OBut) residue but the LJrOBzI 
side-reaction was emphasised in the assembly of NGF o \ 
100-114 [Asp(OBzl) 105 , Pro 091 dValb0 , Cys(Acm) bo$ .hbo]. 
The terminal Fmoc group had been inadvertently left on 
N 
the peptide; this was not discovered until after the TFA 
cleavage (the OBzl group is stable to TFA and also H 	0 /o 0 + - OB 
remained on the peptide). 	An attempt was made to N OH 
remove the Fmoc group using 20% piperidine/DMF for 
two minutes. 	This led to almost 100% conversion to g 
the 	-aspartyl form (Fig. 2.7), with loss of the benzyl Aq=yl pptj j 
protecting group (using 15% piperidinelDMF for 1 mm. Fig. 2.7 J3-Aspartyl 
led to 35% conversion). The suppression of this side- formation when using the 
Asp(OBzl) PG 
reaction remains a challenge in peptide chemistry. 
The coupling reactions used were double-couple cycles, SA then AE. If triple-
coupling was required, an additional AE was used. Some residues were incorporated 
as their AE only, due to previously mentioned problems e.g. Arg(Pmc), His, Asn and 
Gin. The full cycles are considered in section 3.2. Table 2.8a and 2.8b compare the 
two methods of assembly. 
Method 	 ADVANTAGES 
Manual Flexible-changes in methodology e.g. different activation 
methods, increasing coupling times, are easily incorporated. 
Real-time monitoring of the acylation and coupling steps is 
possible and the operator can intervene as required. 
Automatic Continuous assembly thus faster, especially for longer sequences. 
Controlled amounts of reagents, reaction times etc. are used thus 
the assembly may be standardised and is usually reproducible. 
Fig. 2.8a Comparison of Manual and Automatic assembly methods 
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Method 	 LIMITATIONS 
Manual Labour-intensive and generally slow. 
Assembly is not continuous. 
Resin samples must be removed for testing thus reducing the 
yield, especially in longer syntheses. 
Generally impractical for peptides> 30 residues. 
Requires exposure of operator to chemicals. 
Automatic Inflexible-usually conditions and methods must be assigned at the 
start of the assembly. 
Monitoring is retrospective i.e. poor couplings are only detected 
after that residue has been deprotected. This necessitates that 
double-couple and capping cycles must be always be used whether 
needed or not. 
All reagents must be completely soluble in the solvents used 
(DMF or dioxan/DMF). 
Fig. 2.8b Comparison of Manual and Automatic assembly methods 
2.2.3. Monitoring 
In manual assembly, the extent of the acylation reaction could be checked by simple 
colour tests, which detected free amine functions and hence indicated incomplete 
couplings. In the Kaiser test292, a sample of beads would show a blue colouration 
(Ruhemann's purple) due to a complex between any free amine and the ninhydrin 
reagent used. A qualitative assessment of the bead/solution colour (aided by 
experience) determined whether complete acylation had occurred. The test shows 
positive if the coupling is less than 99% complete. To check, a second test using 
2,4,6-trinitrobenzenesulphonic acid (TN aS)293 was used, a positive test here being 
indicated by a red colouration on the resin beads. Quantitative ninhydrin tests 294 can 
also be used here but are laborious to perform. 
Automatic assembly using synthesizers has removed much of the routine involved in 
manual SPPS. With a new generation of synthesizers being evolved that can 
determine in 'real-time' whether incomplete acylation has occurred during assembly, 
the realisation of Merrifield's hope of truly 'automated' peptide synthesis may soon 
be realised. Here, a non-invasive, monitoring method was used which avoided the 
removal and destruction of resin samples (as in manual assembly) and, more 
importantly, enabled some 'post-coupling' information to be obtained. When the 
Fmoc-resin is treated with piperidine during the deprotection step, a dibenzofulvene 
species is released. The excess piperidine present adds to this olefin to give an 
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adduct (Fig. 2.9). This adduct has UV absorption maxima at 267, 290 and 301 
nm' 59 . 
(ö) _ 	0 
) 
I 
HN 	 0 0 IIND 9 D  
Fig. 2.9 Generation of the chromophoric dibenzofulvene adduct 
Monitoring the UV absorbance at 302 nm allows a semi-quantitative determination 
of the deprotection efficiency and hence the level of incorporation of the preceding 
residue. By comparison to the integral for the first deprotection of the original 
derivatised resin, subsequent falls in a.a. incorporation (representing poor acylations) 
could be observed. This proved useful in deciding whether or not to continue a 
particular assembly and also in optimising certain syntheses. Often some predictive 
information was obtained; the integral trace would rise (sometimes even above 
100%) one or two residues before a fall in coupling efficiency. This was thought to 
be due to solvent effects caused by resin desolvation. Poor coupling sequences were 
also apparent when the peak integral for the second (and third or fourth) deprotection 
washes began to appear for particular residues (implying a slow deprotection profile 
for those residues). These signs enabled the next residue to be triple-coupled or 
checked by manual colour tests. Some reports have suggested that the addition of 
low concentrations of I ,8-diazabicyclo(5.4.0)undec-7-ene (DBU) to the deprotection 
mixture may increase the speed of Fmoc removal in difficult cases 295 . Examples of 
monitoring traces are shown in Fig. 2.10 to illustrate some of the above points. 
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Progress of assembly 
Fig. 2.10 Deprotection profiles of NGF 25-54 assembly 
and some NGF 100-116 analogues 
Fig. 2.10 shows drops in incorporation in the assembly of NGF 25-54, and compares 
the monitoring traces for four NGF 100-116 analogues (NT-3 100-116 can be 
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considered to be an NGF analogue). A fall in coupling was predicted for NT-3 by a 
rise in the trace at residue 109 (point 7 on the trace). For the Ser' 07 , Arg"6 analogue, 
although a similar sequence to NT-3, the same fall in apparent incorporation did not 
occur to the same extent and the trace actually rose again towards the end of the 
assembly. Such coupling differences were probably due to the steric/hydrophobic 
effects of using the trityl group on Cys for NT-3 compared to the smaller, more 
hydrophilic Acm group for the other analogue. Substituting some of the residues in 
these two peptides for glycine led to near perfect assemblies (as seen in the traces for 
the Gly analogues). 
2.2.4. Peptide Solvation 
The solvation of the peptide/resin was seen to be a problem in manual assembly of 
some of the peptides from the C-terminal region of NGF. Effective solvation of the 
cross-linked polystyrene resin should leave the peptide chains as accessible as if they 
were in free solution and, under proper solvating conditions, it has been observed 
that no decrease in synthetic efficiency may occur up to residue number sixty 296. 
Thus the swelling of the peptide/resin should never (theoretically at least) limit a.a. 
couplings as long as the correct solvating conditions exist. Using polar solvents such 
as DMF, help the solvation process and aid the solubility of Fmoc-a.a.'s. However, 
in these syntheses, desolvation was observed as a dramatic decrease in the volume of 
the peptide/resin bed in the bubbler reaction vessel. This occurred most frequently 
when the peptide was eight or nine residues long, resulting in slow and incomplete 
couplings. The fall in incorporation was seen to be sequence-dependent but was 
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Fig. 2.11 Sequence-dependent falls in incorporation in NGF peptides 
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Fig. 2.11 shows that triple-coupling Asp' 06 and Thr107 (residue no. 9 and 10) led to 
improved incorporations of these residues in the assembly of NGF 101-115 and 100-
114 compared to 100-115. It has been suggested that such effects may be due to 3-
sheet formation on the resin297 '298 . When this occurred, the addition of 20% 
hexafluoro-2-propanol (HFIP) in 50% dioxan/DMF in extended wash cycles 
improved the solvation as previously observed 299 and aided difficult couplings 
during the manual assembly of some of the C-terminal peptides. 
2.2.5. Acidolysis of the NGF Peptides 
The removal of the side-chain PG's and cleavage of the resin-bound peptides was 
carried out using TFA. This results in the release of highly reactive carbonium ions, 
derived from these PG's e.g. the But  cation (released from Serlrhr/Tyr residues). 
This is held in solution as its trifluoroacetate salt, as opposed to converting to 
isobutylene and being lost as a gaseous by-product, providing a soluble source of 
such carbonium ions 3 . These stable canons can cause the modification of sensitive 
a.a. residues (as mentioned in section 1.4.3) To prevent these side-reactions, various 
nucleophilic scavengers 301 '302, which trap these cations, were added in excess to the 
TFA solution. These are then selectively attacked in' preference to the a.a. side-
chains. Examples of the scavengers used are given in Table 2.12. 
Scavenger Structure Comments 
OCH3 Scavenges tert-butyl 
Anisole r' trifluoroacetate (Bu'TFA). Poor 
1.J scavenger of But  carbonium ions. 
Ethyl methyl sulphide CH3-S cH2 -CH3 Prevents Met oxidation. 
(EMS)  Scavenges tBuTFA. 
1 ,2-ethanedithiol HSCH2 CH1SH 
Best ButTFA scavenger. 
Scavenges Trt. Prevents Tip 
(EDT) alkylation by Pmc group. With 
water, prevents Tip t-butylation. 
Water H-0-11 Good for Bu'/Boc scavenging. 
Essential for Pmc scavenging. 
OH 
Phenol Scavenges ButTFA. 
SCH3 Accelerates Pmc deprotection. 
Thioanisole Partially deprotects Cys(Acm) and 
(SBut). Prevents Met oxidation 
Table 2.12 Scavengers used in acidolytic cleavages 
(after ref. 302) 
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The optimum cleavage conditions were dependant on which residues were present, 
their number and sequence, the side-chain PG's used and the a.a. attached to the 
resin. Small-scale trial reactions using small amounts of resin were carried out, 
varying the reaction time and combination of scavengers in some cases, to optimise 
the cleavage conditions for each peptide. A general mixture of 3% water, 3% EDT 
and 2% (wt./vol.) phenol in TFA was found to be useful in many cases. Similar 
compositions have previously been reported to be applicable to a wide variety of 
peptides303. Thioanisole, although reported to speed the removal of Pmc from 
Arg 179, was omitted from the cleavages of NGF peptides containing Cys(Acm) or 
Cys (SBut) as it causes the partial removal of these PG's 214. It was observed that the 
inclusion of EDT did not remove the SBut group from Cys as had been previously 
reported304. Scavengers were observed to act most efficiently when used from 
freshly opened bottles. 
Tryptophan may be àlkylated on the indole ring by a various species (e.g. Pmc) in 
the absence of the correct scavengers 302 (Fig. 2.13a). However, in the presence of 
EDT and water as scavengers, this side-reaction was not observed in any of the Trp-
containing NGF peptides (with the exception of NT-3 100-116). Cleavages were 
carried out under nitrogen to minimise any possible acid-catalysed oxidation of the 
Trp residues (Fig. 2.13b). 
B 	 B 
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b. 07N 	NO 	 N H 10 O NH2 
H Indolyl Oxyindolyt 	 0 	 Kynureninyl 
Formyl.kyaureninyl 
Figs. 2.13a&b. Alkylation and oxidation of tryptophan 
The presence of Trp in the 53 a.a. NGF peptide did cause severe problems in the 
formation of the disulphide bridges (see section 2.7.7). Fmoc-Trp(Boc) 305 was used 
in the second HL assembly. On cleavage, a relatively stable N"-carboxy-indole 
intermediate is said to form from this protecting group. This appeared to provide 
protection against the tryptophan damage that occurred on extended acidolysis; such 
damage was observed in the first assembly of HL where Trp was unprotected. 
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After cleavage for the appropriate length of time, the free peptide was obtained by 
evaporation of the TFA solution then precipitation of the peptide with excess ice-
cold ether. The crude peptide was further dissolved in either aqueous acidic or basic 
solution, extracted from ether (to remove the scavengers) then lyophilised. HPLC 







Peptide %CH 3CN/min.; Rt Peptide %CH3CN/min.; Rt 
A 	25-54 5-65130; 21.5 mm. E: 100-116 Gly analogue 10-90/30; 21.8 mm. 
B: 100-116G' 11-113  10-50/30; 15.8 mm. 100-115 10-75130; 15.0 mm. 
C: 100-116 S, R" 6  5-95/30; 20.2 mm. 100-114 5-95130; 22.0 mm. 
D : NT-3 100-116 10-90/30; 12.2 mm. 
Fig. 2.14 IJPLC traces of some crude NGF peptides 
2.2.6. Purification Techniques 
2.2.6.1. General 
Initially, the products from SPPS will be impure, as would be expected for any 
technique where multiple reactions were carried out without the isolation and 
purification of intermediate stages. The crude peptide will generally contain a 
mixture of some or all of the following: 
Solvents, scavengers and reagents. 
Terminated peptides (acetylated or truncated by other means). 
Partially protected peptides. 
Modified or rearranged peptides (caused during acidolysis). 





Whilst 1-3 can usually be separated from the required peptide, examples of 4 and 5 
will often have physicochemical properties which are similar to the target sequence. 
These problems can be expected to become more significant with increasing peptide 
length. Additionally, purification often becomes disproportionately more difficult as 
the crude product becomes more impure, generally due to solubility problems. In 
practice, if a crude peptide is not soluble in largely aqueous systems, purification 
may not be possible at all. Considering these points, the value of optimising the 
assembly and cleavage protocols for a peptide cannot be stated highly enough. 
Crude mixtures can be separated by various methods based on: 
Molecular size - gel filtration, 
Hydrophobicity - HPLC (various forms), 
Charge - ion exchange, 
Affinity techniques. 
2.2.6.2. Gel Filtration (Size-exclusion chromatography 
This technique fractionates peptide or protein mixtures on the basis of molecular size 
(strictly hydrodynamic volume). Peptides/proteins partition themselves between the 
mobile phase (eluent, an acetic acid solution was used here) and the stationary phase, 
the liquid inside a bead-formed polysaccharide gel matrix. The partitioning depends 
on the rate of access into the small pores on the beads; large peptides are excluded 
from the internal volume and thus emerge first from the column, whereas smaller 
peptides, which can gain access to the pores, emerge later. The fact that components 
do not bind to the matrix limits the resolution of the technique so it is generally only 
useful for group separation. Various media are commercially available, differing in 
structure, degree of cross-linking (hence fractionation range) and robustness. The 
media used are summarised in Table 2.15. 
Media Uses 
Sephadex G25  to desalt crude peptide mixtures 
 to separate dithiothreitol (DTF) from peptide in 
Cys side-chain deprotection strategies 
Sephadex G50  initial purification of NGF 53-mer peptide 
 initial purification of HL 
Sephadex 075 1. additional purification of HL 
Table 2.15 Uses of Gel Filtration media 
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The principle of separation here relies on the hydrophobic interaction between the 
a.a. side-chains of the component peptides in a crude mixture, and silica-bound 
octyl- (C8) or octadecyl- (C 18) alkyl chains. The crude mixture is applied to a silica 
column under aqueous conditions whereupon the components reversibly 'bind' to the 
silica. These can then be selectively and specifically eluted by increasing the 
percentage of organic modifier (usually acetonitrile) in the aqueous mobile phase; 
hydrophilic components eluting early, more hydrophobic components being retained 
until higher proportions of acetonitrile are reached. With small peptides, the 
processes of partition and adsorption between the mobile and stationary phases 
produce the separation, whereas for large polypeptides/proteins, an adsorption-
displacement model has been postulated 306. 
Analytical HPLC enabled the peptides to be analysed. The speed, resolution and low 
sample requirements made this method especially convenient. Samples were run 
under various gradients and also isocratically to check for impurities running under 
the main peak. The use of different counter-ions e.g. ammonium hydrogen 
carbonate or sodium hydrogen phosphate, in place of 0.1% TFA aided this process. 
Semi-preparative HPLC was used extensively to purify the NGF peptides. Judicious 
adjustment of the counter-ions, organic modifier or, more importantly, the gradient 
of aqueous/organic eluent and flow rate 307, led to the effective isolation of the target 
peptide from its crude product in every case. HPLC traces of some of the purified 





A:NGF95-lI6oz. I 	B:NGFIOO- lISox. C:NGFIOO-ll4oz. D: NT-3 100-116 oz. 
10-90%130 mm.; 17.5 mm. 10-75%/30 mm.; 15.0 mm. 5-95%/30 min.; 20.0mm I0-90%30 mm.; 11.3 mm. 
Fig. 2.16 Some purified NGF peptides 
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2.2.6.4. Other purification methods 
Ion exchange chromatography : peptides display a net charge at all pH values other 
than at their isoelectric point, which is characteristic for individual peptides. A 
counter-ion to this charge can be immobilised on a solid-phase support to act as a 
stationary phase. Partitioning between this stationary and a mobile phase (a buffer at 
a particular pH) affects the separation of components depending on the strength of 
interaction between the component and the support. Altering the ionic strength or 
pH of the eluent selectively elutes the peptides. This method was envisaged for the 
purification of the NGF 53-mer and HL, but was not utilised for reasons which will 
be explained. 
Affinity chromatography : other strategies, based on modifications to the Fmoc 
group of the N-terminal residue, may have future applications in the purification of 
these larger polypeptides. The 9-COR-Fmoc group 308, where R=Lys (for ion 
exchange), R=biotin (for affinity chromatography) or R=2-aminoundecanoic acid 
(for RP-HPLC), has been suggested. Similarly, the Thfmoc group 309  can be used, 
with separations carried out on graphite or activated charcoal columns. Both 
methods rely on increasing the physicochemical differences between the target 
peptides and terminated (by acetylation) peptides lacking the final derivatised 
residue. 
2.2.7. Chemical Formation of Disulphide Bridges 
The formation of disulphide bridges became an integral part of this work. Some 
examples of the removal of acid-labile and acid-stable Cys PG's, and the methods 
used in disulphide bond formation, are summarised in Table 2.17. 
NGF peptides containing a single cysteine residue (thus not requiring a disulphide 
bridge) were assembled using the trityl group. This was easily removed by TFA, 
liberating the trityl cation (which turns the cleavage solution yellow). This cation 
was prevented from adding back to the thiol group by the presence of excess EDT in 
the mixture. The trityl group was also used for many peptides which actually 
required a disulphide. With many of these peptides, a simple air-oxidation strategy 
was adopted. The purified, reduced peptide was dissolved in water (at 0.5 mg/cm 3 
or less) and stirred. The pH was adjusted to around neutrality with concentrated 
ammonium hydroxide, if required. By HPLC, the reduced peak could be seen to 
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decrease in height with time (over 1-6 days), to be gradually replaced by an oxidised 
peak (which almost always eluted slightly earlier). 
NGF peptide Cys PG Removal Disulphide formed by- 
14-28,66-79 Trt EDT/WA - 
100-110, 100-115 Trt"° EDT/TFA Air oxidation 
95-116 Trt''110 EDTITFA Air 
ox., catalysed 
by K3Fe(CN)6 
100-115-NH2 Trt'•"° EDTITFA 10% DMSO/TFA 
100-114 Trt° EDTffFA 20% DMSO/TFA 







10% DMSO[I'FA 100- 114 N1e113  DU/AcOH  
53-mer Acm'11° (CF3CO2)311/TFA 





Acm 68.110 GSSG/GSH 
100-114[Pro-dVal] 109 SBut' 08110 TBPITFE 15% DMSO/TFA 
Table 2.17 Cys PG removal and disulphide formation in NGF peptides 
The extent of the reaction was usually between 90-99% and could be followed by 
Ellman's test (section 2.7.6), in which the colour intensity also decreased over time 
to a constant value. The reactions could be speeded in some cases by the addition of 
small amounts of potassium ferricyanide [K 3Fe(CN)6] 212, although this often 
reduced the final yield of the oxidised product. Separation of the reduced/oxidised 
peaks was most conveniently achieved by first adjusting the solution to low pH (with 
0.1% TFA) then directly pumping this solution onto a semi-preparative HPLC 
column. The peptide components bound to the column and oxidising agents e.g. 
ferricyanide or DMSO (see below), were eluted under mainly aqueous conditions 
before purification was carried out using an acetonitrile gradient in the usual way. 
A few NGF peptides (e.g. 100-114) could not be purified from their crude forms due 
to their insolubility. This led to the use of 10-20% DMSO in TFA as an oxidant. 
These peptides easily dissolved in the solvent system enabling conversion to the 
disulphide form within one h. at 25°C222 . The oxidised products were soluble and 
were able to be purified by conventional means. This method was also used for 
some of the more soluble NGF peptides due to its speed and convenience. Test 
reactions were also carried out using DMSO in aqueous buffer systems 310 but these 
were observed to take longer (> 3 h. at pH 5.0). 
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The poor crude products obtained for some of the peptides when using Cys(Trt) and 
the requirement for selective disulphide formation in the NGF 53-mer (see section 
2.7.1), led to the use of Cys(Acm) and Cys(SBut) in certain assemblies. The SBut 
group could be removed easily using n-tributylphosphine (TBP) in 95% 2,2,2-
trifluoroethanol/water (95% TFE)311 (Fig. 2.18). 
R1—S-S—R2 	R-—R2 	 R—S+S—R2 
Bu3P + H20 	 Bu,PO + 2H 
Fig. 2.18 Generalised cleavage of mixed disulphides with TBP 
Although this PG made the crude peptides much more hydrophobic, its removal 
could easily be monitored by HPLC due to the large reduction in HPLC retention 
time that occurred. 
The Acm group improved the assemblies of some NGF peptides, also giving more 
soluble crude products (compared to SBut protected or free thiol peptides). It has 
conventionally been removed using mercury (IT) acetate at pH 4, followed by 
reduction; some investigators have however reported difficulties in reducing the 
mercuric/thiol complexes that form in this reaction 245 . In this work, the protecting 
group was more conveniently removed using silver trifluoromethanesuiphonate 
(AgOTf) in TFA223 (silver tetrafluoroborate has also been suggested 224), followed 
by reduction with dithiothreitol (DTT). The reduced peptide could be separated 
from the DTT by gel filtration. On one occasion the method was unsuccessful. 
Several methods of forming a disulphide directly from the di-Acm peptide were 
investigated. Using NGF 100-116 S 107,R"6 as a model, the following reactions were 
carried out; 
Iodine (several concentrations) in (i) 80% acetic acid/water or (ii) 80% 
methanol/water (various reaction times). 
DMSO (0.4M)/trimethylchlorosilane (1.OM) in TFA220 for 15 mm. 
Diphenylsuiphoxide (10 equiv.)/methyltrichlorosilane (100 equiv.) in TFA 312 
for 10 mm. 
Method a.) showed that poor conversion to the oxidised form had occurred, with 
several additional peaks present under all conditions. Methods b.) and c.) showed 
the characteristic peak shifts expected; however when the putative oxidised peaks 
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were isolated and examined by FABMS, as well as the correct molecular ion (m/z 
2052), several other unidentified, higher M.W. peaks were observed. These 
reactions were especially time-dependent, increasing the reaction times gave rise to 
many unknown side-products (on HPLC). 
More successful was the direct formation of the disulphide in NGF 100-114[Pro-
dVal] 109 , whilst the peptide was still attached to the resin. Treatment with TBP in 
HFIPIDMF for 3 h. removed the SBut PGs. The free thiol peptide on the resin was 
oxidised using either; (i) a K 3Fe(CN)6 solution in HFIP/DCM for 12 h., or (ii) an 
iodine-saturated solution of HFIPIDCM for 1 h. On cleavage from the resin, it was 
seen that protocol (i) had given only a low (10%) conversion to the oxidised form 
whereas (ii) had led to around 65% conversion (Fig. 2.19). These results were not 
optimised but show that the time of production of such peptides could be reduced in 




A Trial cleavage crude after SBu' protecting groups had been removed from resin-
bound peptide. Grad. 5-95% CH 3CN/30 mm.; main peak eluted at 52% CH 3CN. 
B Pure, reduced 100-114 [Pd V]'° 9 . Elutes at 52% CH3CN. 
C Pure, oxidised 100-114 [PdV] 109 . Elutes at 51% CH3CN. 
D I Resin-bound crude after iodine oxidation. Major peak coeluted with sample C. Purification isolated peak, which gave correct FABMS. 
Fig. 2.19 Traces illustrating resin-bound disulphide formation 
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One NGF peptide (100-1 15-NH 2) was assembled using each of the above PGs (Fig. 
2.20). In this assembly, Tn gave the poorest crude product, with Acm and SBut PGs 
giving similar traces, although the final 
oxidised product was obtained in low 	 • • 	• 
120 
yield when using Acm. SBut was the 
100 
optimal PG in this particular case, 	
80 
although in other closely related 60 	
AM 
assemblies, both Trt and Acm PGs 1 	40 	SBuI 
proved satisfactory. The choice of Cys 	20 ••- lit 
PG is often overlooked in the 0 
optimisation of an assembly but this 	 0 2 4 6 8 10 12 14 16 
example illustrates that it may well be 
Progrcuofauanbly 
vital to successful synthesis of the target 
peptide. The use of Cys PGs for 	Fig. 2.20 NGF 100-115-NH 2 syntheses 
selective disulphide formation is using various Cys protecting groups 
considered in section 2.7. 
2.3. BIOLOGICAL TESTING OF THE NGF PEPTIDES 
2.3.1. General 
The NGF peptides were tested for their ability to bind to the low-affinity NGF 
receptor (05'R).  These assays were can-led out by staff at Parke-Davis 
Pharmaceutical Research Co. (Ann Arbor, MI) and Chiron Corporation (Emeryville, 
CA), following the development of the tests at Chiron. Typically 2-15 mg of the 
purified NGF fragments were sent for testing. Two cell-free systems were mainly 
used for testing; the R2 assay and the Biotin assay. In the R2 assay, a human 
extracellular domain of the p75 NGM  was prepared by recombinant methods from a 
Chinese hamster ovary (CHO) cell line. A monoclonal antibody, R2, which had 
been raised against the extracellular domain of the p75N11,  was adhered to the wells 
of microtitre plates. This system was then used to 'capture' the extracellular domain 
of the receptor, to which the native murine NGF could then bind. The mNGF used 
in these assays was isolated from mouse submandibular glands as before and 
radioiodinated by the lodogen method for use in these assays. The assay could 
tolerate small amounts of organic solvent, e.g. 10% methanol, without the binding 
level of authentic NGF being compromised. This system was used to test some of 
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the first NGF peptides to be made but it did suffer from two problems; (a.) some 
receptor/AB. dissociation occurred during the assay, and (b.) the AB appeared to 
interact with the NGF/receptor affinity, causing a shallow displacement curve. 
These difficulties were overcome by the development of the more widely used Biotin 
assay, which had very low receptor/plate dissociation and gave a well-defined, S-
shaped dose-response curve. In the Biotin assay, a full-length recombinant human 
p75NR was used, again produced from CHO cell lines. The receptor was then 
biotinylated and could be firmly adhered to streptavidin -coated microtitre plates for 




I 000000000000 l 
I 000000000000 l I 000000000000 I -poo 
/ Microtitre plate containing 96 wells  
125 BIND 	125 0 	
O 	 No inhibition off thenj 	0 
ELflfl..1fl_7 WASH _E—O---O-[--.O-1 	125 1-[NGF] binding 
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then 
ASH 	 binding by the test NGF 
fragment 
125 
Symbols; 0 	Radioiodinated murine NGF 	• NGF fragment (test peptide) 
fl-'l Full-length Human p75 receptor D Non-binding NGF test peptide 
Fig. 2.21 Generalised NGF binding assay 
2.3.2. Biotin Assay 
The microtitre plates were derivatised by coating for six hours with 500/well of 
streptavidin (20i1/cm 3) in phosphate buffered saline (PBS). The non-specific sites 
were blocked with 1% bovine serum albumin (BSA) in PBS. The wells were then 
washed with 0.1% BSA/PBS then 50i.i.I/well of biotinylated p75NGFR  (5igJcm 3) was 
added and allowed to incubate for two hours. The plates were then ready for testing. 
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The test peptides were assayed using the following protocol: 
Wells were rinsed three times with binding buffer (0.25 cm 3, 0.2% 
BSA/PBS, 0.05% sodium azide (NaN3). 
98ijl/well of 1251-NGF, (2 nM) in binding buffer, was added. 
2jil/well of the TEST PEPTIDE (in DMSO) was added to final 
concentrations of 1, 10, 30 and lOO1jM. 
The plates were incubated for two hours at room temperature. 
The reaction was terminated with three washes of buffer (0.1% BSA/PBS, 
0.05% NaN3). 
The radioactivity in the wells was determined in a gamma-counter. 
By comparison with control samples, the decrease (if any) in radioactivity (and 
hence in 1251-NGF binding) caused by the test peptides was determined. This implies 
that the test peptides had competed with the radioiodinated NGF for the available 
binding sites on the immobilised p75N,  thus decreasing the level of radioactivity. 
Accordingly, competitive peptides may contain areas important for binding, 
analogous to those in the native protein. By testing each NGF fragment at several 
concentrations, a dose-response curve could be plotted. This enabled IC values, the 
concentration required to cause a 50% reduction in native NGF binding, to be 
calculated as illustrated in Fig. 2.22. These proved useful for comparing the binding 
efficiencies of different fragments, and evaluating changes made to a particular 























-..- 95-116 oxidised 
-0- 95-116 reduced 
0 	10 20 30 40 50 60 70 80 90 100 
Concentration of lest peptide (1) 
Fig. 2.22 Dose response curves for NGF 95-116 peptides 
showing the determination of IC, values 
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2.4. RESULTS OF INITIAL SCREEN ACROSS NGF MOLECULE 
The results of the binding assays for NGF fragments from all areas of the native 
protein are summarised in Table 2.23. IC. values (where they have been 










(or IC 	value) 
10-17 GEPSVCSHDS 0 - 
14-28 VCSHDSVSVWVGDKTFA - 19 
Ac-14-28 Ac-VCDSVSVWVGDKTFA - 14 - 
19-22 SVWV - 14 
Ac-19-22 Ac-SVWV - 11 
25-54 KT'FATDIKGKEVTVLAEVNTNNSVFRQYFF - 21 
34-42 KEVFVLAEV 0 - 
46-54 NSVFRQYFF 0 - 
50-54 RQYFF 2 - 
50-60 KQYFFElKCRD 16 - 
59-67 RASNPVQSG 0 - 
66-79 SGCRGIDSKHWNSY 0 - 
70-74 GIDSK 5 - 
71-79 IDSKHWNSY 0 - 
95-116 red. KQAAWRFIRIDTACSHVCSHVLSRKA 73 (20pM) 
95-116 ox. I 	KQAAWRFIRIDTACOXVCOXVLSRKA - 92%; (15pM) 
Notes: CSH = free thiol cysteine; COA = disulphide-linked cysteine 
Ac = acetyl; ox. = disulphide-linked; red. = free thiol 
Table 2.23 Results of initial screen 
The results showed that most of the linear NGF peptides did not cause much 
reduction in the level of murine 'I-NGF's binding to the p75NO.  In one region, 
however, at the C-terminus of the native protein, a fragment did show that 
significant competition had occurred. The peptide 95-116 showed binding in both 
the R2 and Biotin assays. This sequence contained cysteine residues at positions 108 
and 110 (which form disulphides with cysteines residues at 58 and 68 respectively in 
NGF) The peptide was, at first, tested in its reduced form, having been assembled 
using Cys(Trt). Later, it became clear from HPLC studies that a disulphide bond 
63 
Discussion 
rapidly formed between these residues, even at acidic pH values. Further studies 
confirmed that in relatively dilute solutions (0.5 mg/cm3 or less), an intramolecular 
disulphide readily formed; this could be reversed by DTF reduction. No 
intermolecular dimer could be made to form, even at high peptide concentrations (up 
to 20 mg/cm 3). Testing of the purified, oxidised form showed an improved IC 
value of 15 ;LM against 20 pM for the reduced form; presumably, the reduced peptide 
had formed this disulphide during testing and this lower value reflected the 
advantage of having a 'preformed' disuiphide in the oxidised peptide. All subsequent 
peptides in this region were tested in their more stable, disulphide-linked forms. The 
NGF 95-116 ox. peptide was also tested in a similar epidermal growth factor (EGF) 
assay, but binding was not observed, implying that the peptide can discriminate 
between the two receptors. The possible consequences of the presence of this 
disulphide bridge, as they relate to binding, are further considered below. The next 
stage undertaken was to determine the minimum fragment of the sequence which 
would still maintain this high level of binding. 
2.5. DETERMINATION OF THE MINIMUM BINDING SEQUENCE 
2.5.1. Results of Binding Assays 
The original NGF 95-116 peptide was progressively shortened at the N- and C-
termini to see what effects on binding this would produce. The results of these 
modifications are summarised in Tables 2.24a and b. 
N-TERMINUS 
Peptide Sequence 







95-116 ox. KQAAWRFIRIDTACOXVCOXVLSRKA - 92 15 
100-116S 107 ,  
R 116  OX. 
RFIRIDTSCO)(VCOXVLSRKR - - 7 
100-115 ox. RFIRIDTACOXVCOXVLSP.K 84 - 12 
101-1 15 ox FIRIDTACOXVCOXVLSRK 30 - - 
103-116oxP13 RIDTACOXVCOXVLSRKA - 15 - 
106-116 red. TACSHVCSHVLSRKA - 18 - 
106-116 ox. TACOXVCOXVLSRKA 1 20 - 
111-116 VLSRKA I 	- 13 - 
Fig. 2.24a Optimisation of N-terminus of 95-116 
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C-TERMINUS % binding in assay 
Biotin Biotin @ Peptide Sequence IC50  
@30MM 100pM (pM) 
95-116 ox. KQAAWP.FIRIDTACOXVCOXVLSRKA - 92 15 
100-116 S 107 . 
R116 OX.  
RFIRIDTSCOXVCOXVLSRKR - - 7 
100-115 ox. RFIRIDTACOXVC0XVLSRK 84 - 12 
1004 15-NH2 RFIRIDTACOXVCOVLSRK_NH 2 - 3 
(SBu')_ox.  
- 
100-115-NH2 RFIRIDTAC0XVC0XVLSRK_NH2 - 19 
(Trt) ox.  
- 
100-1 15-NH.heptyl 
(SBu '' 	"° RFIRIDTAC sBVCVLSRK_NH_hepty1 39 - - 
100.1 15-NH.hqnyl 
oxidised  RF IRIDTAC0XVC0XVLSRK_NH_heptyl 68 - - 
100-114 ox. PFIRIDTAC0XVC0XVLSR - - 3 
100-113 oxP 13 RFIRIDTACOXVCOXVLS 23 - - 
100-110ox. RFIRIDTACOXVCOX - 30 - 
100-110 red. RFIRIDTACSHVCSH - 0 - 
(+ data was not able to be fitted to curve to determine IC50  value; Notes SB = Out PG on cysteine) 
Fig. 2.24b Optimisation of C-terminus of 95-116 
2.5.2. Optimisation of the N-terminus 
Starting from residue 95, it was found that the sequence could be reduced to residue 
Arg'°° without any loss in binding. This was convenient as it omitted Trp 99, a fact 
which facilitated the oxidative disulphide formation in some of the later peptides. 
Removal of residues 100-102 drastically reduced the level of binding, although little 
decrease was observed on further reducing the length of this smaller peptide. The 
high binding was retained in NGF 100-115 but subsequent removal of Argloo to form 
NGF 101-115 caused a significant fall in binding. Thus it appeared that Arg'°° was 
important in the maintenance of binding integrity. 
2.5.3. Optimisation of the C-terminus 
Beginning with the peptide NGF 100-116 Ser'07 , Arg"6 ox., the peptide was 
shortened by one residue at a time. NGF 100-115 retained the binding and its C-
terminus became the subject of several changes. Assemblies of the amide form of 
this peptide were achieved using both SBut and Trt as Cys POs. Interestingly, the 
binding values for these peptides were different, although this was probably due to 
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the SBut assembly giving a slightly purer final product. A heptylamide of this 
peptide was. also produced in the hope that increasing the hydrophobicity of the 
peptide may be a way of increasing binding. The final oxidised peptide gave results 
that could not be fitted to a curve to determine an IC value. This was thought to be 
due to solubility difficulties at the higher concentrations used in some of the tests. 
Removing residue 115 to give 100-114 ox. had little effect, but removing Arg 114 
considerably reduced the level of binding. These truncated peptides gave 
considerable solubility problems in their crude forms as previously stated, although 
the purified, oxidised forms were soluble. Overall, it appeared that the smallest 
active fragment was the oxidised form of NGF 100-114. This peptide was used as 
the basic model for further a.a. substitution strategies. 
Significantly, the removal of Arg residues from either end of this peptide led to 
decreased levels of binding. In the original description of the p75 NCWR  receptor53, it 
was observed that the extracellular region contained a large concentration of 
negatively-charged residues (Asp/Gin). It was suggested that this may represent a 
complementary binding pocket to particular positively-charged areas on the NGF 
molecule. It was also further postulated that the Arg residues in NGF were close 
together in the 3-1) structure 53 , thus perhaps presenting such a positively-charged 
surface. It may be that the arginine residues in NGF 100-114 (at 100, 103 and 114) 
may be so arranged as to mimic such a structure, additionally stabilised by the 
disulphide bond formed between Cys'."°. This point is further developed in section 
2.11. 
2.6. REPLACEMENT STRATEGIES 
2.6.1. General 
Before the final optimisation of the NGF 95-116 peptide had been completed, some 
a.a. replacements were carried out on the 100-116 sequence to investigate the 
contribution to binding of some of its constituent residues, and to see if some 
changes might further increase the binding of the parent peptide. The results are 
summarised in Table 2.25. The NGF, BDNF and NT-3 100-116 peptides all bound 
to the recombinant receptor with roughly equal affinities, despite having four or five 
a.a. changes between them. The non-conserved positions were at 99, 107, 111, 113, 
114 and 116. The Ser' 07 , Arg' 16 analogue incorporated the change at Ala' 07 (Ser' 07 in 
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BDNF and NT-3), but again had a similar affinity for the receptor. Thus, it seemed 
clear that some replacements would be tolerated. Certain drastic changes were 
incorporated in which glycine replaced (a.) V 111L112S 113 and (b.) all the residues which 
appeared to tolerate a single substitution as seen in an alanine scan 314 (where each 
residue is replaced in turn by alanine). This effectively removed these side-chain 












100-116 oxP 13 RFIRIDTACOXVCOXVLSRKA - 90 8 
100-116 red .013) RFIRIDTACSHVCSHVLSRKA - 30 >100 
S'°,R"6 diAcm RFIRIDTSCSAVCSAVLSRKR 7 - 
S 107  Al 6 ox. 1FIRIDTscOXvcoXvLsR - - 7 
GII 1-113  diAcm RFIRIDTACSAVCSAGGGRKA 24 - - 
G111-113  ox. RFIRIDTACOXVCOXGGGRKA 27 - - 
Gly analogue RFGP.GGGACOXGCOXGGGRKA 6 - - 
"diSBut RFGRGGGACSBGCSBGGGRKA 0 - - 
BDNF° 13 RFIRIDTSCOXVCOXTLTIKR - - 5 
NT-3 RWIRIDTSCOXVCOXALSRKI - - 13 
Notes : SA = Acm PG on cysteine 
Table 2.25 Binding results for NGF 100-116 analogues 
2.6.2. Results of Residue Replacements 
The Gly"-113 analogue showed a significant loss in binding; although residues 111 
and 113 are not greatly conserved between species (Leu 112  is conserved), the side-
chains may make a contribution to receptor binding or the conformation of the 
peptide. When many residues (even conserved ones) were replaced with Gly, the 
binding was very low (as expected). This showed that the presence of the Arg 
residues and the disulphide alone were not sufficient to maintain the level of binding, 
but that other side-chains must be required to attain the binding conformation. 
Different effects due to the presence or absence of the disulphide bridge could also 
be observed, e.g. the oxidised form of the Ser'° 7 , Argu6  analogue gave an IC of 7 
lIM, whereas its Cys(Acm)-protected form (no disulphide present) gave only 27% 
binding at 30 iiM. This could obviously be due either to the steric effects of having 
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the PG present or the inability of the analogue to form the usual disulphide, and 
consequently not obtaining an optimal conformation. The presence of the SBut PGs 
on the other glycine analogue abolished the already very low binding value. Overall, 
these results show that although the arginine residues are essential and the presence 
of the disulphide also aids binding, certain other a.a.'s are also needed for optimal 
binding. Considering this, it was thought unlikely that simple replacement strategies 
would lead to increases in binding, especially considering the high number of 
conserved residues already in this region (ten a.a.'s in NGF 100-114 are also 
conserved in BDNF and NT-3) and the fact that all of the changes here gave either 
somewhat unchanged or reduced binding. Accordingly, modifications which would 
alter a.a. chirality and backbone flexibility were conceived with the intention of 
incorporating these into the NGF 100-114 sequence. As screening at each a.a. 
position across the whole sequence was impracticable, it was decided to concentrate 
around the 109-113 region (see section 2.8). 
2.7. A DISCONTINUOUS NGF PEPTIDE: NGF 53-MER 
2.7.1. General 
It is possible that the NGF binding site(s) may consist of residues which are distant 
from one another in the primary sequence; only in the three-dimensional 
arrangement of such residues in the folded structure of the native protein would the 
binding site be properly constituted. As previously mentioned, Johnson 53 had 
suggested that the arginine residues in the C-terminal region may well be close to 
one another in NGF and thus form such a binding region complementary to the 
Asp/Glu-rich areas on the p75N0.  It was argued that residues near to the disulphides 
should be close to one another; if disulphides analogous to those in NGF could be 
formed, perhaps certain a.a.'s (especially arginines) could be arranged to give higher 
levels of binding to those observed in the linear fragments. To be included in the 
peptide was the sequence 95-116 which (at this stage) had already shown high 
binding. Considering this, the following 'discontinuous' peptide was suggested; 
residues 95-120 would be joined to residues 50-70. This would enable the 
following: 
The chemical formation of the 'native' disulphides, Cys58Cys1 and 
CysCys0. 
The arginine residues at 59, 69, 100, 103, 114 and 118 to be included. 
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The effect of extending the C-terminus to 120 to be examined as this would 
be made during the first part of the assembly. 
Residues 71-93, including Cys80,  to be omitted as their inclusion would 
hinder the overall objectives. 
It was decided to join the segments together by a small glycine chain. Residues 70 
and 94 are Gly in NGF and an additional five glycines were added between these. It 
was hoped that this would give additional flexibility and hydrophilicity to the 
peptide and enable the disulphides to form more readily. This gave a chain length of 
fifty-three overall. Crucial to the success of the strategy was the choice of Cys PGs, 
as they had to provide the opportunity for selective disulphide bond formation. The 
SBu1 protecting-group was chosen for Cys-" 308 and Acm for Cys"°. The overall 
strategy is summarised below: 
The peptide was assembled stepwise from 120 until residue 95 when about 
half of the resin was removed. 
The assembly was continued with the remaining half of the resin by the 
addition of seven glycines, then residues 70 through to 50 were added. 
The fully, Cys-protected 53-mer was purified. 
The SBut groups on Cysm- 108 were removed, the first disulphide formed then 
the disulphide-linked peptide was purified. 
Attempts were made at forming the second disulphide (68-110) from the 
di-Acm, disulphide-linked peptide using various direct methods. 
2.7.2. Assembly of NGF 53-mer 
The peptide was assembled on a 0.21 mmol scale, using 0.7 g of a Wang resin, 
which had been pre-derivatised with Fmoc-Ala to a loading of about 0.30 mmol/g. 
This lower loading (usually 0.5 mmol/g was used) enabled a greater excess of a.a.'s 
to be used in the coupling reactions and probably led to an improved overall 
assembly. Some of the residues were triple-coupled based on difficulties 
encountered in the NGF 95-116 and 95120 313 assemblies and most of residues 
towards the end of the assembly were triple-coupled also. The traces for the first 
part of the assembly, NGF 95-120 C 1 (SBut), C"°(Acm), and the continuation to 
form NGF 50-70/GGGGGG/95-120 C. 1 (SBut), (6$.IIO(Acm),  are shown in Fig. 
2.26. The initial section showed a gradual fall in incorporation, although no major 
drops occurred. When the assembly of this 95-120 was complete, about half of the 
DMF-wet resin was removed. The remainder was used to form the 53-mer in a 
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continuous assembly. Little change in the assembly trace was observed over the 
sequence Gly-Lys 5° and it was thought that these residues had been incorporated at 
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Progress of assembly 	 Progress of assembly 
Fig. 2.26 Monitoring traces for residues 95-120 and 50-70-(GI y). 
2.7.3. Cleavage of NGF 53-mer 
Both peptides were cleaved as previously outlined. The presence of EDT did not 
appear to affect the integrity of the SBut PGs over the three hour cleavage period. 
HPLCs for the crude peptides are shown in Fig. 2.27. 
I A: 5-95% CH 3CN/30 I 
I mm. Rt=16.3 mm. I 
I B: 5-85% CH3CN/25 I 
I mm. Rt= 18.8 mm. I 
Fig. 2.27 HPLC traces of (a) crude 95-120, (b) crude 53-mer 
2.7.4. Purification of NGF 53-mer 
Both of the crude products were quite soluble. Extraction from 10% acetic acid 
removed most of the scavengers (especially phenol) and initial purification by gel 
filtration gave a reasonably pure product in both cases. Further purification by semi-
preparative HPLC gave a pure, single peak product in each case. At this stage, 
additional purification by ion-exchange chromatography was considered; however, 
in view of the further reactions and purification required on the 53-mer, ion 
exchange was not carried out here but was to be used later if required. A sample of 
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the 95-120 peptide additionally had its SBut group removed from Cys" in the usual 
manner before purification by semi-preparative HPLC. The HPLC traces of each of 







A : 95-120 C'(SBu'), C"°(Acm) 16.3 
B: 95-120 C 1 1 0(Acm) 15.0 
C: 53-mer 18.1 
Fig. 2.28 HPLC traces of the pure peptides 
2.7.5. Analysis of the Peptides 
The level of purification of the fully cysteine-protected 53-mer could be seen by 
considering the amino-acid analysis results for the crude and pure forms. The mean 
error was calculated by totalling the deviations of the experimentally obtained a.a. 
values from the actual values and dividing this by the total number of a.a.'s. The 
crude 53-mer gave a value of 24%, whereas after the two purification steps, this had 
reduced to 6% for the final pure peptide. The crude 95-120 peptide itself gave 
satisfactory results, with a mean error of 4%. 
Fast atom bombardment mass spectrometry (FABMS) was used to show the 
presence of the correct molecular ion. The machine used was accurate to 0.1% (on 
low resolution). The cysteine-protected 95-120 peptide and Cys-reduced form 
both gave molecular ions within this tolerance (3174 and 3089 respectively). The 
M.W. of the Cys-protected 53-mer was probably close to the limit of detection of the 
machine. Nevertheless, a molecular ion of 6105 (calculated value was 6109, thus 
<0.07% error) was observed. These results are illustrated in Fig. 2.29. It was 
observed that only the pure peptides gave these high molecular ion results; the 
signals could not be detected with the crude or partially purified (after the gel 
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NOF 95-120 Cys'°(SBu'), Cys' '°(Acm) 
Observed iWz = 3177.7 
C 139FLN46033S 3 requires 3177.9 
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NOF 95-120 Cy&'°(Acm) 
Observed m/z = 3089.8 























 • 	'— 	5560 	 •'a 63M 63" 6I "aS 	615. 	 6.a. 	 Sa.S 
NGF 53-mer 50-70/GGGGGG/95-120 Cys'"(SBu'), Cys'°(Acm) 
Observed m/z = 6105.1 ; C263H4 N072S6  requires 6107.4 (<0.04% error) 
Fig. 2.29 FABMS traces for the 95-120 and 53-mer peptides 
2.7.6. Selective Disulphide Formation 
150 mg of the pure NGF 53-mer, with all of the protecting groups intact, had been 
produced to enable studies on the selective formation of the disulphide bonds to be 
carried out. The first bond would be that between Cys 08. Samples of this 
disulphide -linked peptide were formed by two methods; 









I Fri Me l 
This system has been used extensively for controlling disulphide formation in 
peptides 315 and proteins242. Reduced glutathione is a tripeptide [GIu-Cys-Gly], 
which is thought to act in vivo (along with its oxidised form) as an electron acceptor-
donor couple in disulphide exchange reactions. The system acts to increase the rate 
and yield of oxidation by facilitating disulphide interchange. Since the process is 
reversible, as shown in Fig. 2.30, the equilibria may be forced between the oxidised 
and reduced states depending on the relative proportions of GSSG and GSH present. 
s. Cc 6550 CS 	 CS. Ci 
Free thiol pq,tidc 	 Dzulplude-linked peptide 
Fig. 230 GSSGIGSH couples in disulphide formation 
Using a two-fold excess of GSSG over GSH, alkaline pH and moderate ionic 
strength, free-thiol peptides may be converted to their oxidised forms within 12-24 h. 
at room temperature. 
Firstly, 70 mg of the Cys-protected 53-mer was reacted with TBPITFE to remove the 
butylsuiphenyl groups from Cys. Their removal was confirmed by the large 
change in retention time observed on analytical HPLC. This reduced peptide (58 
mg) was dissolved in buffer at pH 8.0, containing 0.15 mM GSSG and 0.075 mM 
OSH. Stirring under nitrogen for 20 hours led to the formation of the oxidised 
product. Purification by semi-preparative HPLC gave the pure, disulphide-linked 
53-mer (9.5 mg). Several later-running (by HPLC) peaks were thought to represent 
mixed peptide/glutathione species. These were combined and reoxidised to give a 
further portion (5 mg) of the disulphide-linked product. 
2.7.6.2. Air oxidation 
Another 53 mg of the fully cysteine protected 53-mer had its SBut POs removed as 
before. The reduced peptide was dissolved in water, the solution adjusted to pH 8.0 
then stirred for 24 h. The reaction was followed by HPLC (Fig. 2.31). Purification 




A 	Trace after 6 h. oxidation Grad 10-90% CH3CNI30 man 
B 	Trace after 20 h. oxidation 5-40% C11 3CNI30 mm. RI = 29.0 mm. 
C : Trace alter 30 h. oxidation 5-40% CII 3CN(30 mm. RI = 29.0 mm. 
D: Final purified pcptide 5.40% CII 3CN!30 man. ; Ri = 29.0 mm. 
Fig. 231 Traces showing time-course for air-oxidation of reduced 53-mer 
Both reactions gave the required product in about 20% yield and the peptides 
obtained coeluted with each other on HPLC. EIlman's test 316 (section 3.2.7) 
measures the nitrobenzoate (NTB) released upon the reaction of the thiol with DTNB 
and hence detects free thiol functions (Fig. 2.32). This gave a negative result with 
this peptide, indicating the disulphide had formed, having originally given a positive 
result with the reduced peptide solution before the oxidation reaction had 
commenced. A correct FABMS result was obtained for the pure peptide (Fig. 2.33) 
and a small sample was sent for testing. 
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KS + 02NP—FS - S 	NO2 
Thiol 	DTNBI 
02C 	 Co2 
Is 	 — NO2 + R-S-S --(>-- NO2 
ri co; 	 co 
Fig. 2.32 NTB (A,, at 412 nm) allows 
thiol determination in EHman's test 
"7' Observed m/z = 5928.7 
: 	I 	CHNO72S4 
is requires 5930.8 
'5 
Fig. 2.33 FABMS of 53-mer containing a 
disuiphide between C ysu*N 
2.7.7. Attempted Formation of the Second Disulphide Bond 
18 mg of the disulphide-linked 53-mer, with the Acm groups still on Cys 0, 
remained for attempts to be made at the formation of the second disulphide bond. It 
was thought that this would be problematical, especially due to the presence of Trp 99 , 
which may be affected by the more severe reaction conditions necessary for direct 
disulphide formation. Many small-scale trial reactions were carried out using the 
same conditions as those used for NOF 100-116, S'° 7 . R 1  i 6  (see section 2.2.7); 
Iodine, in various solvents. 
DMS0JMe3SiC1/TFA. 
Ph2SO/MeSiCI 3/I'FA. 
(CF3CO2) 3TIiTFA. (1.2 equiv., 0°C for 20-60 mm.) 317 . 
Reactions 2. and 3. suffered from the obvious deleterious effect that they had on 
Trp99. On addition of these reagents in TFA, the peptide solution rapidly became 
purple (blank solutions remained colourless), indicative of tryptophan damage. This 
was confirmed by the HPLC traces, which showed that many additional peaks had 
appeared. Treatment with iodine (reaction 1), under conditions favoured by Kamber 
for insulin syntheses 216, also showed that many side-reactions had occurred, with 
little evidence that the required oxidised product had formed. 
One of the main difficulties encountered here was in trying to ascertain if the 
disulphide bond had actually formed from the protected species. Experience with 
other NGF peptides indicated that differences in retention time on HPLC between di-
Acm and disulphide-linked peptides were a good indicator of bond formation, 
although the differences were often slight. FABMS could show that the target 
peptides had been made, due to the mass change involved (decrease of 144). 
However in this case, the mass was so great that this was not feasible for trial 
experiments. Additionally, the change in conformation caused by disulphide 
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formation in a small peptide may add to these changes in retention time; here, a 
disulphide was being introduced into a peptide already containing one, thus it was 
thought that any change in retention time, incurred in direct bond formation, may 
well be negligible. 
Reaction 4 initially looked more promising, the reaction leading to a slightly earlier -
eluting product on HPLC (using a shallow gradient to maximise any difference in 
retention). However, a reaction time that produced this effect (20 mm.), also gave a 
purple colouration to the solution, indicating tryptophan damage. A larger scale 
reaction using 5 mg of the 53-mer with 1.2 equiv. of (CF 3CO2)3T1 in TFA (0.6 mg in 
1 cm3 , reacted at 0°C for 20 mm.) gave 1 mg of product after purification by HPLC. 
On analytical HPLC, the pure main peak had moved only slightly. FABMS of this 
product showed a diffuse peak around the area which would represent the loss of two 
Acm groups. However, it was thought that the product of a larger scale reaction 
could not be sufficiently characterised, nor could the integrity of the tryptophan 
residue be ensured to a degree that would make the production and testing of the 
peptide a meaningful exercise. 
2.7.8. Results of Testing Peptides from the NGF 53-mer Synthesis 
The results obtained from the binding assays on these peptides are shown in Table 
2.34. The results for the 95-120 peptides appear somewhat anomalous. 
% binding in assay 
Biotin Biotin @ Peptide Sequence IC, 
@301LM 100 AM (p.]') 
95-120 
C'°(SBut) KQAAWRFIRIDTACSBVCSAVLSPJ(AVRRA - 95 10-20 
C' ' °(Acm)  
95-120 
C"°(Acrn) KQAAWRFIRIDTACVCS.VLSPJ(AVRRA - 10 - 
95-120 ox. 63 KQAAWRFI RID  TACOXVCOXVLSRKAVRRA - 88 20 
NGF 53-mer KQYFFETKCsBRJDPNPVDSGCsRGGGGGGG 
C58.108(SBut) KQAAWRFIRIDTACSBVCSAVLSRKAVRRA - - 2 
C68110(Acm) I  
NOF 53-mer KQYFFETKCOXRDPNPVDSGCSARGGGGGGG 
C53.108 OX. KQAAWRFIRIDTACOXVCSAVLSRKAVRRA 27 - - 
C68310(Acm) 
Table 2.34 Binding results for 95-120 and 53-mer peptides 
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The cysteine-protected 95-120 peptide gave the same binding affinity as the oxidised 
95-120 peptide 313 . Perhaps in this case, the increased peptide length compensated 
for the conformational disturbance that the PG's may have caused. However, it is 
difficult to reconcile this with the results obtained when the SBut had been removed 
(a ten-fold decrease in binding). It may be that due to the testing being carried out in 
DMSO, dimer formation may have been favoured in this peptide, leading to 
decreased solubility or hindering the previously observed binding process. The fully 
cysteine-protected 53-mer gave as high a level of binding as that observed for any 
previous NGF fragment. Disappointingly, when the first disulphide was formed, this 
binding was reduced, implying that the region responsible for eliciting the binding 
process had been masked by the presence of the disulphide bond. It was unfortunate 
that the second disulphide was not able to be formed reliably as it would have been 
interesting to see if the binding could be recovered in the two-disulphide peptide. 
Considering the overall methods used, it would have been advantageous to omit or 
substitute the tryptophan 99 residue; the fact that residues 100-114 could have replaced 
the 95-120 peptide had not been discovered at that time. It may have been easier to 
assemble a 50-70/100-114 peptide and try to form the correct disulphide in this. On 
reflection, the presence of the small glycine chain may not have been necessary, 
although it probably contributed to the success of the assembly. Replacing the Acm 
groups with the more hydrophobic trimethylacetanüdomethyl (Tacm) 223 may have 
facilitated the analysis of the results of attempts to form the second disulphide bond. 
On HPLC, a greater change in retention time between the di-Tacm and oxidised 
product would probably have been observed. 
Before the commencement of the 53-mer assembly, other strategies had been 
considered; forming the residue 59-67 loop by joining two separate peptides 
together, via disulphide bonds, was considered. Similar work had previously been 
carried out using NGF peptides, where fragments with the sequences 10-25 and 78-
88 had been linked by cysteine residues at 15 and 80 on the respective chains 268. 
The idea was rejected, at the time, as being technically too difficult with peptides as 
large as 50-70 and 95-120. However, the method may be viable if smaller fragments 
e.g. 50-70 (or a smaller fragment which still contained the cysteine residues) and 
100-114 were used; this may enable both parallel and anti-parallel dimers to be 
formed form both chains using directed disulphide-bond formation 268 '318 . 
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2.8. FURTHER ATTEMPTS TO INCREASE THE BINDING OF NGF 100-114 
2.8.1. General 
Attempts were made to try to increase the level of binding of the NGF 100-114 
peptide. The investigation of possible methods for carrying out this process was 
carried out in three main areas: 
The chirality of certain a.a.'s was reversed and some conformationally 
constrained a.a.'s were included. 
The conformation around the disulphide bond was altered. 
Various types of macrocycisation of the peptide were also tried. 
Analogues using methods 1 and 2 were confined to the previously examined residue 
109-113 region. 
2.8.2 Altering Chirality and Conformational Freedom of Some Residues 
Reversing the chirality of certain residues is a popular method of enhancing the 
stability of the resulting analogue to enzymic degradation and may sometimes cause 
a favourable change in conformation. Also the commercial availability of protected 
a.a.'s makes such substitutions relatively easy. Here, the valine residues at 109 and 
111 were replaced to see what effect this may have on binding. 
A widely used method for constraining the conformation of an a.a. unit is to replace 
the hydrogen at the a-carbon by a methyl group (or various other alkyl groups) to 
give a dialkylamino acid319. When a single methyl is added, the resulting residue is 
a-aminoisobutyric acid (Aib, (x-methylalanine). A Ramachandran plot 320 of 4) 
(torsional angle about the bond) and if (torsional angle around the  Ca-
Clearbony' bond) verses the calculated conformational energy (showing the 
conformational space allowed to a particular residue), has shown that 50% of the 
plot is accessible to glycine. Adding a methyl group to form alanine reduces this to 
about 16%, whereas only a few percent is available to an Aib residue 321 . This 
available space is particularly favoured by helixes and turns, so including Aib 
residues may lead to the formation of a type I or HI turn conformation 322 . 
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Additionally in this series, norleucineh 13 (Nie) replaced serine' 13 to see the effect 
removing the only hydrophilic side-chain in this area, as well as extending the side-
chain length. A double-norleucine insertion, where Nle' 06 also replaced Thrb 06, was 
also assembled, although the final oxidised form was not achieved in this case. 
2.8.3. Results of Amino-Acid Substitutions 
The results of these substitutions are shown below in Table 2.35. 
de Pepti  Sequence 
@ 10 ILM 
IC 
100-114 ox. IFIRIDTAcOxvcOxvI.sR - 3 
dVal"ox. RFIRIDTACOXVCOXdVLSR 21% - 
dVal' 09 • 1 " ox. RFIRIDTACOXdVCOXdVLSP. - 12.5 
Aib' 09 ox. RFIRIDTACOXAibCOXVLSR 23% - 
Aib" ox. RFIRIDTACOXVCOXA.thLSR 27% - 
Me113 ox. RFIRIDTAC0XVC0XVLN1eR - 1.2 
Me" 3 diAcm RFIRIDTACsAVCsVLN1eR 29% - 
Nle'06•1 13 diAcm 1 RFIRIDN1eAC"vCVLN1eR 44% - 
Table 235 Binding results for NGF 100-114 analogues 
These peptides were tested at 0.1, 0.3, 1.0, 3.0 and 10 .z.M concentrations to enable 
more accurate IC 50 values to be determined. Unfortunately, all of the peptides failed 
to give significantly increased binding levels compared to that of the 100-114 parent, 
thus the percentage binding at 10 pM (the highest concentration tested) is quoted 
here. The IC value for the norleucine" peptide was slightly lower than the parent50 
peptide, although this perhaps reflected the increased accuracy of calculation allowed 
by using these lower peptide concentrations. Overall, it is difficult to draw firm 
conclusions from what was, of necessity, quite a small substitution programme. It 
was interesting to observe that changing the chirality of both valines appeared to 
have relatively little effect on binding. The Aib substitutions may have had 
deleterious effects on the conformation around the disulphide bond, affecting the 
relative positions of other a.a.'s in the peptide; perhaps these constraints prevented 
the peptide from forming the optimum binding conformation. The overall pattern 
caused by such changes may have been more easily observed if the permutations of 
chirality and conformational constraints for each residue could have been 
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investigated. Without additional information, the exact role that these substitutions 
had in changing the binding of the parent molecule remains open to speculation. 
2.8.4. Altering the Conformation around the Disulphide Bond 
The structure around the -C°VC"'-. disulphide bond area was thought to be that of a 
y-turn by analogy with previously published work 323 (Fig. 2.36). The turn has three 
residues, here -CVC-, and is stabilised by the presence of the disulphide bond. The 
carbonyl of residue i (Cys) may be hydrogen-bonded to 
the NH of residue i+2 (Cys"°). Such a structure may be 
contributory to the increased binding affinities seen in the 
109 
oxidised forms of the C-terminal NGF peptides. Indeed, 	H-bxid 
when the cysteine residues were side-chain protected, the ,s 
degree of receptor binding almost always dropped 	H' N-H...o=(( 
 'H 
significantly, although it was unclear whether or not the %4 
disulphide itself remained intact during testing. Initially, 
it was surmised that the disulphide bond may b e Fig. 2.36 Proposed 7-turn 
undergoing exchange with one of the numerous cysteine 	
in NGF 100-114 
residues (or disulphide bonds) on the p75NO,  or even with NGF itself, thus causing 
the observed binding affinity. Some peptide-based affinity labels, possessing a 
disulphide bond, have been described for the derivatisation of cysteine-containing 
enzymes324 : it was conceivable that a similar process may be occurring here. There 
is however no evidence for such a mechanism, although some simple experiments 
which would have disproved such a theory had not been undertaken at the initial 
testing stage. 
As the spatial arrangement of the residues around the disulphide bond may not have 
been greatly altered by any of the former substitutions, the addition of another 
residue between the cysteines was contemplated. It was hoped that this would; 
by increasing the peptide length, alter the linear distance between the important 
residues. If the disulphide did not remain intact during testing, this change 
may change the binding properties of the peptide. 
enable the incorporation of a 3-bend (if the disulphide did remain intact during 
testing). 
80 
Peptide IC (UM) 
NGF 100-114 ox. 3 
NGF100-114 1 
lir&° '-D-Val' °99_OX.  
Table 238 Assay result for 3-bend analogue 
Discussion 
n-bends (also called 13-turns) are well-known features of protein structure, generally 
occurring at -the protein surface, where the peptide chain reverses its overall 
direction. The 13-bend consists of four residues and may, like they-turn, be stabilised 
by an inter-turn hydrogen-bond 322. There are many examples of peptides where a 13-
bend seems likely to be present in the bioaciive conformation of a naturally-
occurring peptide325 . For peptides having the general structure -Cys-X-Y-Cys-, and 
containing a disulphide bond, it appears that the 
presence of the disulphide forces the 14-membered ring 	 ' 	,L... 
system into a favourable conformation, thus allowing ('>....- N -- dVa.1109b 
the internal s4_..1.  hydrogen-bond to form 36,327. The Ff0109a 
NO,0 
model peptide 'Ac-L-Cys°'-L-Pro-D-Val-L-Cys°"-NH 2 ' 
5—N 
was shown to adopt a type II 13-bend in DMS03223. 	 3-,"A 
Accordingly, the [Pro 10 DVal109b] unit replaced YaP09 	
s—s 
in an analogue of NGF 100-114 and the oxidised form Fig. 2.37 Putative j.bend 
of the analogue was produced as before (Fig 2.37). The 	
in NGF 100-114 analogue 
 
result of the assay is shown in Table 2.38. Although only a single result, it seems 
that the incorporation of the extra proline residue, and reversing the chirality of the 
valine' 09 , did not greatly affect the level of binding. This perhaps suggests that the 
conformation around the disulphide bond is less critical than previously thought. 
Overall, the change in structure brought about by the 13-bend may not have altered 
the favoured orientations of the side-chains directly involved in receptor binding. It 
would have been interesting to see the effect caused by increasing the size of the 
disulphide ring by either placing additional residues between the cysteines or moving 
the cysteines further apart, towards 
either end of the 100-114 parent 
peptide. Such substitutions may 
have imposed some favourable (or 
unfavourable) constraints on the 
molecule and helped to elucidate 
the exact role of the disulphide 
bond in the action of these peptides. 
2.8.5. Cyclic Analogues of NGF Peptides 
The simplest way to introduce a conformational constraint into a peptide is by way 
of a cyclisation, either through a disulphide bond or by coupling the a-amino 
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function (or a lysine c-amino group) with the carboxyl terminus (or an 
aspartic/glutamic acid side-chain). Although the resulting peptide may still have 
considerable flexibility, the cyclisation will nevertheless substantially reduce the 
number of accessible conformations and may improve or alter the biological activity 
of the peptide. Several examples of cyclic fragments having greater binding 
affinities and/or biological activities are known e.g. somatostatin 329 , x-
melanotrophin330 and fibronectin331 . Additionally, cyclisation of some of the NGF 
peptides may have enabled structural investigations by N.M.R. 
It was envisaged that cyclic forms of the peptides NGF 100-114 ox. and 100-114 
[PdV] 109  ox. could be created. Several difficulties existed in these peptides. The 
presence of Asp105  would complicate the cyclisation procedures thus it was protected 
in these assemblies as the TFA-stable benzyl ester. This was to be removed later by 
brief treatment with TFMSA. The cysteine residues also required protection; it was 
hoped that if the cyclisation was successful, it might be possible to form the 
disulphide thus making a bicyclic peptide. Initially, a head-to-tail cyclisation was 
attempted using diphenyiphosphoryl azide (DPPA) as the condensing agent and 
using procedures based on previous work 332 . 
The general procedures were carried out as follows. The peptides were assembled 
and purified as before. The pure Cys- and Asp-protected peptides were then 
dissolved in DMF (5 mg/ml) and the solution adjusted to pH 8.0 with TEA. DPPA 
(3 equiv.) was added at 0°C, the solution maintained at -20°C for 72 h., then at 4°C 
for 48 h., and finally for 24 h. at room temperature. Evaporation of the solvent, 
neutralisation with acetic acid, extraction with ether then lyophilisation gave a solid 
product. The reaction had been followed by HPLC and several additional peaks had 
appeared. On separation by semi-preparative HPLC, none of the resulting 
compounds obtained from these peaks gave a FABMS value indicative of 
cyclisation; the major peak appeared to represent a DPPA-derivatised form. 
Adjustment of the peptide/DPPA concentrations and reaction times did not lead to 
the required products either. It was considered that steric factors may have 
hampered the head-to-tail cyclisation process so a side-chain-to-side-chain approach 
was tried. The peptide NOF H-100-115-NH 2 had previously been assembled using 
Cys(Acm) PGs. The peptide/resin was acetylated, the peptide cleaved and the 
resulting acetylated peptide was purified. The pure peptide thus had a free c-amino 
on Lys"-' and a free y-carboxyl on Asp 105. The DPPA reaction was carried out as 
before, but again no evidence of cyclisation was found in the products. 
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As the activation process may not have been optimal, it was 
proposed to -use a resin developed in this laboratory, which 	H...N...NH_Boc 
would release a C-terminal hydrazide on acid cleavage 228 
(Fig. 2.39). This could then be converted to the azide for 	oto 
subsequent head-to-tail cyclisation without the need to Fig. 2.39 Hydrazide 
protect Asp' 05. Unfortunately, despite several attempts using 	resin 
long coupling times, the amount of derivatisation by Fmoc-Arg(Pmc)-OH that could 
be obtained was too low to make a further attempt at a NGF 100-114 assembly 
viable. 
Overall, the cyclisation attempts were unsuccessful. The peptide was probably 
severely hindered by the presence of the protecting groups on the Asp and Cys 
residues, making the head-to-tail cyclisation unfavourable. The peptide itself may 
have had little propensity for a cyclic form, especially considering that the reaction is 
very sequence-dependent 333 . On reflection, while the bicyclic form was seen as the 
ultimate goal, an easier initial route may have been to attempt the reactions in 
peptides lacking the Cys residues e.g. they could have been substituted by Ser, and to 
determine were the problems lay in the overall cyclisation process. 
2.9. NUCLEAR MAGNETIC RESONANCE STUDIES ON NGF FRAGMENTS 
2.9.1. General 
Some of the smaller NGF fragments were examined by nuclear magnetic resonance 
(N.M.R.) for evidence of secondary structure. These were; 
100-110 ox. in 90% H20/10%D20. 
100-115 ox. in 90% H20/10%D20. 
100-114 ox. in d6-DMSO. 
100-114 [PdV]'° ox. in 90% H20/10%D20 and d6-DMSO. 
The large number of protons in even these small peptides necessitated the use of 
various two-dimensional N.M.R. (2-D N.M.R.) experiments to aid in the assignment 
of each resonance. A general scheme for 2-13 N.M.R. is shown in Fig. 2.40. 
83 
Discussion 
EVOLUTION 	 FID 
PREPARATION 	 MIXING 
- 	 LI .- t2 	 . 
Fig. 2.40 Generalised 2-D N.M.R. pulse sequence 
In the preparation period, one or more pulses are applied to the sample to generate a 
magnetisation, which evolves during time t1 . This is followed by a mixing period 
during which more pulses are applied. After this, the signal is recorded as a free 
induction decay (FID) as a function of a second time variable t2. This process is 
repeated for a series of values of t1 to generate a set of FIDs. This data is Fourier 
transformed twice to give a spectrum which is a function of two frequency variables. 
The types of experiment that can be carried out, and the information that can be 
obtained from them, depend on the manipulation of this basic pulse sequence. Table 
2.41 summarises the experiments used in this study and the information that they 
contain. 
Experiment Couplings observed Information 
between...  
COSY Shows through-bond (geminal 
and vicinal) couplings  
CH 
_co_ NH::~~W_  
TOCSY Shows all through-bond  
---x. couplings 
co 	 CO—NH- 
Shows through-space 
f couplings. Used for sequential ROESY/NOESY assignment. May enable 3-D 
information to be gained 
— CO 	NH 	CO—NH 
Table 2.41 Types of 2-D N.M.R. experiment 
2.9.2. Interpretation of the 2-D N.M.R. Spectrum of NGF 100114[PdV]o9 
NGF 100-1 14[PdV] 109 ox. can be considered as an example to show how the spectra 
were interpreted. The procedures used were based on the discussion of WUthrich 334 . 
The initial step in determining whether any preferred structure exists, is to assign all 
of the resonances observed to the respective residues from which they originated. A 
portion of the TOCSY spectrum is shown in Fig. 2.42. This indicates the 
connectivities between the amide proton and the other protons (a, 0, etc.) for some 
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residues in the peptide. Most a.a.'s could be identified by their characteristic 
connectivity patterns; however, some a.a.'s can give the same spin system pattern 
e.g. AMX system is observed here for Asp, Cys, Phe and Ser. These residues cannot 
be differentiated by TOCSY experiments alone. 
I C 	 (öNH) 















9.4 	9.0 	8.6 	8.2 	7.8 	7.4 	7.0 	6.6 
F2 (ppm) 
Fig. 2.42 Part of TOCSY spectrum for NGF 100-114[PdV]'°' showing 
identification of some of the multiple spin systems 
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Furthermore, multiple copies of certain residues were present in this peptide i.e. 
Arg'°°.'°3 "4 , 11eb02.b04,  Cys 1 •"° and ValIo9b.111  (labelled in Fig. 2.42); again these were not 
able to be distinguished, although Arg' 00 could be identified due to the absence of 
backbone-arnide connecthrities for this residue. Additionally, on closer examination, 
the aN peak for Asp' 05 was not present and the all of Thr106  gave a weak signal. 
The identification of the above residues was simplified by the through-space 
information obtained from a ROESY experiment. Usually a ROESY peak will be 
observed between the aH (or sometimes 3H) and the NH proton of the adjacent 




H 	0 	R2 \'H 	0 	R4 
Fig. 2.43 2-D N.M.R. interactions in the peptide backbone 
If the TOCSY and ROESY spectra are overlaid, the resulting spectra can be used to 
'walk the backbone' of the peptide. Starting from the aN of the N-terminal residue 
of the peptide, it was often possible to follow the peptide sequence by joining related 
TOCSY (or COSY) and ROESY cross-peaks with a series of horizontal and vertical 
lines. This is shown in Fig. 2.44 for the [Pro-D-Val] 109 analogue. This completed 
and confirmed the overall assignment. 
After this, evidence of structure, exemplified by ROESY peaks between non-
sequential residues, was sought. All of the remaining ROESY cross-peaks were 
found to be either within a residue or between adjacent residues; none were observed 
between residues distant in the primary structure, indicating the probable lack of a 
preferred conformation. This was also found to be true for the other peptides which 
were examined by N.M.R. It therefore appeared that the highest binding peptides 
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8.8 	8.6 	8.4 8.2 	8.0 	7.8 
F2 (PPM) 
Red = ROESY cross-peak 
107 
Region of Thr aH 
Black = TOCSY cross-peak 
Fig. 2.44 "Walking the backbone" of NGF 100-114 [PdV] 109 ox. 
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2. 10. PROTEIN SYNTHESIS: LYSOZYME 
2.10.1. General 
The total synthesis of NGF was considered as an objective relatively early in this 
study. However, considerable hurdles to the assembly, purification and even 
analysis of such a large and complex peptide (or more accurately, a small protein) 
had to be overcome before such a project could be realised. Some of the major 
problems were; 
The lack of access to authentic NGF. 
It was not known if NGF would fold properly to give an active form. 
The size of the protein lies outside the range and accuracy of most common 
analytical spectroscopic techniques. 
Added to these, of course, were the usual technical difficulties of assembling, 
deprotecting and purifying the protein, as well as attempting to refold it into an 
active form. Whilst these obstacles face all protein syntheses to a greater or lesser 
extent, it was thought that at least some of the hurdles could be addressed by first 
testing our techniques on a well-characterised protein; the small enzyme, hen egg 
white lysozyme (HL) was selected for this task. This protein has the following 
attributes, which may help in the determination of where the major difficulties would 
arise in an overall strategy; 
The authentic material is inexpensive and readily available. 
BL is similar to NGF in length and complexity (129 a.a.'s long, four 
disulphides). 
The protein contains six tryptophan and two methionine residues, thus it 
would represent a good test of the acidolysis and disulphide-forming steps. 
The pure, reduced protein has been shown to refold into an active form. 
This last point was potentially useful: Saxena 242 had shown that reduced and 
denatured HL [HL(red.)] can be reactivated using a GSSG/GSH couple. The 
reactivated protein can also be easily assayed in solution to determine the presence 
and degree of renaturation. It may be that such a system could be utilised to form an 
active enzyme from a chemically synthesised, primary structure. The appearance of 
any enzymic activity would prove to be a good indicator that the synthetic 
procedures were satisfactory. 
88 
Discussion 
2.10.2. Assembly of Synthetic Hen Egg White Lysozyme (SL) 
Considerable experience in the assembly of relatively large peptides (e.g. ubiquitin) 
has been accumulated in this laboratory and the monitoring system used in automatic 
assembly has been shown to be a reliable indicator of the progress of such 
assemblies. In view of the time required for the usual double-couple cycles, the 
expense involved and the fact that some previous assemblies using only single-
couple cycles had been successful 335 , it was decided that a single, ten-fold excess of 
HOBt ester would be used for each residue. The resin loading was lower than usual 
(0.25 mmol/g) as recommended by Kent91 . The cysteine residues were to be 
protected by an acid-stable PG to enable the option of purifying a free- or protected-
thiol protein. The SBuL group was chosen in preference to Acm as its removal could 
be more easily observed and it had previously been reported that Acm-protection 
caused difficulties in a similar lysozyme assembly 245 . 
Two assemblies were carried out. In assembly A, a 30 mm. coupling time was used. 
A large fall in incorporation was observed after only twenty residues. A sample of 
the resin (about 10% was removed for examination, whilst the assembly was 
continued. The assembly was completed, when the final deprotection value 
indicated that only around 30% of the original substitution level remained. 
140 
130 	 —•-- Assembly  
120 
110 
	 •—.o--. Assembly  
100 
0 
















0 4 8 12 16 20 24 28 32 36 40 44 48 52 36 60 64 68 72 76 80 84 88 92 96100104108 112116120124128 
Progress of assembly 
Fig. 2.45 Monitoring profiles for both SL assemblies 
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In assembly B, several modifications were added which improved the overall 
assembly; His(Bum) and Trp(Boc) derivatives were used to give additional 
protection, the HOBt was dried before use 229, and most importantly, the coupling 
time was extended to 90 mm. None of the previously observed falls occurred, 
indeed the trace stayed at (or above) the same value as the initial deprotection for 
much of the assembly. This was perhaps due to minor fluctuations in the sample 
volume (from the deprotection solution) taken for the monitoring tests; this 
difference would have been amplified due to the very small amount of Fmoc present 
(only 0.1 mmol scale was used), causing this effect. About one quarter of the 
peptide/resin was removed towards the end of the assembly to facilitate vortexing. 
The trace gave a final deprotection value of around 55% (allowing for the resin 
already removed). The monitoring traces for both syntheses are shown in Fig. 2.45 
(above). 
2.10.3. Cleavage of SL 
In assembly A, a cleavage protocol using a higher than usual level of scavengers (in 
85% TFA) for three h., followed by a lower level (in 92% TFA) for a further three 
h., was tried. This gave a broad peak on HPLC. Extending this cleavage time by 
two h. led to a purple colouration in the solution and the crude product, indicative of 
tryptophan damage. The crude protein gave a much poorer trace on HPLC. In 
assembly B, the cleavage protocol was more conventional, using the necessary 
scavengers in 90% TFA for six hours. Extending this reaction time did not appear to 
alter the HPLC trace and no Trp damage was apparent, even after 24 hr: presumably 
the Boc protecting group on the indole ring had prevented such acidolytic 
degradation. The crude product of both assemblies gave a reasonable AAA. 
2.10.4. Initial Purification: Gel Filtration 
The crude material from assembly A was passed down a Sephadex G50 column. 
Four areas were collected and combined (fractions K, L, M and N) Some of the 
material eluted at (or near) the void volume, indicating its total exclusion from the 
resin (fractions K, L and M), although a substantial amount of lower M.W. material 
had been separated from this fraction N. This fact was shown by the high V,/V. 
(elution/void volume) ratio for this fraction. The AAA for these four fractions 
showed that while K, L and M had similar compositions to that of native lysozyme 
(HL), fraction N was quite different. Further crude synthetic protein was passed 
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down a G75 Superfine column, in the hope that this would give better discrimination 
between the high M.W. components of the crude sample. HL and reduced, 
denatured HL [HL(red.)] were also subjected to the same conditions. From the 
crude material, four peaks (fractions W, X, Y and Z) were again observed in the UV 
trace. These were combined, lyophilised and the VdV0 ratios calculated as before. 
Fraction W had eluted near to V0. This was thought to represent noncovalent 
oligomeric species, which had formed due to the relatively high protein 
concentrations initially obtained when dissolving the crude protein. Fractions X and 
Y eluted roughly in the same region as HL, and the HL(red.) eluted earlier than the 
native protein as previously observed 251 . 
The crude protein from assembly B was subjected to gel filtration on a Sephadex 
G75 column. Three fractions were collected here; P, Q and R. Fraction P appeared 
again to be due to high M.W. oligomeric forms; fraction R had the appearance of 
lower M.W. peptides; however, fraction Q eluted with approximately the same 
volume as HL. A sample of combined P+Q had its SBut PGs removed in the usual 
way, then the reduced product was passed down the column. This reduced, synthetic 
lysozyme [SL(red.)] eluted with the same volume of eluent as that of the HL(red.), 
and also earlier than the original Cys-protected fractions. HPLC traces of the crude 
Cys-protected SL and SL(red.) proteins, along with HL(red.) are shown in Fig. 2.46. 
J 
(a) Cystelne-protected, SL 	 (b) SL (red.) 	 (c) HL (red.) 
Eath , wu ov 3-9% 	s 30 mu. 
Fig. 2.46 HPLC traces comparing synthetic lysozyme, 
at various stages, with the reduced, natural protein 
2.10.5. Analysis of SL 
Ellman's test on the lyophilised SL(red.) and HL(red.) showed that only 3.6 and 4.1 
thiol groups/molecule respectively, were present. Comparing this to the value of 7.6 
for freshly prepared HL(red.), it is clear that some disulphide formation and folding 
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had occurred during the gel filtration step. However, the effect on the SL(red.) was 
not known; -either the cysteine deprotection had not been complete, or worse, the 
required number of cysteine residues was not present at all, or perhaps partial 
oxidation had also occurred in this case. It would be difficult, of course, to ascertain 
exactly how many Cys residues should be present in this impure sample, in that 
existing deletion/truncated sequences of similar size may have adversely affected the 
calculation of the apparent cysteine content. The deprotection/reduction was thus 
repeated with TBP/TFE, furthermore this was carried out under denaturing 
conditions using 6M guanidinium chloride (Gdm.HC1, pH 8.0) in Tris buffer. The 
SL(red.) was rapidly isolated on a 025 gel column, then lyophilised. The SL(red.) 
now gave a similar value of 3.5 SH groups/molecule. The HL(red.) value had 
declined even further to 1.2. 
AAA results on the HL(red.) and SL(red.) proteins showed that while HL(red.) had a 
mean error/residue of 7%, under the same conditions the SL(red.) gave an error of 
16%. Both samples were subjected to polyacrylamide gel electrophoresis under 
denaturing conditions. The resulting gel showed that the SL(red.) lane had a band at 
the same level as the strong band appearing in the HL(red.) lane (at around the 14.6 
kDal standard). At least two other bands of lesser intensity could be observed in the 
SL(red.) lane, at a level between the 14.6 and 8.2 kDal markers. 
Overall, the results implied that at least some portion of the crude samples from both 
assemblies contained protein material of approx. the same M.W. as that of HL. 
Significantly, in view of the monitoring traces, the crude material from assembly B 
contained a greater proportion of high M.W. material compared to assembly A (70% 
against 50%). The exact nature of this material would be difficult to define without 
the aid of further purification steps; AAA of the fractions from the 050 column were 
the same as that of native HL, and even the crude material from assembly A gave 
largely equivalent results. Some attempts were made at further characterisation. A 
sample of fraction L, a fully Cys-protected product from assembly A (after the 050 
column) was subjected to plasma-desorption mass spectrometry (PDMS), which can 
determine the mass of high M.W. biological molecules e.g. proteins 336. 
Unfortunately, the initial ion-spectrum produced from the sample was too complex 
to permit the calculation of the mass, obviously reflecting the expected lack of purity 
of such a sample. 
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2.10.6. Attempts at Folding SL 
At this stage further purification steps were obviously required. The cysteine-
protected protein could perhaps have been purified by ion-exchange chromatography 
or affinity methods. However, a different approach was tried, which also enabled 
the investigation of the renaturation process in HL. It was clear from the Eliman's 
test results that the reduced and denatured authentic protein, and perhaps the 
synthetic protein also, had lost its free thiol groups over a certain time-period whilst 
in solution, presumably by disulphide formation. It was decided to investigate 
whether the thiols in the synthetic protein could be formed into stable disulphides 
(perhaps even the native ones) using the previously stated GSSG/GSH couple. This 
may have enabled the resulting synthetic protein to be more easily purified by 
applying techniques and conditions already reported for the purification of the native 
protein. Additionally, any enzymic activity which appeared even at this relatively 
crude stage could be assessed. 
Using the conditions suggested by Saxena 242, the HL(red.) was able to be 
regenerated, returning about 56% of the original enzyme activity, as measured in the 
M. lysodeikticus assay of Jo116s252. The same protocol was to be used for samples of 
the SL(red.). To begin with, a portion of the high M.W. gel filtration fractions from 
assembly B, had its SBut groups removed under denaturing conditions (as before). 
The resulting solution was then dialysed against 6M Gdm.HC1 (pH 8.0)/j-
mercaptoethanol at 4°C for 24 h. This should have completely reduced and 
denatured the synthetic protein. Over the next seven days, the protein solution was 
sequentially dialysed against solutions containing decreasing amounts of denaturant: 
These were one litre each of de-aerated and nitrogen-purged 6M, 4M, 2M and finally 
0.5M Gdm.HC1 (all at pH 8.0 and at 40C). It was hoped that the gradual decrease of 
denaturant (in the absence of undesirable air-oxidation processes) would encourage 
any of the correct sequence present to form some secondary structure 337. The final 
step was to use the glutathione couple to reshuffle the disulphide bonds and perhaps 
attain a native-like structure in the synthetic protein. 
One of the things that was not known was the effect that the presence of other 
peptide/protein impurities may have on the folding process; also, assuming that some 
of the correct sequence was present (and full deprotected), it was also not known 
what proportion (presumably small) this represented and whether or not this could be 
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detected if the folding process had proved to be (a) 	 (b) 
completely successful. The dialysis series had 
clearly altered the synthetic protein, comparing 
the HPLC traces of the cysteine-protected 
protein (after the gel column), with the 
reduced, 'folded' protein after dialysis (Fig. 
2.47) shows an obvious narrowing of the peak. 
Presumably the number of conformers had 
been decreased somewhat during the dialysis 	Fig. 2.47 (a) Cysteine-protected SL 
series, leading to a narrower peak on HPLC. (b) 'Folded' SL(red.) after dialysis. 
Using this dialysis solution directly (after dilution to the appropriate concentration), 
the glutathione reaction was carried out under conditions which had succeeded in 
reactivating the authentic reduced and denatured protein. This was not successful; 
extensive investigations into the effects of varying denaturant levels, temperature and 
the concentrations of both the synthetic protein and the GSSG/GSH couple, proved 
fruitless. No enzymic activity could be observed, although this was not really 
surprising in view of the large number of variables involved. What was discovered 
from these reactions was that the reduced protein had to be maintained at very high 
dilutions: the reduced protein could not be increased beyond 1 i.iM (about 14.5 mg/l) 
without extensive loss of the protein material through precipitation. This may have 
significant consequences for any future attempts at reactivating such a synthetic 
protein on a preparative scale. 
In conclusion, it appears that it will be necessary to purify the synthetic protein with 
the cysteine PGs intact. It may be difficult to work with the fully-reduced crude 
product considering its tendency to aggregate, even at relatively low concentrations. 
N° observed in 
Residue N° in entire 
sequence 
N° in final 
25 residues 
N° observed in 
HL(red.) 
Na observed in 
SL(red.) 
Leu 8.0 3.0 8.0 5.5 
Ala 12.0 3.0 12.5 1.3 
Phc 3.0 1.0 3.2 1.8 
Tyr 3.0 1.0 3.1 2.0 
His 1.0 1.0 1.3 0.6 
Met 2.0 1.0 2.3 1.3 
Table 2.48 Comparison of AAA for natural and synthetic reduced lysozymes. 
A comparison of the AAA results for HL(red.) and SL(red.) [Table 2.481 perhaps 
points to the relative lack of purity of the latter: many of the final 25 residues of the 
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assembly are low indicating the probable presence of terminated/deletion sequences 
with comparable molecular sizes (as the protein had been previously subjected to gel 
filtration). Accordingly, the crude protein is now the subject of purification 
strategies which will utilise the Thfmoc/graphite affinity techniques recently 
developed in this laboratory 309. This may provide a facile first route to the rapid 
purification of such large peptides/proteins. 
2.11. SUMMARY: OVERVIEW OF NGF STUDIES 
During the course of this study, other research programmes led to several important 
discoveries in the NGF field. It had long been recognised that while NGF bound to 
the p75N,  this receptor itself did not cause the signal transduction which led to the 
biological effects triggered by NGF binding. As previously stated, the 
demonstration that the protooncogene rrk encodes a functional NGF receptor 65 '339, 
led to the theory that the trk product (a 140 kDal protein, p140th)  acted alone as the 
high-affinity receptor species (and hence elicited the biological effects). 
Alternatively, it was suggested that p140*,  together with the p75NcwR,  formed a two-
protein, high-affinity receptor 64 .339 . Furthermore, although NGF, BDNF and NT-3 
all bind to the p7514O  with roughly equal affinity74, there appear to be distinct high 
affinity forms of the p140", namely p140, p140" 78 and p140" 76 respectively. 
Thus, it has been postulated that NGF may contain two, spatially-separated binding 
sites, with which NGF may be able to interact simultaneously with each receptor. It 
could be surmised that the region which binds to the p75NGFR would be common to all 
three neurotrophins, and that which binds to their respective irk receptors would be 
composed of a region (or regions) not conserved across the proteins. 
In late 1991, a crystal structure of mouse NGF (to 2.3A resolution) was disclosed 40. 
This showed NGF to have a novel structure, consisting of three anti-parallel pairs of 
3-strands, which formed a flat surface (Fig. 2.49). Two NGF subunits associate 
through this surface to form the NOF dimer. Interestingly, these p-strands are linked 
by four, surface-lying loop regions, which contain most of the variable regions 
present in the NGF-related proteins. It may be that these variable loop regions will 




In mid-1992, Ibáñez and co-workers 339 , using site-directed mutagenesis on NGF, 
had shown that the mutation of residues Lys343.  abolished binding to the p75NO. 
Importantly, these mutants did retain binding to the p140 receptor and stimulated 
outgrowth from chick sympathetic ganglia (a biological assay for NGF). These 
residues do not play a structural role in NOF and, in the dimer, the area close to and 
around this f3-loop, between residues Asp°-Lys3 , forms a continuous, positively-
charged surface 40 . Thus, it was suggested that the positively-charged a.a.'s around 
this loop constituted the low affinity binding site on NGF339 . The lysine residues at 
32 and 34 are, however, not conserved in BDNF and NT-3, perhaps implying a 
separate binding region for these proteins. Ibáflez suggested that in BDNF, the three 
positively-charged residues at 95-97 (KKR), in the near-by variable loop 94-98 of 
BDNF, may compensate for the lack of these lysine residues. 
Fig. 2.49 Ribbon cartoon of mNGF showing n-strand structure 
(loops regions 31-34, 4546, 94-95 and 60-78 are in black) 
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How the highest binding fragments discovered in this study relate to the 3-D 
structure of the NGF protein itself, is illustrated in the following photographs (Plates 
1-4), which show the configuration of the murine protein as found by X-ray 
crystallography40. The plates were prepared from the Brookhaven Protein Databank 
model of murine NGF and manipulated using the SYBIL programme on an Evans 
and Sutherland workstation. Residues 1-11 and 112-118 were poorly defined on the 
original X-ray map and are likely to be flexible and solvent accessible 40. The key to 
Plates 1-4 gives a full explanation of the residues highlighted. 
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KEY TO PLATES 1.4 
Residues 50-70 (magenta) run from the top right side to the bottom right side of the 
molecule. The positions of Cys (with its disulphide-bonded Cys') and Cys (with 
its disulphide-bonded CyshIo)  are labelled. 
Residues 95-120 (green) run from top left to bottom left. Residues 113-120 have 
been added and set to a random-coil conformation. The positively-charged residues 
in this region are highlighted (yellow) and labelled (from the top; Lys 95, Arg', LysTM, 
Lys 32, Arg103 , Arg11 ' and Arg 118 : Lys"' is also labelled). 
This shows the reverse view of Plate 1. The positively-charged area comprising 
Lys95, Arg1 , LysM,  Lys32 and Arg' 03 , can clearly be seen jutting out from the top right 
of the molecule. Note again that residues 113-120 have been added and have no 
defined position in this structure. The surface-lying, accessible variable loop 
segment comprising residues 59-66 (magenta) can also be observed in this reverse 
view. Note also that the position of this model corresponds closely to that of Fig. 
2.49 so that it is just possible to follow the backbone and secondary structure 
elements on Plate 2 by comparison with Fig. 2.49. 
The backbone is shown as a ribbon (magenta) in the same orientation as Plates 1 and 
4. The lysine and arginine residues highlighted in Plate 1 are coloured red and blue 
respectively. The clustering of the disulphides (from top to bottom), Cys 18-Cys 
(green), Cys1Cyss0  (orange) and Cys-Cys"° (yellow) can be observed. The turns 
of the 59-66 loop region can just be seen behind the disulphides. 
The position of residues 100-114 (113 and 114 have been added) is shown (magenta) 




PL.T 3 	 PLATE 4 
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These models suggest possible theories for the observed binding of the NGF 
fragments. The lysine residues (32, 34 and 95), implicated in p75 NcwR interaction, are 
in the immediate vicinity of Arg'°° and Arg 103. It has been suggested that these 
together form the binding site to the p75 receptor 339. In the 100-114 ox. fragment, a 
similar binding region may have been simulated by the Arg 100103 residues present, 
with additional aid by Arg' 04. The latter may have been manoeuvred into a 
favourable position by the presence of the disulphide bond in this fragment and 
together these may have mimicked a positively-charged surface. Significantly, 
neither Arg'°° nor Arg" 4 could be removed from this peptide without causing a 
substantial reduction in the binding affinity. Considering Ibáflez's explanation for 
BDNF binding339, it may be that simply a concentration of positively-charged a.a.'s, 
in the correct conformation (or able to form the required conformation), is necessary 
to constitute a binding peptide. As it is thought that NGF may bind as a dimer, it 
may be that a single peptide could never achieve the level of binding observed for 
NGF, in that the high density of positively-charged residues required could not be 
reached in a single peptide chain. 
From the crystal structure information, it is clear that many of the residues in the 
100-114 fragment are intimately involved in the stabilisation of the NGF dimer 40. 
The residues Phe'°', Ala 107 , VaJ 109 and Val" all contribute to interactions between the 
two chains constituting the dimer, and, in addition to the polar Thr' 06, these residues 
are buried in the dimer interface. Perhaps, at the concentrations used in the assays, 
the 100-114 peptide itself interacted with the NGF dimer, thereby reducing the 
apparent level of 'I-NGF binding to the recombinant p75NG. 
The models of the X-ray structure show that the sequences 50-70 and 95-120 (which 
are present in the NGF 53-mer as the discontinuous fragments) run parallel to one 
another in the native NGF protein, thus residues 70 and 95 are at opposite ends (and 
sides) of the molecule. The 53-mer peptide would probably not have mimicked the 
relative positions of many of the residues in NGF; also to form the correct 
disulphides would have required the disulphides to form across each other in the 53-
mer - this may have been sterically inhibited in a single, continuous chain. However, 
it would have been interesting to form the variable loop bordered by the two 
disulphides, if it could have been achieved. In view of the variability and obvious 
surface-accessibility of this loop (see Plate 2), it may be that this region could be 
responsible for the interaction with the p140" receptor: it is tempting to suppose 
that the loop is held in place by the disulphides due to its biological importance. 
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Also, as mentioned, not one of the residues in this loop between 59-66 is conserved 
across NGF, BDNF and NT-3. Such an area could account for the existence of the 
different trk receptors, each different loop region being responsible for defining 
which of the proteins bound to which rrk sub-class3 . 
Overall, current ideas perhaps indicate that creating an NGF agonist may be difficult 
if the 'two-component' (p75 NGm and 140' receptors), high-affinity receptor theory is 
confirmed. Such a peptide would presumably have to span both receptors and 
provide two binding sites, thus would probably have to be both large and complex. 
However, there seems to be a growing body of evidence and opinion that suggests 
that the p140 receptor alone may represent the high-affinity receptor and mediate 
the biological responses of NGF, and that the two receptors may interact only 
through their signal transduction mechanisms 69. The interpretation of the results of 
many of the current receptor experiments (especially from cultured cells) is complex 
(and sometimes contradictory) and many of the issues involved are still the subject 
of considerable controversy. 
If the pi4O receptor alone does prove to represent the high-affinity receptor, it 
should be possible to follow a similar approach to that undertaken here in order to 
determine which regions may bind to this receptor. Such binding may directly 
trigger the biological activity and lead to the elucidation of structures required for 
agonist activity. The basis of this work would, of course, be the creation of a 
reliable pi40 receptor assay. Advances towards such an approach, perhaps even 




CHAPTER THREE: EXPERIMENTAL 
3.1. NOTES 
All a.a.'s were purchased from Novabiochem or Raylo Chemicals and were of the L-
configuration unless otherwise stated. The integrity of each was confirmed before 
use by MP, TLC and optical rotation under conditions stated on the data sheet 
supplied, and additionally by N.M.R. (200 MHz). TLC was carried out on some 
peptides using plastic plates, precoated with silica gel 6OGF-254 (Merck 5735) in the 
following systems: n-butanol/pyridine/acetic acid/water, a.) (15:10:3:12) or b.) 
(1:1:1:1). Visualisation of certain a.a. residues in peptides was achieved using a 
suitable combination of the following methods: UV absorption at 254 nm, ninhydrin 
for compounds with free amino groups, Mary's spray [4,4'-
bis(dimethylamino)cliphenylcarbinol] for acid functions, Pauli's spray for tyrosine-
and histidine-containing peptides, Ehrlich's spray for tryptophan and Sakaguchi's test 
for arginine (see section 3.2.7. for details). Optical rotations were measured on an 
AA1000 polarimeter (Optical Activity Ltd.) in DMF (for a.a. derivatives) using a 10 
cm cell. UV and visible spectra were recorded on a Varian Cary 210 double-beam 
spectrophotometer in the appropriate solvent. Infrared spectra were recorded 
between 4000 and 600 cm -1  on a Perkin-Elmer 781 spectrophotometer using KBr 
discs. Polystyrene was used as the standard (1603 cm -1 ). Amino acid analysis was 
performed on a LKB 4150 alpha amino acid analyser on a hydrolysate obtained from 
one of the methods described in section 3.2.9. High and low resolution fast atom 
bombardment mass spectra (FABMS) were obtained from a Kratos MS50TC 
machine, using thioglycerol or 3-nitrobenzyl alcohol as a matrix. 1 H N.M.R. spectra 
were recorded on either a Bruker WP200 (200 MHz) or a Varian VXR5000 (600 
MHz) machine in the solvents indicated using tetramethylsilane (TMS) as an internal 
standard. 2-D experiments were carried out using the 600 MHz machine. Peptide 
sequencing was carried out on an Applied Biosystems (ABI) 477A sequencer at the 
WeliMet sequencing facility, University of Edinburgh. Polyacrylamide molecular 
weight gels (for lysozyme) were run using 20% gels on a LKB Pharmacia PhastGel 
electrophoresis system and developed using Coomassie Blue and silver staining. 
All solvents were distilled before use and the following were dried using the reagents 
given in parentheses: diethyl ether (sodium wire) ; dichloromethane (calcium 
hydride) ; tetrahydrofuran (sodium). Dimethylformamide, 1,4-dioxan and piperidine 
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were Peptide Synthesis grade supplied by Rathburn Chemicals, Walkerburn, 
Scotland. Biochemical grade trifluoroacetic acid (TFA) was obtained from ABI. 
H20 used was Milli-Q grade. High performance liquid chromatography (HPLC) 
was carried out using an ABI system, comprising 2 x 1406A solvent delivery 
systems, a 1480A injector/mixer and a 1783A detector/controller. 
ANALYTICAL COLUMNS used were as follows: 
ABI Aguapore RP300 reverse-phase silica (300 A pore size. 7 urn spherical silica 
Column A: 220 x 4.6 mm C18 or C8, as stated in text, flow rate = 1.0 cm 3/min. 
Column B: 110 x 4.6 mm C18 or C8, flow rate 1.0 cm 3/min. 
Vvthc C18 reversed-phase silica (5 urn particle size 
Column C: Column 218TP54, 250 x 4.6 mm, flow rate 1.0 cm 3/min. 
PREPARATIVE COLUMNS used were: 
ABI (matched to analytical columns 
Column D: 250 x 9.2 mm C18 or C8, flow rate 5.0 cm3/min. 
Column E: 110 x 9.2 mm C18 or C8, flow rate 5.0 cm3/min. 
Vvdac Cl 8 reversed-phase silica 00 urn particle size 
Column F: Column 218TP1022, 250 x 22 mm, flow rate 10.0 cm 3/min. 
Components were eluted from these columns with a gradient of acetonitrile (far UV 
grade, Rathburn Chemicals) in double-distilled, deionised water with 0.1% TFA in 
both solvents. The appropriate gradients are quoted in the text in (time, % 
acetonitrile) e.g. gradient of 10-30% acetonitrile (CH 3CN) over 30 mm., is quoted as 
(0,10), (30,30). Eluents were detected at either 214 or 229 nm. The following 
standard analytical gradients are referred to in the text: 
Gradient time, % CH3CN Gradient time, % CH3CN 
A (0,0), (20,40) E (0,5), (30,65) 
B (0,5), (20,55) F (0,5), (30,95) 
C (0,5),(25,85) G (0,10),(25,75) 
D (0,5), (30,35) H (0,10), (30,90) 
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3.2. SOLID-PHASE PEPTIDE SYNTHESIS 
3.2.1. Preparation of Fmoc-Amino Acid Resins 
The Fmoc-amino acid residues used were as previously stated, the individual types 
used in a particular assembly are referred to in the text. 
A solution of Fmoc-a.a. (5.0 mmol) and N,N'-diisopropylcarbodiimide (0.39 cm 3 , 
2.5 mmol) in DMF (10 cm3) was stirred for 15 mm., then p-benzyloxybenzyl alcohol 
polystyrene resin (cross-linked with 1% divinylbenzene, functionalised to 0.80 
mmol/g, 1.0 g, 0.80 mmol) was added. The slurry was swirled and more DMF 
added to ensure mobility. 4-(NN'-dimethylamino)-pyridine (DMAP, Aldrich 
Chemicals, 15 mg, 0.1 mmol) was added in a little DMF and the entire mixture 
sonicated for 2 hr. The resin was collected by filtration, washed thoroughly with 
DMF then dioxan and stored at 4°C until required. A sample of this was washed 
with ether then dried in vacuo to give the Fmoc-a.a.-resin as off-white granules. The 
loading was determined by treating an accurately weighed sample (2-5 mg) with 
20% piperidine/DMF (10 cm 3) and sonicating for 20 mm. The UV absorbance of 
the supernatant was measured at 302 nm and the loading calculated using the Beer-
Lambert Law (e,02 = 15,400). The coupling efficiency was usually in the region of 
60-80%, giving a typical loading of 0.5-0.6 mmol/g. 
3.2.2. Capping Unreacted Resin/Peptide Sites 
The Fmoc-a.a.-resin (0.5 mmol) was treated with acetic anhydride (0.1 g, 1.0 mmol) 
and pyridine (0.08 g, 1.0 mmol) in DMF (7 cm3). The mixture was shaken/vortexed 
for 2.5 mm., filtered then the treatment repeated, with shaking for a further 3.5 mm. 
The resin was filtered off and washed thoroughly with DMF. This process was used 
in automatic assembly after the coupling cycles for each residue were complete, and 
in manual assembly only when required. 
3.2.3. Methods Used in Manual Assembly of Peptides 
The bubbler apparatus used in manual assembly is shown, and its operation 
described, in Appendix A. Manual assembly of the NGF peptides was carried out on 
the pre-loaded resin using the following protocol. Volumes of reagents used were 
approximately 10 cm 3/g of resin: 
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Operation - Reagent Time (no. x mm.) 
 Wash DMF lox  
 Deprotect 20% Pip./DMF 2 x 3 
 Wash DMF lox  
 Test resin KaiserffBNS 1 x 5 
 1 	Couple SAorAE 1x60(SA); 1x90(AE) 
 Wash DMF lOx 1 
 Test resin 	I Kaiser/TBNS 1 x 5 
8a If test is negative, continue cycle at Step 2 
8b 
- 
If test is still positive, repeat coupling with AE using an 
appropriate activation method. Continue coupling (twice 
more only) until the resin test is negative. Cap the resin if 
required. Continue at Step 2. 
3.2.3.2. Manual activation of Fmoc-amino-acids 
The Fmoc-a.a. derivative (4 equiv.) and DIC (2 equiv.) were stirred in a 
minimum of DMF (5-10 cm3) for 15 mm. then added to the resin. 
SE,: The Fmoc-a.a. derivative (2 equiv.), HOBt (Fluka, 2 equiv.) and DIC (2 
equiv.) were stirred in a minimum of DMF (5-10 cm3) for 30 mm. then added to the 
resin. 
AE/other: The Fmoc-a.a. derivative (2 equiv.), BOP or HBTU (Novabiochem, 2 
equiv.) and diisopropylethylamine (DIPEA, 4 equiv.) were stirred in a minimum of 
DMF (5-10 cm 3) for 5 mm. then added to the resin. 
At the end of the assembly, the completed peptide/resin was washed in excess DMF, 
dioxan then ether, with final drying overnight in vacuo. 
3.2.3.3. Manual monitoring 
i.) Kaiser test : A small sample of washed resin was withdrawn from the reaction 
vessel, placed in a vial then three drops of each of the following solutions were 
added, 
Ninhydrin in ethanol (5 g in 100 cm3). 
Phenol in ethanol (80 g in 20 cm 3). 
1.0 mM aqueous solution of KCN in water (2 cm 3) added to distilled pyridine 
(98 cm3). 
The vial was heated at 100°C for 5 mm. A positive test (indicating the presence of 
free amine groups) was shown by a blue colouration. 
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ii.) TBNS : 5 mg of trinitrobenzenesulphonic acid was dissolved in 10% 
DIPEA/DMF (0.5 cm3) then three drops of this solution added to a small sample of 
washed resin. A positive test indicating the presence of free amine was observed 
when the beads became strongly orange-coloured. 
3.2.4. Methods Used in Automatic Assembly of Peptides 
3.2.4.1. General 
This was carried out using an Applied Biosystems 430A peptide synthesizer. 
Deprotection integrals were calculated by UV detection at 302 nm on an ABI 759A 
absorbance detector, with on-line integration via a Spectra-Physics SP4400 
ChromJet integrator/printer. The machine compartmentalises the dissolution of the 
a.a. derivative (in small plastic cartridges), the activation (in a glass activator vessel) 
and the coupling steps (in a Teflon reaction vessel containing the resin). Mixing the 
resin/reagents was by vortexing and draining by positive-nitrogen pressure. 
Syntheses were on a 0.50 or 0.25 mmol scale using the appropriate amount of pre-
derivatised resin. The washing, deprotection, coupling and capping steps used were 
similar to the manual synthesis protocols and are outlined below. All washes used 
50% DMF/dioxan. Coupling was via double-couple cycles, a SA then an AE, except 
that some residues e.g. Asn, Gln, His and Arg were double-coupled with AE only. 
3.2.4.2. Removal of the Fmoc group 
The peptide/resin was treated with 20% piperidine/DMF (9 cm 3) in four batches 
reagent for periods of 5, 3, 3 and 1 mm., with washing steps in between each batch. 
A sample of each deprotection mixture was passed through the on-line UV (with 
detection at 302 nm) and the peak integrated. The steps were reduced to 3 and 1 
mm. only in later syntheses, with no adverse effects. 
3.2.4.3. Activation of the Fmoc-amino-acids 
For a 0.25 mmol scale synthesis; 
SA : The Fmoc-a.a. (0.5 mmol) was dissolved by adding DMF (4 cm 3) and bubbling 
nitrogen through the solution for 3 mm. [extended to 15 mm. for Arg(Pmc) and 20 
mm. for Asn/Gln]. The solution was transferred to the activator where DIC/dioxan 
(2 cm3 , 0.25M) and dioxan (2 cm 3) were added. This solution was left to stand for 
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15 mm. before transfer to the reaction vessel. The resin/SA solution was then 
vortexed for- 30 mm. to couple the a.a. This was later extended to 60 mm., which 
gave better results in some circumstances. 
The Fmoc-a.a. (0.5 mmol) was dissolved by adding DMF (2 cm 3) and 
HOBt/DMF (2 cm 3, 0.25M). This solution was transferred to the activator, where 
DIC/dioxan (2 cm 3, 0.25M) and dioxan (2 cm 3) were added. The solution was left 
to stand for 20 mm. before transfer to the reaction vessel. The resin/SA solution was 
then vortexed for 30 mm. to couple the a.a. derivative. This was extended to 90 mm. 
in some of the later syntheses. 
At completion of the assembly, the peptide/resin was washed with excess dioxan 
then ether and dried overnight in vacuo. 
3.2.5. Acidolytic Cleavage 
The ether-dried peptide/resin (0.20-1.00 g) was placed in a small round-bottomed 
flask along with a stirring bar. The appropriate scavengers (specified in the text) 
were mixed together then TFA added to the required amount (5-20 cm3). This was 
added to the resin and stirred (usually under nitrogen) for 2-5 hr. as necessary. 
Small samples (0.1-0.2 cm 3) were withdrawn at hourly intervals, evaporated to 
dryness under a stream of nitrogen, partitioned between 10% aqueous acetic acid and 
ether then the aqueous layer examined by HPLC. Cleavage was halted when two 
identical traces were obtained. At this point, the solution was concentrated in vacuo 
to an oil (often yellow or brown) and the crude peptide precipitated by the addition 
of excess ice-cold ether. The crude peptide was collected by filtration and washed 
with excess ether to remove the scavengers. The crude peptide was usually taken up 
in a minimum volume of aqueous acetic acid (10-30%) or ammonium hydroxide 
(10%, if it was more soluble in this and Cys was absent) then extracted twice from 
large excesses of ether (x 10-20 volumes). The aqueous layer was then lyophilised 
to give the extracted crude peptide as a white solid. 
3.2.6. Hydrolysis of Peptides for Amino Acid Analysis (AAA) 
i.) HC1 hydrolysis : The peptide (2-4 mg) was treated with constant boiling HC1 (2 
cm3) and placed in a sealed, evacuated Carius tube. This was heated at 110°C for 
18-48 hr. as required. The hydrolysate was then evaporated to dryness in vacuo, 
taken up in a little H 20 (5 cm3) and again evaporated to dryness. This process was 
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repeated twice then the residue dissolved in the appropriate loading buffer (2 cm 3) 
for subsequent analysis. 
ii.) 4-TSA hydrolysis The peptide (2-4 mg) was treated with 3M aqueous p-
toluenesuiphonic acid (1 cm 3), which had been saturated with tryptamine, and 
hydrolysed as above. The resulting hydrolysate was treated with 1M NaOH (2 cm 3) 
and water (2 cm 3) then analysed. 
3.2.7. Detection of Individual Amino Acids in the Peptides 
These were used on TLC plates and electrophoresis paper for qualitative assessment 
of a peptide's composition; 
1.) Ninhydrin : Detected free amine groups. The plate was sprayed with a 0.2% 
solution of ninhydrin in acetone then heated at 100°C for 5 mm. 
2.) Pauli's Detected Tyr and His. The following solutions were required; 
Suiphanilic acid (0.1 g) in 1 cm 3 of conc. HCl, diluted with 20 cm 3 of water, 
4°C, 
NaNO2 (5% in water at 40C), and 
Na2CO3 (10% in water at 40C). 
1 cm3 of a.) and 1 cm 3 of b.) were mixed and allowed to stand at 200C  for 5 mm. 2 
cm3 of c.) was added and the plate lightly sprayed. Tyr-containing peptides stained 
pink, His-containing peptides stained orange. 
3.) Ehrlich's : Detected tryptophan. Plates were sprayed with a solution of 20% p-
dimethylaminobenzaldehyde (10% in conc. HCl) in acetone. Trp-containing 
peptides turned purple after a few minutes. 
4.) Sakaguchi's : Detected arginine. Plates were sprayed with 8-hydroxyquinoline 
(1% in acetone) then air-dried for 10 mm. The plate was then sprayed with 
Br2INaOH solution (0.67 cm 3 in a 0.1M NaOH solution). Arginine-containing 
peptides gave orange-red spots. 
5.) Eliman's This detects free thiol groups and can be used quantitatively or 
qualitatively. 
A sample of the thiol-containing peptide (20-50 pmol) was dissolved in 0. 1M Tris-Cl 
buffer (pH 8.0, 2.5 cm3), containing 8M urea and 10mM EDTA (denaturing buffer). 
A fresh solution of 5,5'-dithiobis-(2-nitrobenzoic acid) [DTNB, 0.01M in 0.05M 
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sodium phosphate buffer, pH 7.01 was prepared. With 2.5 cm3 of denaturing buffer 
alone in the--reference cell, and the peptide/denaturing buffer solution (2.5 cm3) in 
the sample cell (of a double-beam spectrophotometer), a small amount of DTNB 
solution (0.10 cm 3) was added to each and the absorbance read at 412 nm after a few 
minutes. The value of C42 for the carboxylate-4-nitrothiophenolate used to calculate 
the thiol content was 14290 Mcm. 
For qualitative analysis, a small sample of the peptide (<0.5 mg) was dissolved in 
the denaturing buffer (0.20 cm 3) and two drops of the DTNB solution added. The 
immediate appearance of a strong yellow colour indicative a positive test. 
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3.3. EXPERIMENTAL 
Conserved NGF 10-17 
The initial resin had been derivatised with Fmoc-Ser(But)-OH (0.60 mmol/g; 1.00 g 
0.60 mmol). Cysteine was incorporated as Fmoc-Cys(Trt). The peptide was 
assembled manually, using single-couple cycles, except Asp(OBut) and Cys(Trt) 
which required an additional AE/HOBt coupling, resulting in 1.77 g of dried 
peptide/resin. A portion of this (0.82 g) was cleaved for 3 hr. in a solution of 4% 
water, 4% EDT and 2% anisole in TFA (15 cm3, nitrogen-purged) to yield the crude 
peptide (0.21 g) as a white solid. This was relatively insoluble and appeared to 
polymerise readily. On ether extraction (2 x 70 cm 3) from 10% aqueous acetic acid 
(21 cm3), a crystalline white solid (0.17 g) was obtained. A portion of this material 
(90 mg) was dissolved with difficulty in glacial acetic acid (5 cm3) then water (10 
cm3) was added. Some insoluble material had to be filtered from this solution 
(through a 0.45 gm membrane filter). The filtrate was purified in four portions by 
semi-preparative HPLC [column D(C18), gradient (0,15), (2,15), (27,55)]. The 
purest fractions, as judged by analytical HPLC , were combined and lyophilised to 
give the title compound as a fluffy, white solid (10 mg). 
FABMS m/z 843 (M+H), hr,ns found 842.31163, C34H50N8015S 1 requires 
842.31161 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient B] Rt 12.4 
minutes (in the absence of added acetic acid, a small peak appeared at Ri 13.6 
minutes, probably due to dimerisation) ; Amino acid analysis (HC1 hydrolysis, 18 
hr.) Asp 1 1.03, Ser2 1.77, G1u 1 1.08, G1y 1 0.98, Va1 1 1.01, Phe l 1.01, Cys 1 N.D. 
Ellman's test was positive. 
Conserved Nerve Growth Factor 14-28 
The initial resin had been derivatised with Fmoc-Ala-OH (0.58 mmol/g; 1.20 g; 
0.70 mmol). Cysteine was protected as Cys(Trt), Trp was unprotected. Automatic 
assembly was carried out on the ABI machine, using the normal double-couple 
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cycles and monitoring showed that no drops in incorporation had occurred. On 
completion of assembly, the DMF-wet resin was divided into three portions : one 
portion (0.61 g) was used in this synthesis, 0.59 g was acetylated to form NGF Ac-
14-28-OH and 0.80 g used in unsuccessful dansylation reactions. Some dried 
peptide/resin (0.30 g) was cleaved for 3 hr. in a mixture of 3% water, 2% EDT and 
2% phenol in TFA (10 cm3), resulting in a crude product (0.13 g). A sample of this 
material (70 mg) was dissolved in 20% aqueous acetic acid (21 cm 3), filtered and 
purified in seven portions by semi-preparative HPLC [column D(C18), gradient 
(0,10), (20,30), (30,30)]. The purest fractions yielded an almost pure, white solid 
(30 mg). Final purification by semi-preparative HPLC [column E(C18), gradient 
(0,10), (30,35)] yielded the title compound (7.5 mg) as a white powder. 
FABMS m/z 1566.8 (M+H) ; hrms found 1565.73950, C67H 107N17024S 1 requires 
1565.73956 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 12.7 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp2 1.98, Thr2 2.00, Ser2 
1.65, Gly 1 0.95, Ala 1 0.97, Val4 3.73, Lys1 1.21, Cys1 N.D., Trp 1 N.D. 
Conserved Nerve Growth Factor acetylated 14-28 
Half of the resin from NGF H-14-28-OH was acetylated and dried to give 0.59 g. 
The cleavage was under the same conditions used for the initial peptide, yielding the 
crude peptide (0.15 g). Ether extraction of this crude product gave 96 mg. A 
portion of this (20 mg) was dissolved in 15% aqueous acetic acid (8 cm 3), filtered 
and purified by semi-preparative HPLC [column D(C18), gradient (0,10), (30,40)] to 
yield the title compound (8 mg) as a white solid after lyophilisation of the 
appropriate fractions. 
FABMS m/z 1608.7 (M-i-H), C69H 1 N 17025S 1 requires 1607.8 ; Analytical HPLC 
[column A(C1 8), gradient F] Rt 14.6 minutes ; Amino acid analysis (HCl hydrolysis, 
18 hr.) Asp2 1.98, Thr2 2.00, Ser2 1.65, Gly 1 0.95, Ala 1 0.97, Val4 3.73, Lys 1 1.21, 
Cys1 N.D., Trp 1 N.D. 
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Conserved Nerve Growth Factor 19-22 
H-Ser-Val-Trp-Val-OH 
The initial resin had been derivatised with Fmoc-Val-OH (0.52 mmol/g; 1.00 g; 
0.52 mmol). Trp was unprotected. The peptide was assembled manually, using 
single SA couplings. The weight of dried resin obtained was 1.50 g (half of this was 
used to form NGF Ac-19-22-OH). A portion of the resin (0.30 g) was cleaved for 2 
hr. in a solution of 5% water, 2% anisole and 1% EDT in TFA (5 cm3), to give the 
crude peptide (77 mg) as a single peak product (by HPLC). A sample of crude 
material (30 mg) was purified in a single portion by semi-preparative HPLC [column 
D(C18), gradient (0,10), (15,40)]. Lyophilisation of the purest fractions gave the 
title compound (17.5 mg) as a crystalline, white solid. 
FABMS m/z 490 (M+H), hr,ns found 489.25877, CH35N506 requires 489.25873 
(<1 ppm); Analytical HPLC [column A(C18), gradient F] Rt 13.3 minutes ; Amino 
acid analysis (4-TSA hydrolysis, 18 hr.) Ser 1 0.98, Trp 1 0.76, Va12 2.05. 
Conserved Nerve Growth Factor acetylated 19-22 
Ac-Ser-Val-Trp-Val-OH 
Half of the resin from NGF 19-22 was acetylated. The cleavage was under the same 
conditions used for the initial peptide, yielding the crude peptide (78 mg) as a single 
product (by HPLC). A portion of this (40 mg) was purified in four runs by semi-
preparative HPLC [column D(C18), gradient (0,10), (20,45)] to yield the title 
compound (19 mg) after lyophilisation of the appropriate fractions. 
FABMS m/z 532 (M+H), hrms found 531.26941, C26H3 7N507 requires 531.26931 
(<1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 14.7 minutes ; Amino 
acid analysis (4-TSA hydrolysis, 18 hr.) Ser 1 0.98, Trp 1 0.76, Va12 2.05. 
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Mouse Nerve Growth Factor 25-54 
H-Lys-Thr-Thr-Ala-Thr-Asp-Ile-Lys-Gly-Lys-Glu-Val-Tbr-Val-Leu-Ala-Glu-Val-
Asn-Ile-Asn-Asn-Ser-Val-Phe-Arg-Gln-Tyr-Phe-Phe-OH 
The initial resin had been derivatised with Fmoc-Phe-OH (0.35 mmol/g; 1.00 g; 
0.35 mmol). Asn and Gin were unprotected. Automatic assembly was carried out 
on the ABI machine, using the normal double-couple cycles, except in the following 
cases ThrI6 and Va142 (1 x SA, 2 x AE/HOBt), Asn 4 (2 x AE/HOBt) and Asn (3 x 
AE/HOBt). Monitoring showed that significant fails in incorporation had occurred 
over the regions Gly33 -Gln3I and VaP8-Ile". The weight of dried peptide/resin after 
assembly was 2.60 g. Several different conditions were investigated to optimise the 
cleavage protocol. Finally, a portion of resin (1.00 g) was cleaved for 4 hr. in a 
mixture of 4% water, 3% anisole, 2% EDT and 1% thioanisole in TFA (25 cm3). 
After ether extraction, the crude peptide was obtained as a white solid (0.51 g). Full 
analysis on this material was carried out. 
A portion of crude material (0.20 g) was dissolved in 15% CH3CN/H20 (75 cm3), 
with 10% aqueous acetic acid added (25 cm3) and purified in twenty portions by 
semi-preparative HPLC [column E(C8), gradient (0,15), (25,40)]. The combined 
fractions yielded an almost pure, white solid (55 mg). This was repurified in five 
lots [dissolved in 10% aqueous acetic acid (11 cm 3)] by semi-preparative HPLC 
[column D(C18), gradient (0,10), (30,50)], to give the title compound as a white 
solid (22 mg) after lyophilisation of the appropriate fractions. 
Crude product 
FABMS m/z 3530, 3511, 3494, 3434 (M+W); Analytical HPLC [column A(C18), 
gradient E] Rt 21.5 minutes [major peak (70%)] ; Amino acid analysis (HCl 
hydrolysis, 24 hr.) Asx4 6.13, Thr4 3.89, Ser 1 1.57, Glx3 5.10, Gly,  1.01, Ala2 2.26, 
Va14 5.78, lie2 2.64, Leu 1 1.41, Tyr 1 1.71, Phe3 5.43, Lys3 2.97, Arg 1 1.85. 
Title compound 
FABMS m/z found 3434.1 (M+H), C156H2N4004 7 requires 3433.9; Analytical 
HPLC [column A(C18), gradient F] Rt 14.7 minutes ; Amino acid analysis (HCJ 
hydrolysis, 18 hr.) Asx4 4.20, Thr4 3.39, Ser 1 1.04, G1x3 2.88, G1y 1 1.05, Ala2 1.89, 
Val4 3.84, lie2 1.99, Leu 1 0.94, Tyr1 0.92, Phe3 3.14, Lys3 2.79, Arg 1 1.12. 
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Mouse Nerve Growth Factor 34-42 
H-Lys-Glu-Val-Thr-Val-Leu-Ala-Glu-Val-OH 
The initial resin had been derivatised with Fmoc-Val-OH (0.55 mmol/g; 1.00 g; 
0.55 mmol) Automatic assembly was carried out on the ABI machine using the 
normal double-couple cycles (SA and AE). Monitoring showed that no major drops 
in incorporation efficiency had occurred. The weight of dried resin obtained was 
1.28 g. A portion of this (0.60 g) was cleaved for 2 hr. in a solution of 5% water and 
5% anisole in TFA (10 cm3), to yield the crude peptide (0.24 g) as a single peak 
product (by HPLC). Some of the crude material (50 mg) was dissolved in 5% 
CH3CN/H20 (5 cm3) and purified in two portions by semi-preparative HPLC 
[column E(C18), gradient (0,5), (2,5), (17,20)]. Combining the purest fractions, as 
judged by analytical HPLC, and lyophilisation gave the title compound as a white 
solid (19 mg). 
FABMS m/z 988 (M+H), hrms found 986.56474, CH78N 1 0015 requires 
986.56481 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 15.6 
minutes ; Amino acid analysis (HC1 hydrolysis, 18 hr.) G1112 2.37, Thr1 1.07, Ala1 
1. 16, Va13 3.20, Leu 1 1. 11, Lys 10.87. 
Mouse Nerve Growth Factor 46-54 
H-Asn-Ser-Val-Phe-Arg-Gln-Tyr-Phe-phe-OH 
The initial resin used was the remaining half of NGF 50-54. Fmoc-Asn was not 
side-chain protected. The peptide was assembled manually using single-couple, SA 
cycles, except Val" (double-coupled with AE/BOP) and Asn (double-coupled, 1 x 
AE/BOP, I x AE/HBTtJ). The weight of dried resin after assembly was 2.10 g. A 
portion of this (1.00 g) was cleaved for 2 hr. in a solution of 5% water, 5% anisole 
and 5% phenol in TFA (10 cm 3), to yield a rather insoluble crude product (0.50 g). 
This was subsequently ether extracted (2 x 150 cm) from 20% aqueous acetic acid 
(50 cm3) and lyophilised to yield the crude product (0.31 g). A portion of this 
material (60 mg) was dissolved in 5% CH3CN/H20 (15 cm3) then purified in six 
portions by semi-preparative HPLC [column D(C18), gradient (0,5), (5,5), (20,25)]. 
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Combining the purest fractions, as judged by analytical HPLC, and lyophilisation 
gave the title compound as a white solid (12 mg). 
FABMS m/z 1207 (Mt), hrms found 1206.58224, C59H78N14014 requires 
1206.58219 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Ri 23.9 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asn 1 1.03, G1u 1 1.19, Ser 1 
0.91, Va! 1 1.01, Tyr 1 1.04, Phe3 3.05, Arg 1 1.01. 
Mouse Nerve Growth Factor 50-54 
H-Arg-G!n-Tyr-Phe-Phe-OH 
The initial resin had been derivatised with Fmoc-Phe-OH (0.57 mmol/g; 2.00 g; 
1.14 mmol). The peptide was assembled manually using single-couple, AE/BOP 
cycles. Gin was unprotected. Half of the DMF-wet resin (about 3 g) was removed 
and dried to give 1.40 g dried peptide/resin (the remainder was used in assembly of 
NGF 46-54). A portion of this (0.50 g) was cleaved for 2 hr. in a solution of 5% 
water, 5% anisole and 5% phenol in TFA (10 cm 3) to yield the crude peptide (0.17 
g) as a white solid, which was essentially a single peak on analytical HPLC. A 
portion of this material (50 mg) was dissolved in 5% CH3CN/H20 (5 cm3) and 
filtered. Purification was in three portions by semi-preparative HPLC [column D 
(C18), gradient (0,0), (5,5), (15,25), (25,25)]. The purest fractions, as judged by 
analytical HPLC, were combined and lyophilised to give the title compound as a 
fluffy, white solid (22 mg). 
FABMS m/z 760 (M+H), hr,ns found 759.99472, C38H49N908 requires 759.99481 
(<1 ppm) ; Analytical HPLC [column A(C18), gradient F] Ri 16.8 minutes; Amino 
acid analysis (HCl hydrolysis, 18 hr.) GIn 1 1.16, Tyr1 0.99, Phe2 2.01, Arg 1 1.01. 
Human NGF 50-60 
The initial resin had been derivatised with FmocAsp(OBut)OH (0.58 mmol/g ; 0.95 
g ; 0.55 mmoi). Cysteine was incorporated as Fmoc-Cys(Trt), Gin was unprotected. 
The peptide was assembled manually, using SA cycles, except Arg(Pmc), Cys(Trt) 
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and Gin (double-coupled), which were by AE/HOBt couplings. Assembly 
proceeded well until Tyr(But)  was added, when the resin began to aggregate badly. 
Washes were carried out in 50% DMF/dioxan to try to resolvate the resin. The 
deprotection steps at Tyr(But), Gin and Lys(Boc) were extended by three minutes. 
Lys(Boc) required triple-coupling (SA, AEIHOBt, AE/BOP). The weight of the 
peptide/resin after chain assembly was 1.77 g. A portion of this (1.50 g) was cleaved 
for 3 hr. in a solution of 5% water, 5% EDT and 5% anisole in TFA (20 cm3) to 
yield the crude peptide (0.64 g) as a white solid. On ether extraction, a crystalline 
white solid (0.52 g) was obtained. A portion of this material (50 mg) was dissolved 
in glacial acetic acid (2 cm 3) then water (8 cm 3) was added. Some DMF (1 cm 3) 
was added and the solution sonicated (for 30 mm.) to solubilise the crude mixture. 
The solution, was filtered and purified in five portions by semi-preparative HPLC 
[column B(C18), gradient (0,5), (30,35)]. The purest fractions, as judged by 
analytical HPLC, were combined and lyophilised. A small amount of contaminating 
material still remained. The purest fractions (20 mg) were dissolved in 10% aqueous 
acetic acid (4 cm 3) and purified again by semi-preparative HPLC [column B(C18), 
isocratic at 20% acetonitrile for 30 min.]. Lyophilisation of the appropriate fractions 
gave the title compound as a fluffy, white solid (6 mg). 
FABMS m/z 1466 (M+H), hrms found 1463.68671, CH97N170 1 9S 1 requires 
1463.68673 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient A] Rt 13.1 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.01, Thr1 0.90, Glx2 
2.06, Tyr1 0.93, Phe2 1.97, Lys2 2.01, Ar92 2.06, Cys1 N.D. ; Eliman's test was 
positive. 
Mouse Nerve Growth Factor 59-67 
H-Arg-Ala-Ser-Asn-Pro-Val-Gln-Ser-Gly-OH 
The initial resin had been derivatised with Fmoc-Gly-OH (0.45 mmol/g; 1.10 g; 0.5 
mmol). Automatic assembly was carried out on the ABI machine using normal 
double-couple cycles (SA/AE). Monitoring showed that no major drops in a.a. 
incorporation had occurred. The weight of dried resin obtained was 1.38 g. Some of 
the resin-bound peptide (0.70 g) was cleaved for 3 hr. in a solution of 5% water, 
2.5% thioanisole and 2.5% phenol in TFA (15 cm3), giving a mixture of crude 
peptide and scavengers (0.35 g). Ether extraction (2 x 100 cm 3) of this solution 
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from 10% aqueous acetic acid (15 cm3) and lyophilisation gave the crude peptide 
(0.20 g) as almost a single peak (by HPLC). A portion of this crude material (60 
mg) was dissolved in 10% aqueous acetic acid (6 cm 3) and purified in three runs by 
semi-preparative HPLC [column E(C18), gradient (0,2), (2,2), (12,12)]. Combining 
the purest fractions then lyophiisation gave the title compound as a white solid (45 
mg). 
FABMS m/z 916 (M4 ), hr,ns found 915.44090, C361161N130 1 5 requires 915.44101 
(<1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 16.6 minutes ; Amino 
acid analysis (HC1 hydrolysis, 18 hr.) Asn 1 0.98, Ser1 1.62, Glu1 1.09, Pro 1 0.93, 
G1y 1 0.97, Ala 1 1.20, Va1 1 0.98, Mg 1 0.94. 
Mouse Nerve Growth Factor 66-79 
The initial resin had been derivatised with FmocTyr(But)OH (0.61 mmol/g ; 0.50 g 
0.31 mmol). Cys and His were incorporated as their trityl derivatives, Asti and Trp 
were unprotected. The peptide was assembled manually, using double-couple (1 x 
SA, 1 x AE/HBTU) cycles, except in the following cases: His(Trt), (2 x AE/HBTU) 
Arg(Pmc), (2 x AEIHOBt); Ser, Cys and Gly'. 70 were coupled by single SA. 
The weight of dried resin obtained was 0.96 g. A portion of this (0.50 g) was 
cleaved for 2.5 hr. in a solution of 3% water, 3% EDT and 2% anisole in TFA (15 
cm3), to give 0.22 g (after ether extraction) as almost a single peak product (by 
HPLC). A sample of crude material (50 mg) was dissolved in 10% aqueous acetic 
acid (6 cm3) and purified in five portions by semi-preparative HPLC [column 
D(C18), gradient (0,2), (25,19), (35,19)]. The purest fractions yielded the title 
compound as a white solid (15 mg) after lyophilisation. 
FABMS m/z 1610 (M-i-H), hrms found 1608.71021, C68H1yN22022S 1 requires 
1608.71032 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 12.3 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asx2 1.97, Ser3 3.06, G1y 2 
2.13, 11e 1 0.99, Tyr1 1.08, His 1 1.04, Lys 1 0.86, Arg 1 1.03, Cys 1 N.D., Trp 1 N.D. 
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Conserved Nerve Growth Factor (NGF) 70-74 
H-Gly-Ile-Asp-Ser-Lys-OH 
The initial resin had been derivatised with Fmoc-Lys(Boc)-OH (0.42 mmol/g ; 0.90 
g; 0.38 mmol). The peptide was assembled manually, using double-couple cycles 
(SA and AE) resulting in 1.21 g of dried peptide/resin. A portion of this (0.90 g) 
was cleaved for 2 hr. in a solution of 5% water in TFA (10 cm3), to yield the crude 
peptide (0.30 g) as a white solid. On ether extraction (2 x 50 cm 3) from 10% 
aqueous acetic acid (5 cm3), a crystalline white solid (0.27 g) was obtained. A 
portion of this material (40 mg) was dissolved in 10% aqueous acetic acid (4 cm 3) 
and purified in four portions by semi-preparative HPLC [column C (C18), gradient 
(0,0), (30,20)]. The purest fractions, as judged by analytical HPLC, were combined 
and lyophilised to give the title compound as a fluffy, white solid (19 mg). 
FABMS m/z 519 (M+W), hr,ns found 519.27786, C2 1H39N609 requires 519.27783 
(<1 ppm) ; Analytical HPLC [column A(C18), gradient A] Rt 12.5 minutes; Amino 
acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.11, Ser 1 0.94, G1y 1 1.07, Ile 1 1.07, 
Lys 1 0.92. 
Conserved NGF 71-79 
H-Ile-Asp-Ser-Lys-His-Trp-Asn-Ser-Tyr-OH 
The initial resin had been derivatised with FmocTyr(But)OH (0.50 mmol/g; 1.00 g 
0.50 mmol). Asn and Trp were unprotected. Histidine was incorporated as Fmoc-
His(Trt). The peptide was assembled manually, using single-couple SA cycles, 
except Asn (1 x AE/HOBt), resulting in 2.06 g of dried peptide/resin. A portion of 
this (0.83 g) was cleaved for 3 hr. in a solution of 3% water, 3% EDT, 3% anisole, 
3% phenol (w/v) and 3% ethyl methyl sulphide (EMS) in TFA (15 cm 3, nitrogen-
purged) to yield (after ether extraction) the crude peptide (0.39 g) as a white solid. 
The material contained two peaks, as detected by analytical HPLC. A portion of the 
crude peptide (60 mg) was dissolved in 10% aqueous acetic acid (9 cm 3) then 
acetonitrile (1 cm 3) was added. After sonication and filtration, the filtrate was 
purified in ten portions by semi-preparative HPLC [column E(C18), gradient (0,2), 
(30,12), (45,12)]. Lyophilisation of the appropriate fractions yielded the major peak 
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(10 mg) as a white solid and the minor peak (5 mg) as a brown, sticky oil. The 
major peak was confirmed as the title compound by subsequent analysis. 
FABMS m/z 1149 (M+H), hrms found 1148.52501, C52H72N14016 requires 
1148.52507 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient D] Rt 19.0 
minutes ; Amino acid analysis (4-TSA hydrolysis, 18 hr.) Asx2 1.85, Ser2 1.83, lie 1 
1.01, Tyr 1 1.03, His 1 1.01, Trp 1 0.83, Lys1 1.12 ; The major peak was confirmed by 
the successful sequencing of the peptide to give correct values for all a.a.'s. 
Conserved NGF 95-116 (reduced form) 
Leu-Ser-Arg-Lys-Ala-OH 
The initial resin had been derivatised with Fmoc-Ala-OH (0.50 mmol/g ; 1.10 g 
0.55 mmol). Cysteine was incorporated as Fmoc-Cys(Trt), Gln and Tip were 
unprotected. The peptide was assembled manually, using single-couple SA cycles, 
except in the following cases: Arg' 03 and Cysbos  were triple-coupled (2 x AE/BOP, 1 
x AE/HOBt :1 x SA, 2 x AE/BOP), Trp 99 and Thr' 06 were double-coupled (2 x SA), 
Arg100 was double-coupled (2 x AE/BOP) and Lys 95 Gln were coupled singly (1 x 
AE/BOP). Resin desolvation was seen after the coupling of Val'° 9. The weight of 
dried resin obtained was 3.00 g. A portion of this (0.35 g) was cleaved for 2.5 hr. in 
a solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3, under nitrogen) to 
yield the crude peptide (0.20 g). On ether extraction, a crystalline white solid (0.17 
g) was obtained. A portion of this material (66 mg) was dissolved in glacial acetic 
acid (3 cm3) then aqueous 0.1% TFA (27 cm 3) was added. The solution was filtered 
and purified in six portions by semi-preparative HPLC [column E(C1 8), gradient 
(0,5), (30,35)]. The purest fractions, as judged by analytical HPLC , were combined 
and lyophilised to give the title compound as a fluffy, white solid (6 mg). 
FABMS m/z 2536.4 (M+W), hrms found 2536.38367, C1 12H188N35028S2 requires 
2536.38370 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Rt 18.1 
minutes ; Amino acid analysis (HC1 hydrolysis, 18 hr.) Asp 1 1.06, Thr 1 0.93, Ser 1 
0.96, G1u 1 1.13, Ala4 3.98, Va12 1.99, lie2 1.87, Leu 1 1.02, Phe 1 0.95, Lys2 2.00, 
Ar93 2.85, Cys2 N.D., Tip 1 N.D. ; Ellman's test was positive. 
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Conserved NGF 95-116 (oxidised form, Cystwile disulphide-linked) 
Leu-Ser-Arg-Lys-Ala-OH 
A further batch of dried NGF H-95-116-OH resin (1.60 g) was cleaved under the 
same conditions as above to yield the crude product (0.79 g). A portion of this (0.30 
g) was dissolved in a minimum amount of 30% aqueous acetic acid (30 cm 3), passed 
down a column of G25 Sephadex (Fine, 2.5 x 150 cm) and eluted at 30 cm 3/hr. with 
the same solvent. UV absorbance was monitored at 254 and 277 nm. Fractions 
containing peptide were verified with Ehrlich's spray. The purest of these was 
combined and lyophilised to yield a white solid (0.20 g). This was dissolved in 
glacial acetic acid (4 cm 3), diluted with aqueous 0.1% TFA (16 cm 3) and purified in 
three portions by semi-preparative HPLC [column F, gradient (0,5), (45,30)]. 
Combining the appropriate fractions yielded a further amount of reduced NGF H-95-
116-OH (21 mg). A portion of this (15 mg) was dissolved in H 2O (50 cm3) and 
stirred continuously. The original reduced peak decreased in height to be replaced 
by a new, more hydrophilic peak [by analytical HPLC, column A(C18), gradient 
(0,10), (20,60), Ri changed from 13.6 to 12.4 mm.]. After 24 hr., 50% conversion 
had occurred. Addition of K 3Fe(CN)6 (0.7 cm 3, 2 mg/cm3 solution in H20), led to 
80% conversion in a further 2 hr. The entire solution (50 cm3) was loaded onto a 
semi-preparative HPLC column through the aqueous pump and the mixture purified 
[column F, gradient (0,5), (10,5), (40,30)]. Lyophilisation of the appropriate 
fractions gave the title compound as a white solid (4.5 mg). 
FABMS m/z 2534.8 (M+H), hrms found 2534.36798, C112H 1 86N35028S2 requires 
2534.36805 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient B] Ri 12.4 mm. 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.01, Thr 1 0.97, Ser f 0.96, Glu 1 
1.11, Ala4 4.05, Va1 2 1.99, lie2 1.88, Leu 1 1.02, Phe 1 1.09, Lys2 2.06, Ar93 3.01, 
Cys2 N.D., Trp 1 N.D. ; Eliman's test was negative. 
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Conserved NGF 100-115, Cys1110 disulphide-linked 
The initial resin had been derivatised with Fmoc-Lys(Boc)-OH (0.67 mmol/g; 1.00 
g; 0.67 mmol). Cysteine was incorporated as Fmoc-Cys(Trt). The peptide was 
assembled automatically, using the normal double-couple cycles. A drop in 
incorporation occurred over the residues Asp lO5 ThrI06. The weight of dried resin 
obtained was 2.02 g. All of this was cleaved for 2.5 hr. in a solution of 3% water, 
3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude peptide (0.73 g) as a 
white solid. This was purified in nine runs [9 x 80 mg, each portion dissolved in 
25% aqueous acetic acid (10 cm 3)] by semi-preparative HPLC [column F, gradient 
(0,5), (30,40)]. Lyophilisation of the combined fractions gave the reduced peptide 
(0.13 g) as a white solid. 
A sample of this pure, reduced peptide (32 mg) was dissolved in H 20 (32 cm3), 
stirred continuously and the reaction followed by analytical HPLC. After 24 hr., the 
reduced peak showed partial conversion to an oxidised form [column A(C18), 
gradient G, a change from reduced peak (75%) Ri 22.9 to oxidised peak (25%) Ri 
12.7 mm. was observed]. To speed the reaction, K 3Fe(CN)6 (0.5 cm3 of a solution 
of 2 mg/cm 3 in H20) was added. The solution became light yellow and turbid. 
After a further four hours, the entire solution was filtered to remove a fine, white 
insoluble precipitate that had formed. The filtrate was loaded onto a semi-
preparative HPLC [column F] and the components separated [gradient (0,0), 
(60,35)]. The appropriate lyophilised fractions gave the title compound (6.5 mg) in 
low yield. A further amount (45 mg) of the pure, reduced peptide was dissolved in 
H20 (45 cm3) and allowed to oxidise over a 48 hr. period. 80% conversion to the 
oxidised form was seen to occur. The same purification procedure as before [except 
TFA (45 IL1) was added and the gradient was (0,0), (0,5), (60,35)] yielded a further 
18.5 mg of the title compound as a white solid. 
Reduced form 
FABMS m/z 1880.3 (M+H), hrms found 1879.02838, C81H142N26021 S2 requires 
1879.02842 (< 1 ppm) ; Analytical HPLC [column B(C18), gradient 0] Ri 15.0 




FABMS m/z 1878.1 (M+W), hrms found 1877.01280, C8 1H 140N26021S2 requires 
1877.01272 (< 1 ppm) ; Analytical HPLC [column B(C18), gradient 0] Rt 14.1 
minutes ; Amino acid analysis (HCI hydrolysis, 18 hr.) Asp1 1.06, Thr1 0.92, Ser 1 
0.62, Ala1 1.02, Va12 1.92, Ile2 1.89, I_eu1 1.00, Phe1 0.94, Lys1 1.00, Ar93 2.83, 
Cys2 N.D. ; Ellman's test was negative. 
600 MHz 1H NMR (90% H20, 10%D20) 
0 in ijum 
Residue a-NH a-CH 13-CH Others 
Arg - 4.02 1.903.90 'yl.59;63.21;NH7.21 
Phe 101 8.82 4.71 3.03,3.07 Ring7.04,7.12 
lie102 8.35 4.18 1.85 CH21.17,1.45;'CH 30.88;0.88 
Arg 103 8.28 4.25 1.72,1.80 yl.56,1.63;63.25;NH7.28 
lie'04 8.15 4.08 1.70 CH21.08,1.43;7CH 30.80;60.80 
8.64 - 2.80,2.92 
fl IO6 8.25 4.35 4.25 
AlaIO7 8.13 4.28 1.21 
Cys 108 8.10 4.68 3.103.28 
Vai 09 9.04 4.12 2.22 'Yl.00 
Cys 110  8.33 4.52 3.20,3.50 
Vai 111 8.11 4.13 2.15 10.94 
Leu 112 8.36 4.40 1.66,1.66 71.60;80.86,0.93 
Ser113 8.24 4.44 3.85,3.85 
Arg 114 8.30 4.39 1.76,1.90 yl.66;63.21;NH7.19 
Lys 115 8.26 4.27 1.75,1.86 yl .43;81 .67;c2.99;cNH 3 7.54 
Conserved NGF 101-115, Cys108110  disulphide-linked 
The initial resin had been derivatised with Fmoc-Lys(Boc)-OH (0.53 mmol/g ; 0.95 
g ; 0.50 mmoi). Cysteine was incorporated as Fmoc-Cys(Trt). The peptide was 
assembled automatically, using the normal double-couple cycles, except Asp'° 5 and 
Thr', which were triple-coupled. A drop in incorporation occurred over the 
residues Thr' 06-A1a107 . The weight of dried resin obtained was 2.75 g. All of this was 
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cleaved for 3 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (20 
cm3) to yield the crude peptide (1.05 g) as a white solid. Purification of some of the 
crude product (0.65 g) was in thirteen runs [13 x 50 mg, each portion dissolved in 
10% aqueous acetic acid (5 cm3)] by semi-preparative HPLC [column F, gradient 
(0,5), (25,35)]. Lyophilisation of required fractions gave an almost pure product (73 
mg) Repurification under the same conditions [except gradient was (0,5), (25,35)] 
yielded the pure, reduced peptide (31 mg) as a white solid. 
Oxidation of this product in H 20 (150 cm3) led to 80% conversion to the oxidised 
form [by HPLC; column A(C18), gradient G, a change in Ri from 18.7 to 18.1 
minutes was observed]. TFA (0.15 cm 3) was added to the solution, followed by 
filtration then the filtrate was loaded onto a semi-preparative HPLC [column F] and 
the components separated [gradient (0,0), (10,0), (55,35)]. The appropriate fractions 
were lyophilised to give the title compound (9 mg) as a white solid. 
IfforrIMIF =I 
FABMS mlz 1725.2 (M+H) ; Analytical HPLC [column A(C18), gradient 0] Ri 
18.7 minutes ; Eliman's test was positive. 
Title compound 
FABMS m/z 1722.4, hr,ns found 1720.91159, C75H 1 28N22020S2 requires 
1720.91161 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient 0] Ri 18.7 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 0.98, Thr 1 0.80, Ser 1 
0.61, Ala 1 0.97, Va12 1.95, Ile2 1.83, Leu 1 1.01, Phe 1 0.93, Lys 0.97, Ark 1.82, 
Cys2 N.D. ; Ellman's test was negative. 
Conserved NGF 106-116 (reduced form) 
The peptide/re sin NGF H- 111- 116-OH was used in this assembly. Cysteine was 
incorporated as Fmoc-Cys(Trt). All residues were added using single-couple SA 
cycles, except Thr' 06 and Cys' (2 x SA). Resin desolvation was apparent after the 
incorporation of Va1' 0 . The weight of dried resin obtained was 1.32 g. A portion of 
this (0.61 g) was cleaved for 2.75 hr. in a solution of 3% water, 3% EDT and 2% 
anisole in TFA (15 cm 3) to yield the crude peptide (0.22 g) as a white solid. A 
portion of this material [40 mg dissolved in 15% aqueous acetic acid (8 cm 3)] was 
purified in four runs by semi-preparative HPLC [column D(C18), gradient (0,10), 
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(2,10), (10,20), (25,20)]. The purest fractions were combined and lyophilised to 
give the title compound as a fluffy, white solid (11 mg). 
FABMS mlz 1151 (M+H), hrms found 1150.11479, C47H87N 15014S2 requires 
1150.11479 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient C] Rt 11.6 
minutes ; Amino acid analysis (HCI hydrolysis, 18 hr.) Thr 1 0.97, Ser 1 0.94, Ala2 
2.11, Va12 1.97, Leu 1  1.00, Lys 0.99, Arg 1.06, Cys2 N.D. ; Ellman's test was 
positive. 
Conserved NGF 106-116 (oxidised form, Cys"L'1' disulphide-linked) 
H-Thr-Ala-Cys°-Val-Cys-va1.userArg.Lys..Ala..oH 
The remainder of the crude material (0.17 g) from NGF H-106-1 16-OH (reduced 
form) was purified in two lots by semi-preparative HPLC [column F, gradient 
(0,10), (30,25)], to yield a further 43 mg of pure reduced product. 40 mg of this was 
dissolved in H20 (200 cm 3) and stirred continuously over six days. After this time, 
analytical HPLC [column C, gradient (0,10), (25,50)] showed a change in Rt from 
15.9 to 16.3 minutes, to give a main peak (75% by peak height) and two later 
running peaks (X and Y), where X = 12%, Rt 16.9 mm. ; Y = 15%, Rt 19.4 mm. 
The entire solution was therefore pumped onto a semi-preparative HPLC [column F, 
gradient (0,0), (10,0), (40,25), (45,25), (55,30), (65,30)]. Lyophilisation of the 
separated peaks gave the major peak (17.5 mg) and peaks X (5 mg) and Y (3.5 mg). 
Subsequent analysis showed that the major peak represented the title compound. 
Peaks X and Y appeared to represent dimeric forms (FABMS m/z 2296.0). 
FABMS m/z 1148.5 (Mt), hrms found 1147.99921, C47H85N 1 5014S2 requires 
1147.99912 (< 1 ppm) ; Analytical HPLC [column C, gradient F] Rt 15.3 minutes; 
Amino acid analysis (HCl hydrolysis, 18 hr.) Thr 1 0.97, Ser 1 0.94, Ala2 2.11, Va12 
1.97, Leu 1 1.00, Lys 1 0.99, Arg 1  1.06, Cys2 N.D. ; Eliman's test was negative. 
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Conserved NGF 111-116 
H-Val-Leu-Ser-Arg-Lys-Ala-OH 
The initial resin had been derivatised with Fmoc-Ala-OH (0.45 mmol/g; 1.50 g; 
0.68 mmol). The peptide was assembled manually, using single-couple SA cycles. 
Half of the Fmoc-protected resin was dried down to give 0.58 g (the assembly was 
continued to form NOF H-106-116-OH using the other half). A portion of this dried 
resin (0.25 g) was cleaved for 2 hr. in a solution of 5% water and 5% thioanisole in 
TFA (10 cm3) to yield the crude peptide (0.11 g) as a white solid. The soluble crude 
product [45 mg dissolved in 10% aqueous acetic acid (6 cm 3)] was purified in three 
portions by semi-preparative HPLC [column D(C18), gradient (0,5), (15,25)]. The 
purest fractions, as judged by analytical HPLC , were combined and lyophilised to 
give the title compound as a dense, crystalline solid (27 mg). 
FABMS m/z 673 (M+H), hrms found 672.42831, C29H56N 1008 requires 
672.42826 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient C] Rt 9.1 
minutes ; Amino acid analysis (HC1 hydrolysis, 18 hr.) Ser 1 0.96, Ala 1 1.08, Va! 1 
0.95, Leu 1 0.98, Lys 1 0.96, Arg 1 1.06. 
Conserved NGF 100-115 amide, Cys10.11e  disulphide-linked 
The initial resin used had the dibenzosuberyl linker to provide an amide on cleavage 
(0.45 mmol/g ; 0.50 g; 0.23 mmol). Cysteine was incorporated as FmocCys(SBut). 
The peptide was assembled automatically, using the normal double-couple cycles, 
except for residues Argi 00 Ala107 , which were triple-coupled. A drop in incorporation 
again occurred over the residues Ile' 04-Ala' 07 . The weight of dried resin obtained was 
1.18 g. A portion of this (0.60 g) was cleaved for 2.5 hr. in a solution of 3% water, 
3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude peptide (0.30 g) as a 
white solid. A portion of this material (0.10 g) was placed in a silanised flask and 
was completely dissolved in 95% aqueous TFE (5 cm3) by stirring under nitrogen. 
Excess tributylphosphine (TBP, 0.3 cm 3) was added under nitrogen. Stirring was 
continued under N2 for 2 hr., after which time the entire solution was evaporated in 
vacuo to a colourless oil and the crude, reduced peptide precipitated by the addition 
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of excess ether. Filtration gave a solid which was immediately taken up in 10% 
aqueous acetic acid (25 cm3), extracted with ether (2 x 150 cm3) then loaded directly 
onto a semi-preparative HPLC [column F] and the components separated [gradient 
(0,20), (10,20), (40,40)]. Lyophilisation of the required fractions gave the pure, 
reduced peptide (16 mg) as a white solid. This was dissolved in H 20 (32 cm3) and 
oxidised over 36 hr. with stirring, to form the pure, oxidised peptide. No further 
purification was required. Lyophilisation of the entire solution gave the title 
compound (15 mg) as a white solid. 
Reduced form 
FABMS m/z 1880.8, hrms found 1879.05221, C8 1H 1 N27020S2 requires 
1879.05216 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 14.6 minutes 
for di-SBu' peptide, Rt 17.6 mm.) ; Eliman's test was positive. 
Title compound 
FABMS m/z 1877.6 (M+H), hr,ns found 1877.03655, C8 1H 142N27020S2 requires 
1877.03651 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 14.1 minutes; 
Amino acid analysis (HC1 hydrolysis, 18 hr.) Asp 1 0.80, Thr1 0.87, Ser 1 0.78, Ala1 
1.00, Va12 2.11, lie2 1.85, Leu 1 1.04, Phe 1 0.94, Lys 1.05, Ar93 3.15, Cys2 N.D. 
Eliman's test was negative. 
Conserved NGF 100-115 amide, Cys10110  disulphide-linked 
The initial resin used had the dibenzosuberyl linker to provide an amide on cleavage 
(0.45 mmol/g ; 0.50 g ; 0.23 mmol). Cysteine was incorporated as Fmoc-Cys(Trt). 
The peptide was assembled automatically, using the normal double-couple cycles, 
except for the sequence Arg' 00-Ala' 07 , in which each residue was triple-coupled. A 
drop in incorporation occurred over the residues Ile'04-Ala'07. The weight of dried 
resin obtained was 1.14 g. A portion of this (0.60 g) was cleaved for 2.5 hr. in a 
solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude 
peptide (0.23 g) as a white solid. The analytical HPLC trace of this crude was poor. 
A sample of this crude (90 mg) was purified by semi-preparative HPLC [column F, 
gradient (0,10), (40,40)] to give the pure, reduced peptide in low yield (4.5 mg) and 
a deletion product (7 mg), which analysis showed to lack the residues R100F1102.  The 
remainder (0.14 g) was stirred in 10% DMSO/TFA (5 cm3) for 1 hr., evaporated in 
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vacuo to near dryness and a white solid (0.35 g), precipitated by the addition of 
excess ice-cold ether. Filtration and drying gave the crude, oxidised product. 
Purification of this was by semi-preparative HPLC [column F, gradient (0,20), 
(40,40)]. Lyophilisation of appropriate fractions gave the title compound (6 mg) as a 
white solid. 
Reduced form 
FABMS m/z 1881.0 (M+H), hr,ns found 1879.05217, C8 1H 1 N27020S2 requires 
1879.05216 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 17.4 minutes; 
Eliman's test was positive. 
Title compound 
FABMS rn/z 1877.9 (M+H), hrms found 1877.03655, C8 1H 142N27020S2 requires 
1877.03651 (<1 ppm) ; Analytical HPLC [column C, gradient H] Rt 16.9 minutes; 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 0.84, Thr 1 0.86, Ser1 0.70, Ala1 
1.29, Va12 2.29, Ile2 1.87, L.eu 1 1.11, Phe l 0.96, Lys 1 1.16, Ar93 2.91, Cys2 N.D. 
Eliman's test was negative. 
2-Copoly(styrene- 1% -divinylbenzene)methoxy-5-heptyliminodibenzocyclo-
heptadiene 
Resin [Compound 1 (ref. section 2.2.1, p.  45), 0.62 mmol/g, 0.80 g] was swollen in 
DCM (16 cm3) along with heptylamine (1.29 cm 3, 1.00 g, 8.70 mmol), cooled in an 
ice/salt bath and stirred under an atmosphere of dry nitrogen. A solution of 1.OM 
titanium (IV) chloride in DCM (1.50 cm3, 1.50 mmol) was added dropwise then the 
mixture heated under reflux for three hours. After cooling for one hour under N 2 , 
the resin was filtered off, washed with copious amounts of DCM and dried in vacuo 
to yield the title compound (Compound 2, 0.88 g) as a pale-yellow solid. 
Nitrogen analysis found: N, 0.79% ; expected for 100% loading, 0.81% ; V max  (KBr 
disc) : 3080-2840 (CH), 1600 cm -1 (C=C) [the original band at 1640 cm -1 (C=O) 





Resin [Compound 2 (ref. p.45), 0.76 g] was stirred in THF (20 cm 3), LiBH4 added 
(0.10 g, 4.55 mmol) and the mixture heated under reflux for two hours under an 
atmosphere of dry nitrogen. The mixture was then cooled in an ice/salt bath, 
methanol (5 cm3) added then acetone (5 cm3) was added dropwise. The resin was 
filtered off and washed extensively with methanol, water, then methanol again. 
Drying in vacuo gave the title compound (Compound 3, 0.71 g) as a white solid. 
Vm (KBr disc): 3420 (NH), 3080-2840 (CH), 1600 cm -1 (C=C) 
2-Copoly(styrene-1 % divinyIbenzene)methoxy5(NafluorenyImethoxy. 
carbony1IysyI(NC1ertbutyIoxycarbonyI)hepty1amjnodjbenzocycJo 
heptadiene 
Fmoc-Lys(Boc)-OH (2.30 g, 5.00 mmol) was dissolved in a minimum amount of 
DMF/dioxan (1:1, 4.0 cm 3) then DIC (0.4 cm 3, 2.5 mmol) was added. After 20 mm. 
stirring, a portion of resin [Compound 3 (ref. p.45), 0.35 g, 0.25 mmol] was added 
and the slurry sonicated at 200c for twenty-two hours. After this time, the resin was 
washed with excess DMF and a small sample (5 mg) dried with ether then in vacuo 
overnight. The functionality of the resin by UV monitoring was 0.29 mmol/g (total 
—0.1 mmol). The loading reaction was repeated for a further sixteen hours using all 
of the resin to give the title compound (Compound 4, 0.36 g) as a pale-yellow solid 
with a functionality of 0.40 mmol/g (total —0.14 mmol). 
Vmax (KBr disc): 3410 (NH), 3080-2840 (CH), 1730 (C=O), 1640 (C=O), 1600 cm -1  
(C=C). 
Conserved NGF 100-115 heptylamide, Cys''° (SBut) 
(CH2)6CH3 
The resin [Compound 4 (ref. p.45)] used was to provide a heptylamide on cleavage 
(0.40 mmol/g ; 0.36 g;  0.14 mmol). Cysteine was incorporated as FmocCys(SBut). 
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The peptide was assembled automatically, using triple-couple cycles for each 
residue. The weight of dried resin obtained was 0.62 g. A portion of this (0.31 g) 
was cleaved for 4 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (10 
cm3) to yield the crude peptide (0.11 g) as a white solid. A portion of this material 
(50 mg) was dissolved in 25% aqueous acetic acid (12 cm 3), filtered and purified by 
semi-preparative HPLC [column F, gradient (0,20), (45,60)]. Lyophilisation of the 
purest fractions gave the title compound (10 mg) as a fluffy, white solid. 
FABMS m/z 2154.7 (M+H), hnns found 2154.23442, C96H 174N27020S4 requires 
2154.23440 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 20.1 minutes; 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 0.84, Thr1 0.73, Ser f 0.76, Ala 1 
1.00, Va12 2.17, lie2 2.13, Leu 1 1.08, Phe 1 0.87, Lys 1 1.09, Ar93 3.10, Cys2 N.D. 
Eliman's test was negative. 
Conserved NGF 100-115 heptylamide, CysOv IO disulphide-linked 
(CH2)6CH3 
The remainder of the crude from the above assembly (60 mg) was extracted from 
20% aqueous acetic acid (30 cm 3) with ether and lyophilised to yield a more soluble 
product (45 mg). A portion of this (26 mg) was dissolved in 95% aqueous TFE (4 
cm3), TBP (0.1 cm3) added then stirring continued under nitrogen for 3 hr. 
Evaporation in vacuo followed by the addition of ether gave the crude, reduced 
peptide (20 mg). This was purified by semi-preparative HPLC [column F, gradient 
(0,15), (45,45)] and the purest fractions lyophilised to gave the pure, reduced peptide 
(5 mg) as a white solid. This was dissolved in H 20 (30 cm3) and air-oxidised, with 
stirring, over five days to form the pure, oxidised peptide. No further purification 
was required. Lyophilisation of the entire solution gave the title compound (3.5 mg) 
as a white solid. 
FABMS m/z 1975.5, hrms found 1975.14609, C88H156N27020S 2 requires 
1975.14614 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Ri 15.0 minutes; 
Amino acid analysis (HO hydrolysis, 18 hr.) Asp 1 0.84, Thr 1 0.73, Ser 1 0.76, Ala 1 
1.00, Va12 2.17, 11e2 2.13, Leu 1 1.08, Phe 1 0.87, Lys 1 1.09, Ar93 3.10, Cys2 N.D. 
Eliman's test was negative. 
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Conserved NGF 100-114, CyShhl.111 disulphide-linked 
The initial resin had been deiivatised with Fmoc-Arg(Pmc)-OH (0.60 mmol/g; 1.00 
g; 0.60 mmol). Cysteine was incorporated as Fmoc-Cys(Trt). The peptide was 
assembled automatically, using the normal double-couple cycles, except Asp' 05 and 
Thr' 06, which were triple-coupled. The weight of dried resin obtained was 2.37 g. 
All of this was cleaved for 3.5 hr. in a solution of 3% water, 3% EDT and 2% phenol 
in TFA (20 cm 3) to yield the crude peptide (0.82 g) as an insoluble white solid. An 
attempt was made to purify some of the crude product [50 mg, dissolved in 20% 
aqueous acetic acid (10 cm 3)] by semi-preparative HPLC, which led to poor 
recovery of the pure, reduced product (2 mg). The remainder of the crude peptide 
was ether extracted from 20% aqueous acetic acid to yield a more soluble white solid 
(0.52 g). A sample of this (0.40 g) was dissolved in 20% DMSOTFFA (25 cm3), 
with anisole added (0.1 cm 3) and stirred for 2 hr. at RT. The solution was 
evaporated in vacuo to near dryness (some DMSO remained) and a white solid (0.30 
g) formed on the addition of excess ice-cold ether. A change in Ri from 24.0 to 23.3 
minutes for the major peak was seen on analytical HPLC [column A(C18), gradient 
E]. Purification of all of the oxidised, crude product was in six runs [6 x 50 mg, 
each portion dissolved in 20% aqueous acetic acid (10 cm 3)] by semi-preparative 
HPLC [column F, gradient (0,10), (45,30), (55,30)]. Lyophilisation of the required 
fractions gave the title compound (46 mg) as a white solid. 
Reduced form 
FABMS mlz 1753.3 (M+H) ; Analytical HPLC [column A(C18), gradient El Rt 
24.0 minutes ; Eliman's test was positive. 
Title compound 
FABMS m/z 1751.7 (M+H), hrms found 1749.92656, C75H129N24020S 2 requires 
1749.92654 (cz 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Ri 20.0 
minutes ; Amino acid analysis (HC1 hydrolysis, 18 hr.) Asp 1 1.12, Thr 1 0.69, Ser 1 
0.63, Ala 1 0.98, Va12 1.95, Ile2 2.20, Leu 1 1.00, Phe 1 1. 11, Ar93 3.16, Cys2 N.D. 
Eliman's test was negative. 
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600 MHz 1H NMR (d6-DMSO) 
0 m num 
Residue a-NH a-CH [3-CH Others 
Arg 1 - 3.74 1.68 yl.49;63.05;NH7.64 
Phe 101 8.54 4.69 2.77,3.00 Ring7.26 
HOW 8.24 4.22 1.72 'CH31.06,1.41;'CH30.80;80.80 
Arg 103 8.04 4.20 1.75 y1.59;63.08;NH7.51 
Ile' 04 8.58 4.28 1.68 21.06,1.49 30.850.85 
AspIOS 8.48 4.65 2.52,2.70 
Thr106 7.58 4.18 3.98 'yl.Ol 
AjaI07 7.87 4.32 1.19 
Cys 108  8.24 4.55 2.51,2.62 
Va! 109 8.81 4.01 2.09 10.89 
Cys"° 7.34 4.63 2.83,3. 14 
Va1 8.03 4.34 1.95 O.84 
Leu 2 7.93 4.22 1.70 yl.70;80.80 
Ser113 7.81 4.28 3.54 
Arg 4 8.00 4.18 1.75 yl.49;83.08;NH7.51 
Conserved NGF 100-110 (reduced form) 
The initial resin had been derivatised with Fmoc-Cys(Trt)-OH (0.32 mmol/g ; 0.80 g 
0.26 mmol). Cysteine was incorporated as Fmoc-Cys(Trt). Automatic assembly 
was carried out on the ABI machine, using the normal double-couple cycles and 
monitoring showed that no drops in incorporation had occurred. The weight of dried 
resin obtained was 1.61 g. A portion of this (0.78 g) was cleaved for 2.5 hr. in a 
solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3, under nitrogen) to 
yield an insoluble crude product, which on ether extraction (2 x 150 cm 3) from 20% 
aqueous acetic acid (50 cm3), yielded a more soluble crude product (0.18 g). A 
portion of this material (60 mg) was purified in six runs by semi-preparative HPLC 
[column D(C18), gradient (0,15), (2,15), (20,25)1. The purest fractions were 
combined and lyophilised to give the title compound as a fluffy, white solid (10 mg). 
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FABMS m/z 1297 (M+W), hnns found 1295.64790, C55H93N 1 7015S2 requires 
1295.64785--(< 1 ppm) ; Analytical HPLC [column A(C18), gradient B] Rt 14.8 
minutes ; Amino acid analysis (HO hydrolysis, 18 hr.) Asp 1 1.04, Thr 1 0.97, Ala 1 
1.14, Va1 1 1.00, 11e2 1.85, Phe 1 0.96, Ark 1.95, Cys2 N.D. ; Ellman's test was 
positive. 
Conserved NGF 100-110 (oxidised form, Cys'" disulphide-linked) 
A portion of the crude product from NGF 100-110 reduced (0.80 g) was purified in 
by semi-preparative HPLC [column F, gradient (0,10), (35,30)], with poor recovery 
of the pure, reduced product (7 mg). The remainder of the resin (0.83 g) was 
cleaved under the same conditions as above to yield a further amount of crude 
peptide (0.25g). All of this material [dissolved in 15% aqueous acetic acid (35 cm3)] 
was purified in six portions [column F, gradient (0,10), (35,30)] to give the pure, 
reduced peptide (50 mg). The combined pure, reduced peptides (57 mg) were 
dissolved in H20 (250 cm3) and stirred continuously for six days. After this time, 
analytical HPLC [column A(C18), gradient (0,10), (25,50)] showed a change in Ri 
from 22.9 to 22.1 minutes for the main peak. TFA (0.25 cm 3) was added, the entire 
solution filtered, loaded onto a semi-preparative HPLC [column F] and the 
components separated [gradient (0,0), (5,0), (55,30)]. The lyophilised main peak 
fractions gave the title compound (26 mg), with two trace hydrophobic impurities 
appearing as dimeric forms (3 mg, m/z 2588.8 ; 2 mg, m/z 2591.0). 
FABMS m/z 1294.6 (M+H), hrms found 1293.631201, C55H9 1 N1701 5S2 requires 
1293.631195 (< 1 ppm) ; Analytical HPLC [column A(C18), gradient F] Ri 16.7 
minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.04, Thr 1 0.97, Ala 1 
1.14, Va! 1 1.00, Ile2 1.85, Phe 1 0.96, Ark 1.95, Cys2 N.D. ; EIlman's test was 
positive. N.M.R. results are included below. 
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600 MHz 1H NMR (90% H201  10%D20) 
0 in ppm 
Residue a-NH a-CH 3-CH Others 
Arg - 4.01 1.89 yl.58;83.20;NH7.22 
Phe 101 8.82 4.71 3.05 Ring7.34 
lie102 8.31 4.16 1.86 CH21.18,1.45;7CH30.90;60.85 
Arg 103 8.28 4.24 1.72,1.79 yl.55,1.62;83.23;NH7.26 
Il& 04 8.16 4.06 1.72 CH21.08,1.40;'1CH30.80;80.80 
4&.)105 8.64 - 2.84,2.97 
Thr106 8.26 4.35 4.16 
Ala 107 8.13 4.29 1.19 
Cys 108  8.16 4.51 3.07,3.28 
Vai 8.87 4.07 2.10 70.98 
Cys 0 8.24 - 3.10,333 
NGF 100-116 Ser'°, Arg 116, Cys10$.110 (Acm) 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.51 mmol/g; 1.00 
g; 0.51 mmol). Cysteine was incorporated as Fmoc-Cys(Acm). The peptide was 
assembled automatically, using the normal double-couple cycles. The weight of 
dried resin obtained was 2.77 g. A portion of this (1.50 g) was cleaved for 2 hr. in a 
solution of 3% water, 3% EDT and 2% phenol in TFA (20 cm 3) to yield the crude 
peptide (0.74 g) as an almost single product (by HPLC). The crude peptide was 
ether extracted from 10% aqueous acetic acid to yield a white solid (0.54 g). 
Purification of crude product (0.50 g) was in five runs [each portion dissolved in 
10% aqueous acetic acid (4 cm 3)] by semi-preparative HPLC [column F, gradient 
(0,5), (25,25), (35,25)]. Lyophilisation of required fractions gave the title compound 
(57 mg) as a white solid, with a further portion of almost pure product (57 mg, 90% 
pure by HPLC). 
FABMS m/z 2196.0 (M+H), C93H 164N32025S2 requires 2194.6; Analytical HPLC 
[column A(C1 8), gradient E] Rt 19.3 minutes ; Amino acid analysis (HC1 hydrolysis, 
18 hr.) Asp 1 1.08, Thr1 0.84, Ser2 2.12, Va12 2.17, lie2 2.11, l..eu 1 1. 10, Phe1 1.04, 
Lys 1 1.07, Arg4 3.74, Cys2 N.D. ; Ellman's test was negative. 
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NGF 100-116 Ser°, Arg", Cysb0 hb0  disulphide-linked. 
H-Arg-Phe-fle-Arg-Ile-Asp-Thr-Ser-Cys°"-Val-Cys°'-Val-Leu-Ser-Arg-Lys-Arg-OH 
A sample of the pure, di-Acm protected peptide (50 mg, 0.03 mmol) and silver 
triflate (AgOTf, 0.15 g, 0.6 mmol) were dissolved in TFA (4 cm 3) and stirred at 00c 
for 90 mm. in the absence of light. The solution was then evaporated to dryness in 
vacuo and a fine, white solid precipitated on the addition of excess ether. Collection 
by filtration and drying gave the silver salt of the peptide as a white powder (70 mg). 
By HPLC [column E, gradient. F], the original peak due to the di-Acm compound, 
had been replaced by a later-running, broad peak [Rt changed from 16.3 to 17.0 
mm.]. Dithiothreitol (DTT, 0.45 g, 3.0 mmol) was dissolved in glacial acetic acid (2 
cm3) then H20 (2 cm3) added. The silver salt of the peptide (65 mg) was added to 
this with vigorous stirring, which was continued for 2 hr. in the absence of light. 
After this time, the milky, yellow suspension that had formed was centrifuged (6000 
x g, 30 mm.) to pellet an insoluble, yellow precipitate. Analytical HPLC [column 
A(C18), gradient El of the filtrate showed that a single peak had formed, with a Rt of 
19.2 minutes. The filtrate (4 cm 3) was diluted to 30% aqueous acetic acid [H 20 (2 
cm3) added] then passed down a Sephadex G50 column (Fine, 1.5 x 35 cm), eluting 
at 15cm3/hr. with the same solvent. Fractions containing peptide were identified 
using Sakaguchi's test, then examined by HPLC. The purest, reduced fractions were 
combined and lyophilised to yield the reduced form of NGF H-100-1 16-OH, Ser', 
Arg 1 1 6 (21 mg) as a white solid [m/z 2053.7 (M+W)]. 
A portion of the pure, reduced peptide (15 mg) was dissolved in H 2O (50 cm3) and 
allowed to air oxidise, with constant stirring over three days. By HPLC [column 
A(C18), gradient E], a change in Rt from 17.5 to 17.0 mm. was observed. No 
further purification was required (conversion > 99%). Lyophilisation of the entire 
solution gave the title compound (14 mg) as a fluffy, white solid. 
FABMS mlz 2050.7 (M), C87H 152N30023S2 requires 2050.5 ; Analytical HPLC 
[column C, gradient E] Rt 13.1 minutes; Amino acid analysis (HCl hydrolysis, 18 
hr.) Asp 1 1.08, Thr1 0.84, Ser2 2.12, Va12 2.17, 11e2 2.11, Leu 1 1.10, Phe 1 1.04, Lys 1 
1.07, Arg4 3.74, Cys2 N.D. ; Ellman's test was negative. 
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NGF 100-116 G1y111.113,  Cys'°"° (Acm) 
The initial resin had been derivatised with Fmoc-Ala-OH (0.58 mmol/g ; 050 g 
0.29 mmol). Cysteine was incorporated as Fmoc-Cys(Acm). The peptide was 
assembled automatically, using the normal double-couple cycles. No drops in 
incorporation were observed. The weight of dried resin obtained was 0.89 g. A 
portion of this (0.70 g) was cleaved for 2.5 hr. in a solution of 3% water, 3% EDT 
and 2% phenol in TFA (10 cm 3) to yield the crude peptide (0.23 g) as essentially a 
single product (by HPLC). Purification of crude product (0.22 g) was in two runs by 
semi-preparative HPLC [column F, gradient (0,10), (30,30)]. Lyophilisation of the 
appropriate fractions gave the title compound (100 mg) as a fluffy, white solid. 
FABMS m/z 1966.2 (M+H); hrms found 1965.02749 C82H142N29023S2 requires 
1965.02755 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 15.8 minutes; 
Amino acid analysis (HC1 hydrolysis, 18 hr.) Asp 1 1.05, Thr1 0.97, G1y3 3.28, Ala2 
2.21, Va1 1 1. 12, 11e2 1.86, Phe 1 0.88, Lys 1 1. 14, Ar93 2.94, Cys2 N.D. ; Ellman's test 
was negative. 
NGF 100-116 G1y111 -113, Cys10110 disulphide-linked 
The pure, di-Acm peptide was oxidised using essentially the same procedures as 
used for NGF H-100-1 16-OH, Ser' 07 , Arg"6 . 
A sample of the di-Acm peptide (50 mg) was treated with AgOTf (0.15 g) in TFA (5 
cm 3) to yield the silver salt (73 mg). This was then reduced with DTT (0.45 g) in 
50% aqueous acetic acid for 2 hr. Centrifugation, gel filtration of the filtrate (as 
before) then lyophilisation gave the pure, reduced peptide (20 mg). 
A sample of this (15 mg) was dissolved in H20 (50 cm3) and allowed to air oxidise, 
with constant stirring. The oxidation proceeded slowly, HPLC [column C, gradient 
H] showing a change in Rt from 16.5 to 15.9 mm. After ten days, the entire solution 
was lyophilised to give the title compound (14 mg) as a fluffy, white solid. 
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FABMS m/z 1822.3 (M+H), C76H 1 29N27021 S2 requires 1821.0; Analytical HPLC 
[column C, gradient HI Rt 15.9 minutes ; Amino acid analysis (HC1 hydrolysis, 18 
hr.) Asp 1 1.05, Thr1 0.97, G1y3 3.28, Ala2 2.21, Va! 1 1.12, lie2 1.86, Phe 1 0.88, 
Lys 1 1. 14, Ar93 2.94, Cys2 N.D. ; Eliman's test was negative. 
NGF 100-116 G1y 1o21o4.1o6.1o9.111.113, Cys''° (SBut) 
OH 
The initial resin had been derivatised with Fmoc-Ala-OH (0.58 mmol/g ; 0.50 g 
0.29 mmo!). Cysteine was incorporated as Fmoc-Cys(SBu'). The peptide was 
assembled automatically, using the normal double-couple cycles. No drops in 
incorporation were observed. The weight of dried resin obtained was 0.92 g. A 
portion of this (0.60 g) was cleaved for 2.5 hr. in a solution of 3% water, 3% EDT 
and 2% phenol in TFA (10 cm3) to yield the crude peptide (0.2 g) as essentially a 
single product (by HPLC). Purification of all of the crude product was in two runs 
by semi-preparative HPLC [column F, gradient (0,10), (30,40)]. Lyophilisation of 
the appropriate fractions gave the title compound (94 mg) as a fluffy, white solid. 
FABMS m/z 1744.3 (M+W), C69H 1 19N2701 8S2 requires 1743.1; Analytical HPLC 
[column C, gradient H] Rt 21.8 minutes; Amino acid analysis (HC1 hydrolysis, 18 
hr.) G1y8 7.97, Ala2 2.03, Phe 1 0.98, Lys 1 1.03, Ar93 2.92, Cys2 N.D. ; Eliman's test 
was negative. 
NGF 100-116 GJy1o11o11.113, Cys'"° disulphide-finked 
OH 
A sample of pure, Cys-protected peptide from the above synthesis (67 mg) was 
placed in a silanised flask and was completely dissolved in 95% aqueous TFE (4 
cm3) by stirring under nitrogen. Excess tributylphosphine (TBP, 0.1 cm 3) was 
added under nitrogen. Stirring was continued under N 2 for 2 hr. Analytical HPLC 
[column E, gradient. H] showed a change in the Rt of the main peak from 12.9 to 7.5 
minutes. After this time the entire solution was evaporated in vacuo to a colourless 
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oil, which was taken up by stirring in 10% aqueous acetic acid (30 cm 3) for 20 
minutes. This solution was extracted with ether (3 x 100 cm 3) then lyophilised to 
yield the reduced peptide (51 mg). Purification of crude product was by semi-
preparative HPLC [column F, gradient (0,10), (40,20)]. Lyophilisation of the 
appropriate fractions gave the pure, reduced peptide (20 mg) [FABMS m/z 1567.9] 
A sample of this (15 mg) was dissolved in H20 (50 cm3) and allowed to air oxidise, 
with constant stirring, over 36 hr. A change in Rt from 12.0 to 11.3 mm. was 
observed by HPLC [column. E, gradient (0,10), (30,30)] over this period. After 
complete conversion to the oxidised form, the entire solution was lyophilised to give 
the title compound (8.5 mg) as a fluffy, white solid. 
FABMS m/z 1564.5 (M), C61H101N270 1 8S2 requires 1564.8 ; Analytical HPLC 
[column C, gradient (0,10), (30,30)] Ri 11.3 minutes ; Amino acid analysis (HC1 
hydrolysis, 18 hr.) Gly8 7.97, Ala2 2.03, Phe 1 0.98, Lys 1 1.03, Ar93 2.92, Cys2 N.D. 
Eliman's test was negative. 
NT-3 100-116, Cyslos.110 disulphide-linked 
The initial resin had been derivatised with Fmoc-Ile-OH (0.51 mmol/g ; 0.60 g; 0.31 
mmol). Cysteine was incorporated as Fmoc-Cys(Trt). The peptide was assembled 
automatically, using the triple-couple cycles for every residue. The weight of dried 
resin obtained was 1.91 g. A portion of this (0.97 g) was cleaved for 2.5 hr. in a 
solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude 
peptide (0.45 g) as a white solid. The analytical HPLC trace of this crude showed 
three major peaks (named X, Y and Z). A portion of the crude (0.24 g) was purified 
in three runs by semi-preparative HPLC [column F, gradient (0,10), (60,50)], 
fractions containing each of the three peaks were lyophilised separately and analysed 
by AAA and HPLC (column C., gradient H). Peak X (Ri 12.0 mm., 48 mg) was 
shown to lack the residues R'°°WIR'°, peak Y (Ri 13.1 mm., 22 mg) was the pure, 
reduced peptide and peak Z (Ri 15.8 mm., 14 mg) had the correct AAA but the 
FABMS was +265 (corresponding to a Pmc group). The reduced peptide (20 mg) 
was dissolved in H20 (50 cm3), stirred for 72 hr., then the solution was lyophilised 
to give the oxidised peptide (18 mg). This was purified further by semi-preparative 
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HPLC [column F, gradient (0,20), (40,40)] and lyophilisation of appropriate 
fractions gave the title compound (7.5 mg) as a white solid. 
Reduced form 
FABMS m/z 2021.3 (M+W), hrms found 2020.09480, C97H 1 5 1 N28023S2 requires 
2020.09475 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 12.2 minutes; 
Eliman's test was positive. 
Title compound 
FABMS m/z 2018.7, hrms found 2018.07913, C97H 149N28023S2 requires 
2018.079 10 (< 1 ppm) ; Analytical HPLC [column C, gradient H] Rt 11.3 minutes; 
Amino acid analysis (4-TSA, 18 hr.) Asp 1 1.11, Thr, 0.82, Ser2 1.47, Ala 1 1.15, 
Va1 1 1.15, lie3 3.11, Leu 1 1.13, Lys 1 1.19, Trp 1 0.78, Ar93 2.97, Cys2 N.D. 
Eliman's test was negative. 
Human NGF 95-120 Cysbo8(SBut), Cys"°(Acm). 
Leu-Ser-Arg-Lys-Ala-Val-Arg-Arg-Ala-OH 
The initial resin had been derivatised with Fmoc-Ala-OH (0.30 mmol/g; 1.50 g; 
0.45 mmol). Cys was incorporated as CysboS(SBut) and Cyshbo(Acm). Gin and Trp 
were unprotected. The peptide was assembled automatically with the normal cycles 
except Arg', I10 02, Thr'06 and Val", which were triple-coupled. Monitoring showed 
no major drops in incorporation. The DMF-wet peptide/resin (6.6 g) was left Fmoc-
protected and divided into two portions. One half was dried with ether to give the 
required resin for the above peptide (1.30 g), the remainder was used in the synthesis 
of NGF H-50-70-(Gly)5-94-120-OH. A portion of this (1.20 g) was cleaved for 2.5 
hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (15 cm3) to yield a 
mixture of crude peptide and scavengers (0.51 g). Part of this product was dissolved 
in a minimum amount of 10% aqueous acetic acid (25 cm3), passed down a column 
of G50 Sephadex (Superfine, 2.5 x 150 cm) and eluted at 30 cm 3/hr. with the same 
solvent. UV absorbance was monitored at 254 and 277 nm. Fractions containing 
peptide were verified with Ehrlich's spray. The purest of these was combined and 
lyophilised to yield a white solid (0.18 g). This was purified in four portions by 
semi-preparative HPLC [column F, gradient (0,10), (10,10), (30,35), (45,35)]. 
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Combining the appropriate fractions yielded the title compound as a fluffy, white 
solid (66 mg) after lyophilisation. 
FABMS m/z 3177.7 (M+H), C139H238N46033S 3 requires 3177.9 ; Analytical 
HPLC [column A(C18), gradient F] Ri 16.3 minutes ; Amino acid analysis (HCl 
hydrolysis, 20 hr.) Asp 1 1.08, Thr 1 1.02, Ser 1 0.98, Ala5 5.19, Va13 3.18, Ile2 1.85, 
Leu1 1. 10, Phe 10.94, Lys2 1.99, Ar95 5.22, Cys2 1.97, Trp 1 N.D. ; Ellman's test was 
negative. 
Human NGF 95-120 Cys 110(Acm). 
Leu-Ser-Arg-Lys-Ala-Val-Arg-Arg-Ala-OH 
A portion of the crude material from the above synthesis (0.16 g) was dissolved in 
95% aqueous trifluoroethanol (TFE, 12cm 3) and stirred until complete dissolution 
had occurred (30 mm.). Excess tributylphosphine (TBP, 0.15 cm 3) was added under 
nitrogen. Stirring was continued under N 2 and the course of the reaction followed by 
HPLC. After 10 minutes, the Ri of the main peak had changed from 12.8 to 11.6 
mm. [column A(C18), gradient C]. After one hour, the entire solution was 
evaporated in vacuo to dryness and the reduced peptide was precipitated as a white 
solid by the addition of ice-cold ether (100 cm 3). Isolation by filtration and further 
ether washes removed most of the remaining TBP to give the crude reduced product 
(0.14 g). This was purified in three portions by semi-preparative HPLC [column F, 
gradient (0,10), (30,35)]. Lyophilisation of the appropriate fractions gave the title 
compound as a fluffy, white solid (24 mg). 
FABMS m/z 3089.8 (M), C135H230N46033S2 requires 3089.7 ; Analytical HPLC 
[column A(C1 8), gradient E] Ri 24.0 minutes ; Amino acid analysis (HCl hydrolysis, 
20 hr.) Asp 1 1.08, Thr 1 1.02, Ser 1 0.98, Ala5 5.19, Val3 3.18, lie2 1.85, Leu 1 1.10, 
Phe 1 0.94, Lys2 1.99, Arg5 5.22, Cys2 1.97, Trp 1 N.D. ; Ellman's test was positive. 
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Human NGF 50-70-(GJy)5-94-120 CysUIN(SBut), Cys1hb0(Acm). 
Gly-Cys-Arg-Gly-Gly-G1y-Gly-G1y-Gly-Gly-Lys-Gln-A1a-Ala-Trp-Arg-Phe-I1e-
OH 
This peptide was a continuation of half of the resin used in the synthesis of NGF H-
95-120-011, Cys'(SBu'), Cys"°(Acm). Cys was incorporated as Cys(SBut) and 
Cys(Acm). Gin and Asn were unprotected. The peptide was assembled 
automatically with the normal cycles except across the sequences Lys 30-Gin-Tyr-Phe-
Phe-Glu-Thr and ro 61-Asn-Pro, in which each a.a. was triple-coupled. 
Monitoring showed no major drops in incorporation across the sequence. The resin 
weight after assembly was 1.80 g. The majority of this (1.70 g) was cleaved for 3 
hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (30 cm 3, under 
nitrogen) to yield a mixture of crude peptide and scavengers. This was ether 
extracted from 10% aqueous acetic acid to yield the crude peptide (0.93 g). This 
product was dissolved in a minimum amount of 10% aqueous acetic acid (35 cm 3), 
passed down a column of 050 Sephadex (Superfine, 2.5 x 150 cm) and eluted at 30 
cm3/hr. with the same solvent. UV absorbance was monitored at 254 and 277 nm. 
Fractions containing the peptide were verified with Ehrlich's spray. The purest of 
these was combined and lyophilised to yield a white solid (0.85 g). This was 
purified in seventeen portions by semi-preparative HPLC [column F, gradient (0,5), 
(60,40)]. Combining the appropriate fractions yielded the title compound as a fluffy, 
white solid (0.15 g) after lyophilisation, and a further amount (38 mg) of almost pure 
product (90% by HPLC). 
FABMS m/z 6105.1 (error < 0.04%) , C3H426N840 72S6 requires 6107.4 
Analytical HPLC [column A(C18), gradient C] Rt 18.8 minutes. 
Amino acid analysis; 
Crude (HC1 hydrolysis, 18 hr.) Asx4 4.19, Thr2 2.00, Ser2 2.45, G1x3 2.70, Pro2 
1.87, 01Y8  8.00, Ala5 8.00, Va14 6.01, lie2 2.84, Leu 1 1.64, Tyr1 0.84, Phe3 3.20, 
Lys4 5.35, Arg. 9.20, Cys4 3.64, Trp 1 N.D. 
Title compound (HC1 hydrolysis, 24 hr.) Asx4 3.68, Thr2 1.62, Ser2 1.72, G1x3 2.67, 
Pro2 4.02*,  Gly8 8.00, Ala5 5.60, Va!4 4.20, lie2 2.02, Leu 1 1.10, Tyr 1 0.77, Phe3 
2.57, Lys4 3.52, Ar97 7.17, Cys4 1.72*,  Trp 1 N.D. : *cys degrades on extended acid 
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hydrolysis to form a species which coelutes with Pro. : Eliman's test on the title 
compound was negative. 
Human NGF 50-70-(GIy) 5-94-120 Cys811I(Acm), CysU108 disulphide-linked. 
H-Lys-Gln-Tyr-Phe-Phe-Glu-Thr-Lys-Cys°'--Arg-Asp-Pro-Asn-Pro-Val-Asp-Ser- 
OH 
A sample of pure, fully Cys-protected peptide from the above synthesis (70 mg) was 
placed in a silanised flask and was completely dissolved in 95% aqueous TFE (10 
cm3) by stirring under nitrogen (30 mm.). Excess tributylphosphine (TBP, 30 p.1) 
was added under nitrogen. Stirring was continued under N 2 and the course of the 
reaction followed by HPLC. After 90 minutes, the original peak (on HPLC) had 
almost completely vanished, to be replaced by a more hydrophilic peak [column 
A(C18), gradient (0,10), (30,90), the Rt of the main peak had changed from 20.3 to 
18.0 mm.]. After three hours, the entire solution was evaporated in vacuo to a 
colourless oil, which was taken up by stirring in 15% aqueous acetic acid (100 cm 3) 
for 20 minutes. This solution was extracted with ether (3 x 300 cm 3) then 
lyophilised to yield the Cys"°-reduced peptide (58 mg), which was not analysed. 
Oxidation of the reduced peptide. 
Glutathione oxidation : A portion of the reduced peptide (50 mg) was oxidised in a 
Tris buffer solution (0.1M, pH 8.0, 100cm 3), containing EDTA (29 mg, 0.1 mmol.), 
oxidised glutathione (GSSG, 92 mg, 150 p.mol.) and reduced glutathione (GSH, 23 
mg, 75 p.mol.). After 20 hr., the entire solution was filtered, TFA added (0.1 cm 3) 
then pumped onto a semi-preparative HPLC [column F] at 10 cm 3/min. The 
components were separated [gradient (0,0), (20,0), (60,35)] and the fractions 
lyophilised to yield the title compound (9.5 mg) along with some other products, 
which were identified as mixed disulphide (peptide/glutathione) species. These were 
reoxidised and purified under the same conditions to yield a further amount of the 
title compound (5 mg). 
Air oxidation : Another portion of the fully cysteine-protected peptide (53 mg) was 
treated with TBP under the above conditions to again give a colourless oil. H 20 (40 
cm3) was added to this with stirring. An additional amount of H20 (100 cm 3) was 
added and stirring continued until all of the residual oil had dissolved (15 mm.), 
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leaving a cloudy, white solution. This was extracted with ether (2 x 300 cm 3) to 
give a clear, solution, the pH adjusted to 8.0 by the addition of three drops of 2M 
NaOH and the solution stirred vigorously. After 24 hr., the entire solution was 
filtered, TFA added (0.1 cm 3) then pumped onto a semi-preparative HPLC [column 
F] at 10 cm 3/min. The components were separated [gradient (0,0), (15,0), (40,30)] 
and lyophilisation of the appropriate fractions yield gave more of the title compound 
(9 mg) as a fluffy, white solid. 
FABMS m/z observed 5928.7. For C255}L8N072S4, calculated average mass = 
5930.8, calculated monoisotopic mass = 5926.973. ; Analytical HPLC [column 
A(C18), gradient E] Rt 21.8 minutes ; Ellman's test on the title compound was 
negative. 
NGF 100-114, dVaJ' 1', CysIo8.110  disulphide-linked 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g ; 0.50 
g ; 0.25 mmol). Cysteine was incorporated as FmocCys(SBut), Val" was replaced 
by dVal111 . The peptide was assembled automatically, using the normal double-
couple cycles. A 50% drop in incorporation was observed in R 103 to 1104 coupling. 
The weight of dried resin obtained was 1.27 g. A portion (0.70 g) of this was 
cleaved for 3 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (10 
cm3) to yield the crude peptide (0.33 g) as an insoluble white solid, which showed 
two major peaks on HPLC (X and Y ; column C, gradient F, Rt for X, 19.3 mm. ; Ri 
for Y, 21.3 mm.). A portion of the crude (0.25 g) was dissolved in 95% aqueous 
TFE (20 cm3) then TBP (0.25 cm3) was added. HPLC showed that the main peaks 
had moved to give a Rt of 18.6 (for X) and 19.3 minutes (for Y). Evaporation in 
vacuo, precipitation with ether, collection by filtration and extensive ether washing 
gave an insoluble crude, reduced product (0.20 g). Purification of half of this 
material was by semi-preparative HPLC [column F, gradient (0,10), (15,10), 
(55,40)] and the two peaks lyophilised to give peak X (14 mg) and peak Y (11 mg) 
as white solids. Subsequent analysis (AAA, FABMS) showed peak X to be a 
deletion product (m/z 1220 thus corresponds to AcI 04 RhI4 OH) and peak Y to be the 
pure, reduced peptide (m/z 1752). Peak Y (10 mg) was stirred in 10% DMSO/TFA 
(5 cm3), with anisole added (0.1 cm 3) for 2 hr. at RT., then evaporated in vacuo to 
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near dryness. The oily residue was taken up in 20% aqueous acetic acid (5 cm3) and 
purified by semi-preparative HPLC [column F, gradient (0,5), (10,5), (50,45)]. 
Lyophilisation of appropriate fractions gave the title compound (6 mg) as a fluffy, 
white solid. 
FABMS m/z 1751 (M+H), hrms found 1749.92569, C75H129N24020S2 requires 
1749.92557 (< 1 ppm) ; Analytical HPLC [column C, gradient C] Rt 13.8 minutes; 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.05, Thr1 0.95, Ser 1 0.98, Ala 1 
0.83, Va12 2.23, lie2 1.77, Leu 1 1.21, Phe 1 0.83, Ar93 2.67, Cys2 N.D. ; Eliman's 
test was negative. 
NGF 100-114, dVat 1 O911 , Cys10*.10  disulphide-linked 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g; 0.50 
g ; 0.25 mmol). Cysteine was incorporated as FmocCys(SBut), Vai' 09•" were 
replaced by dVal' 09 .111 . The peptide was assembled automatically, using the normal 
double-couple cycles. The weight of dried resin obtained was 1.40 g. A portion 
(0.70 g) of this was cleaved for 3 hr. in a solution of 3% water, 3% EDT and 2% 
phenol in TFA (10 cm3) to yield the crude peptide (0.35 g) as a white solid. A 
portion of the crude (0.15 g) was dissolved in 95% aqueous TFE (20 cm3) then TBP 
(0.25 cm3) was added. Evaporation in vacuo, precipitation with ether, collection by 
filtration and extensive ether washing gave a crude, reduced product, which was 
directly stirred in 10% DMSOITFA (10 cm 3), with anisole added (0.1 cm 3) for 1.5 
hr. at RT., then evaporated in vacuo to near dryness. The oily residue was taken up 
in 20% aqueous acetic acid (15 cm3) and purified by semi-preparative HPLC 
[column F, gradient (0,5), (20,5), (60,40)]. Lyophilisation of appropriate fractions 
gave the title compound (13 mg) as a fluffy, white solid. 
FABMS m/z 1751.1 (M+H), hrms found 1749.92565, C75H 129N24020S2 requires 
1749.92557 (< 1 ppm) ; Analytical HPLC [column C, gradient B] Rt 13.2 minutes; 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 0.92, Thr1 0.86, Ser 1 1.16, Ala 1 
1.09, Va12 2.13, lie2 1.93, Leu 1 1.18, Phe 1 1.07, Ar93 2.70, Cys2 N.D. ; Eliman's 
test was negative. 
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NGF 100-114, Aib"9, Cys'"A10 disulphide-linked 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g ; 0.50 
g ; 0.25 mmol). Cysteine was incorporated as FmocCys(SBut), Val' 09 was replaced 
by a-aminoisobutyric acid, Aib'°. The peptide was assembled automatically up to 
Cys 11° then Fmoc Aib-OH coupled manually as an AE/HOBt for 2 hr. The coupling 
was confirmed by a Kaiser test. Assembly was continued by machine. The weight 
of dried resin obtained was 1.5 g. A portion (0.70 g) of this was cleaved for 3 hr. in 
a solution of 3% water, 3% EDT and 2% phenol in TFA (15 cm3) to yield the crude 
peptide (0.36 g) A portion of the crude (0.26 g) was dissolved in 95% aqueous TFE 
(20 cm3) then TBP (0.20 cm3) was added. A peak shift from Ri of 17.8 to 14.7 
minutes was observed [by HPLC, column C, gradient H]. Evaporation in vacuo, 
precipitation with ether, collection by filtration and extensive ether washing gave the 
crude, reduced product (0.21 g). This was purified in two runs by semi-preparative 
HPLC [column F, gradient (0,5), (30,30)] and lyophilisation of appropriate fractions 
gave the pure, reduced peptide (86 mg). A portion (60 mg) of this was stirred in 
10% DMSO[FFA (10 cm3) for 1.5 hr. at RT, then evaporated in vacuo to near 
dryness. The oily residue was taken up in 20% aqueous acetic acid (3 cm3) and 
purified by semi-preparative HPLC [column E(C18), gradient (0,5), (30,95)]. 
Lyophilisation of appropriate fractions gave the title compound (33 mg) as a fluffy, 
white solid. 
Reduced pentide 
FABMS m/z 1740 (M+H), hr,ns found 1737.92564, C74H129N24020S2 requires 
1737.92557 (< 1 ppm) ; Analytical HPLC [column C, gradient F] Ri 19.8 minutes. 
Title compound 
FABMS m/z 1736.1 (M+H), hrms found 1735.91000, C74H127N24020S2 requires 
1735.90993 (< 1 ppm) ; Analytical HPLC [column C, gradient F] Ri 19.0 minutes. 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.10, Thr 1 1.09, Ser 1 1.03, Ala 1 
1.19, Val 1 1.08, Ile2 2.20, Leu 1 1.07, Phe 1 1.12, Ar93 132, Cys2 N.D., Aib 1 N.D.; 
Eliman's test was negative. 
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NGF 100-114, Aib", Cys'°"° disulphide-linked 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g ; 0.50 
g ; 0.25 mmol). Cysteine was incorporated as Fmoc-Cys(Acm), Val" was replaced 
by cc-aminoisobutyric acid, Aib hll . The first five residues were coupled manually as 
AE/HOBt for 1.5 hr. each. The couplings were confirmed by Kaiser tests. The 
assembly using FmocCys 11o(Acm)Arg 114 resin was continued by machine. The 
weight of dried resin obtained was 1.60 g. A portion (0.80 g) of this was cleaved for 
3 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3) to yield 
the crude peptide (0.35 g) as a single product by HPLC. All of this crude was 
purified in five runs by semi-preparative HPLC [column F, gradient (0,10), (25,50)] 
and lyophilisation of appropriate fractions gave the pure, di-Acm peptide (84 mg). 
The Acm groups were removed as in NGF H-100-116-011, Ser1, Arg" 6 , Cysbo8.hbo 
disulphide-linked: A portion of the di-Acm peptide (50 mg, 0.03 mmol) and silver 
triflate (AgOTf, 80 mg, 0.3 mmol) were dissolved in TFA (5 cm3) and stirred at 00c 
for 1 hr. in the absence of light. The solution was then evaporated to dryness in 
vacuo and a fine, white solid precipitated on the addition of excess ether. This was 
reduced with excess DTT (0.45 g, 3.0 mmol) in 50% aqueous acetic acid (10 cm 3) 
with vigorous stirring, for 2 hr. Centrifugation as before removed an insoluble, 
yellow precipitate. The supernatant was directly purified by semi-preparative HPLC 
[column F, gradient (0,10), (10,10), (30,30), (40,30)] and lyophilisation of the 
appropriate fractions gave the pure, reduced peptide. This was directly oxidised in 
10% DMSOTFFA (10 cm 3) for 1.5 hr. at RT, then evaporated in vacuo to near 
dryness. The oily residue was taken up in 20% aqueous acetic acid (5 cm3) and 
purified, again by semi-preparative HPLC [column F, gradient (0,5), (5,5), (40,45)]. 
Lyophilisation of the purest fractions gave the title compound (11 mg) as a fluffy, 
white solid. 
FABMS m/z 1737.2 (M+H), hrms found 1735.91001, C74H 127N24020S2 requires 
1735.90993 (< 1 ppm); Analytical HPLC [column C, gradient F] Rt 12.7 minutes. 
Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 1.08, Thr 1 0.91, Ser 1 1.30, Ala 1 
1. 11, Va1 1 1.01, 11e2 1.95, Leu 1 1.02, Phe 1 0.99, Ar93 2.78, Cys2 N.D., Aib 1 N.D.; 
Ellman's test was negative. 
145 
Experimental 
NGF 100-114, NJe 1 1 3, Cysbo*hh  (Acm) 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0..60 mmol/g; 1.00 
g ; 0.60 mmol). Cysteine was incorporated as Fmoc-Cys(Acm), Ser' 1' was replaced 
by norleucine, Nie". The first seven residues were coupled manually as AEII -IOBt 
for 1.5 hr. each. The couplings were confirmed by Kaiser tests. Severe resin 
desolvation was seen after the coupling of Cys'(Acm). The resin was halved after 
the addition of Ala' 07 (the other half was used in the assembly of NGF H-100-114- 
OH,  ile'°"). The assembly using the Fmoc-Ala' 07-Arg"4-resin was continued by 
machine. The weight of dried resin obtained was 1.41 g. A portion (1.00 g) of this 
was cleaved for 3 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (10 
cm3) to yield the crude peptide (0.48 g) as an insoluble crude product. A portion (95 
mg) of this was dissolved in 20% aqueous acetic acid (10 cm 3), filtered and purified 
by semi-preparative HPLC [column F, gradient (0,20), (45,50)]. Lyophilisation of 
appropriate fractions gave the title compound (30 mg) as a fluffy, white solid. 
FABMS m/z 1919.6 (M+H), CH1N02 1 S2 requires 1918.4; Analytical HPLC 
[column C, gradient F] Rt 13.3 minutes ; Amino acid analysis (HCl hydrolysis, 18 
hr.) Asp 1 0.86, Thr 1 1.03, Ala 1 1.03, Va12 1.92, lie2 1.89, Leu 1 0.89, Phe 1 0.86, 
Ar93 2.75, Cys2 N.D., N1e 1 N.D. 
NGF 100-114, NI0 3, CyslO$.110  disulphide-linked 
The Acm groups were removed as in NGF H-100-116-OH, Ser' 07, Arg" 6, Cys'."° 
disulphide-linked: A portion of the di-Acm crude peptide (0.15 g) and silver triflate 
(AgOTf, 80 mg, 0.3 mmol) were dissolved in TFA (15 cm3) and stirred at 00c for 
1.5 hr. in the absence of light. The solution was then evaporated to dryness in vacuo 
and a fine, white solid precipitated on the addition of excess ether. This was reduced 
with excess DY!' (0.45 g, 3.0 mmol) in 50% aqueous acetic acid (20 cm 3) with 
vigorous stirring for 3 hr. Centrifugation as before removed an insoluble, yellow 
precipitate. The supernatant was directly purified by semi-preparative HPLC 
[column E(C8), gradient (0,20), (10,20), (40,70)] and lyophilisation of the 
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appropriate fractions gave the pure, reduced peptide (42 mg). This was oxidised in 
10% DMSO/TFA (15 cm 3) for 1.5 hr. at RT, then evaporated in vacuo to near 
dryness. The oily residue was taken up in 20% aqueous acetic acid (10 cm 3) and 
purified, again by semi-preparative HPLC [column F, gradient (0,10), (15,10), 
(55,50)]. Lyophilisation of the purest fractions gave the title compound (16 mg) as a 
fluffy, white solid. 
FABMS m/z 1777.9, C78H 1 N019S2 requires 1776.4; Analytical HPLC [column 
C, gradient F] Rt 13.0 minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 
0.86, Thr1 1.03, Ala 1 1.03, Va12 1.92, Ile2 1.89, Leu1 0.89, Phe1 0.86, Ar93 2.75, 
Cys2 N.D., Me1 N.D. 
NGF 100-114, N1e106,113, Cys10110  (Acm) 
H-Arg-Phe-Ile-Arg-Ile-Asp-Me-Ala-Cys-Va1-Cys-Val-Leu-Nle-Arg-OH 
The initial resin used was a continuation of NGF H-100-114-OH, N1e 113 synthesis. 
Thr' 06 was replaced by Nle' 06. All subsequent a.a.'s were added manually via double-
AE/HOBt couplings for 1.5 hr. each. The couplings were confirmed by Kaiser tests. 
Problems with resin aggregation occurred and washes with 50% DMF/dioxan were 
used. The weight of dried resin obtained was 1.50 g. A portion (1.00 g) of this was 
cleaved for 3 hr. in a solution of 3% water, 3% EDT and 2% phenol in TFA (10 
cm3) to yield the crude peptide (0.40 g) as an very poorly soluble crude product. A 
portion (0.10 g) of this was dissolved in 40% CH3CN/H20 (9 cm3) with glacial 
acetic acid (1 cm 3) added, filtered and purified by semi-preparative HPLC [column 
F, gradient (0,20), (30,60)]. Lyophilisation of appropriate fractions gave the title 
compound (23 mg) as a fluffy, white solid. 
FABMS m/z 1932.9 (M+W), C86H 1 50N020S2 requires 1932.4; Analytical HPLC 
[column C, gradient F] Rt 14.7 minutes ; Amino acid analysis (HCl hydrolysis, 18 
hr.) Asp 1 0.95, Ala 1 1.12, Va!2 2.18, 11e2 1.80, Leu 1 0.93, Phe 1 0.95, Ar93 3.07, 
Cys2 N.D., N1e2 N.D. 
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NGF 100-114 [Pro 09'-dVa1], Cys'"A lo disulphide-linked 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g ; 0.50 
g; 0.25 mmol). Cysteine was incorporated as FmocCys(SBut). Val109  was replaced 
by two residues, referred to as Pro 109' and dVal'°9'. The peptide was assembled 
automatically, using triple-couple cycles for Pro109'  and dVal 109t. The weight of dried 
resin obtained was 0.93 g. A portion of this (0.43 g) was cleaved for 3 hr. in a 
solution of 3% water, 3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude 
peptide (0.23 g) as a white solid, almost a single product by HPLC. A portion of this 
material (0.15 g) purified in two runs by semi-preparative HPLC [column F, gradient 
(0,15), (30,45)]. Lyophilisation of the purest fractions gave the pure, diSBut 
peptide (51 mg) as a fluffy, white solid. 35 mg of this was stirred for 3 hr. in 95% 
aqueous TFE (4 cm 3) with TBP (0.1 cm 3) added. The solution was evaporated in 
vacuo to an oily residue, which was dissolved in 10% aqueous acetic acid (20 cm 3), 
ether extracted then lyophilised to give the pure, reduced peptide (27 mg). Most of 
this compound (25 mg) was dissolved in 15% DMSOIFFA (10 cm3) and stirred for 1 
hr. This was concentrated in vacuo, !0% aqueous acetic acid (10 cm 3) added then 
the solution applied directly to a semi-preparative HPLC column (column F). The 
components were separated [gradient (0,5), (30,75)] and lyophilisation of the purest 
fractions gave the title compound (13 mg) as a fluffy, white solid. 
Reduced peptide 
FABMS m/z 1850.4 (M+H), hr,ns found 1848.99366, C80H 1 38N2502 1 S2 requires 
1848.99398 (< 1 ppm) ; Analytical HPLC [column B(C8), gradient F] Rt 12.8 
minutes. 
Title compound 
FABMS m/z 1847.8 (M+H), hr,ns found 1846.97838, C80H136N2502 1 S2 requires 
1848.97833 (< 1 ppm) ; Analytical HPLC [column B(C8), gradient F] Ri 12.4 
minutes ; [column C, gradient F] Ri 13.5 mm. ; Amino acid analysis (HCl 
hydrolysis, 18 hr.) Asp 1 0.94, Thr1 0.92, Ser 1 1.09, Pro 1  2.00*,  Ala1 1.09, Va12 
2.10, He2 2.06, Leu 1 1.12, Phe 1 1.06, Ar93 2.79, Cys2 N.D*. ; Ellman's test was 
negative ; *Cys degrades on acid hydrolysis to give a product which coelutes with 
Pro. N.M.R. results are included below. 
148 
Experimental 
600 MHz 1H NMR (90% H201  10%D20) 
0 in num 
Residue a-NH a-CH 3-CH Others 
Arg 100 4.08 1.93,1.93 'yl.62;63.21;NH7.24 
Phe 101 8.85 4.74 3.09,3.12 Ring7.29 
lie102 8.19 4.14 1.73 CH2 1.10,1.43;CH30.84;60.84 
Arg 103 8.31 4.32 1.75,1.84 y1.57,1.65;3.25;NH7.38 
lie'04 8.36 4.23 1.88 'CH21.19,1.48;CH30.91;80.87 
A.sp105 8.64 - 2.76,2.89 
Thr' 06 8.14 4.42 4.32 'yl.22 
AlaIO7 8.31 4.43 1.42 
Cys 108  8.23 4.88 2.89,3.51 
p.l09a 4.63 2.03,2.23 y2.03;83.69 
dVaIl 09b 8.62 4.13 2.34 O.99 
Cys"° 7.84 4.43 3.23,3.33 
Va1 111 8.38 4.16 2.06 10.95 
Leu 112 8.42 4.49 1.65 ?1.65;80.89,0.95 
Ser113 8.32 4.52 3.89 
Arg114 8.13 4.32 1.75,1.81 yl.61;63.22;NH7.21 
Formation of NGF 100-114 [Probo dVaI109b], Cysb0hb0  disulphide-linked on the 
resin 
A sample of dried resin from the above assembly (90 mg) was swollen with 50% 
hexafluoroisopropanol (HFIP)/DMF (1 cm 3) then TBP (0.2 cm 3) added and the 
solution sonicated for 3 hr. at 40°C. The resin was filtered off and washed with 
excess DMF (x 5), isopropanol (x 3), DMF (x 3), then dioxan (x 3). A sample (20 
mg) of this was further dried with ether then cleaved as before (5 cm3 ) for 2.5 hr. to 
give the crude product (5 mg). Analytical HPLC showed that deprotection of the 
SBut groups had occurred (84% by peak integration). The remainder of the resin 
(ether dried to give 40 mg) was then treated in two ways: 
(a) 20 mg was suspended in an iodine-saturated solution of HFIPIDCM (1:3, 1 
cm3) and sonicated for 1 hr. The resin was then collected by filtration, 
washed with excesses of DCM, DMF and dioxan, then dried with ether. 
149 
Experimental 
(b) 20 mg was suspended in a solution of 1M aqueous K3Fe(CN)6, HFIP and 
DCM (1:1:8, 1 cm 3) and sonicated for 12 hr. The resin was then collected by 
filtration, washed with excesses of DMF, H 20, DMF and dioxan, then dried 
with ether. 
Each resin was then cleaved for 3 hr. with 2% anisole, 2% water and 1% EDT in 
TFA (5 cm3) to give 6 mg for (a.) and 4 mg for (b.). Comparison of the analytical 
HPLC traces of authentic reduced and oxidised NGF 100-114 [Pro b091 dVaP 0 ] with 
those for the crude products for protocols (a.) and (b.), showed, that (a.) had given 
65% conversion to the oxidised form, whereas (b.) had given only 10% conversion 
(by peak integrals). Purification of the crude of (a.) by semi-preparative HPLC 
[column E(C18), gradient. 25% isocratic] gave a small sample of the title compound 
(0.8 mg). 
FABMS m/z 1847.5 (M+H), hrms found 1846.97840, C80H 1 36N2502 1 S2 requires 
1848.97833 (< 1 ppm) ; Analytical HPLC [column C, gradient F] Rt 13.5 mm. 
NGF 100-114, Asp(OBzt) 105, Cys1o10 (SBut) 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.60 mmol/g ; 0.40 
g; 0.24 mmol). Cysteine was incorporated as FmocCys(SBut), Asp' 05 was added 
with its side-chain protected as a TFA-stable benzyl ester. Automatic assembly was 
carried Out until Thr' 06 was coupled then assembly was continued manually by single 
SA couplings, except Arg' 03 and 1le 104 (2 x AEIHOBt). The weight of dried resin 
obtained was 0.70 g. All of this was cleaved for 3 hr. in a solution of 3% water, 3% 
EDT and 2% phenol in TFA (10 cm3) to yield the crude peptide (0.30 g) as a poorly 
soluble, although a single product (by HPLC), crude product. A portion (0.25 g) of 
this was dissolved in 20% aqueous acetic acid (25 cm3), filtered and purified by 
semi-preparative HPLC [column E(C8), gradient (0,20), (10,20), (40,70)]. 
Lyophilisation of appropriate fractions gave the title compound (70 mg) as a fluffy, 
white solid. 
FABMS m/z 1984.8 (M+H), C88H 146N26022S2 requires 1984.4; Analytical HPLC 
[column C, gradient F] Rt 14.0 minutes ; Amino acid analysis (HCl hydrolysis, 18 
will 
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hr.) Asp 1 0.89, l'hr1 0.87, Ser 1 1.00, Ala1 1.07, V1112 2.14, lie2 2.00, Leu 1 1.11, Phe 1 
0.92, Ar93 101, Cys2 N.D. 
NGF 100-114 Asp(OBz1) 10 , [Pro10 .dVaI119b], Cys1010  (Acm) 
OH 
The initial resin had been derivatised with Fmoc-Arg(Pmc)-OH (0.52 mmol/g; 0.50 
g ; 0.25 mmol). Cysteine was incorporated as Fmoc-Cys(Acm). Asp' 03 was added as 
Asp(OBzl). Val' 09 was replaced by two residues, referred to as Pro'° and dVa1'°'. 
The peptide was assembled automatically using the normal cycles. The weight of 
dried resin obtained was 0.89 g. All of this was cleaved for 3 hr. in a solution of 3% 
water, 3% EDT and 2% phenol in TFA (10 cm 3) to yield the crude peptide (0.40 g) 
as a white solid, a single hydrophobic product by HPLC. This material was purified 
in five runs [5 x 80 mg in 25% aqueous acetic acid (20 cm 3)] by semi-preparative 
HPLC [column F, gradient (0,40), (30,70)]. Lyophilisation of the purest fractions 
gave a pure peptide (0.15 g). Analysis showed that the terminal Fmoc group had not 
been removed (FABMS m/z 2336.6 .. +221) due to a machine error. The Fmoc 
group was removed by dissolving a sample of peptide (93 mg) in 15% 
piperidinefDMF (5 cm3), stirring for 1 mm. then immediately evaporating the 
solution to dryness in vacuo. The residue was taken up in 50% aqueous acetic acid 
(10 cm3) and the components separated by semi-preparative HPLC [column F, 
gradient (0,20), (20,35), (25,35), (40,50), (50,50)]. Two major products (X and Y) 
had formed: by HPLC (column C, gradient F), compound X (35%, Rt 15.3 mm., 
FABMS mlz 2006.7) and compound Y (50%, Rt 15.7 mm., FABMS m/z 2115.8). 
Compound X corresponded to the aspartimide-rearranged peptide (Bzl group was 
lost) whereas compound Y gave the title compound (33 mg) as a white solid. 
FABMS m/z 2115.8, C95H 1 59N2502 1 S4 requires 2115.7 ; Analytical HPLC [column 
C, gradient F] Rt 15.3 minutes ; Amino acid analysis (HCl hydrolysis, 18 hr.) Asp 1 
0.88, Thr1 0.98, Ser 1 1.12, Pro 1 0.71, Ala 1 1.08, Va12 2.11, lIe2 2.08, Leu 1 1.12, 
Phe 1 0.97, Ar93 3.12, Cys2 N.D. 
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Conserved NGF acetylated 100-115 amide, Cys"" (Acm) 
The initial resin used had the dibenzosuberyl linker to provide an amide on cleavage 
(0.45 mmol/g ; 0.50 g; 0.23 mmol). Cysteine was incorporated as Fmoc-Cys(Acm). 
The peptide was assembled automatically using the normal double-couple cycles. A 
large drop in incorporation occurred over the residues 11e104-Asp'05. The weight of 
dried resin obtained was 0.83 g. 0.40 g was replaced in the machine and acetylated. 
All of this was cleaved for 2.5 hr. in a solution of 3% water, 3% EDT and 2% phenol 
in TFA (10 cm 3) to yield the crude peptide (0.14 g) as a white solid. The crude was 
purified in three runs by semi-preparative HPLC [column F, gradient (0,10), 
(30,30)]. Lyophilisation of appropriate fractions gave the title compound (20 mg) as 
a white solid. 
FABMS m/z 2063.5, C89H 155N29023S2  requires 2063.5 ; Analytical HPLC [column 
C, gradient F] Rt 11.8 minutes; Amino acid analysis (HC1 hydrolysis, 18 hr.) Asp 1 
0.97, Thr1 0.98, Ser 1 1.20, Ala 1 1.08, Va12 2.22, lie2 1.93, Leu1 1.10, Phel 0.92, 
Lys 1 1. 10, Ar93 2.9 1, Cys2 N.D. ; Eilman's test was negative. 
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Hen Egg White Lysozyme (HL) 1-129 
V120-Q-A-W-I-R-G-C 1 .R-L1" 
Disulphides: 6-127, 30-115,64-80,76-94. 
Two assemblies were undertaken, A and B ; each will be considered separately. 
The resin used here had been derivatised with Fmoc-Leu-OH (0.25 mmollg ; 0.40 g; 
0.10 mmol). The following derivatives were used : Arg (Pmc); Cys (SBu'); Ser, 
Thr, Tyr as (But); Asp, Glu as (OBu'); Lys (Boc); Asn, Gin, Trp were unprotected. 
Each residue was single-coupled with a ten-fold excess of AE/HOBt (1.0 mmol) for 
30 mm. The continuous assembly took eight days. A large drop in the apparent 
incorporation was seen over residues Ala"°-Arg 1 14 (50% fall). 10% of the resin was 
removed at this stage and investigated whilst the assembly continued. Manual UV 
testing confirmed the observed fall. A further gradual decline (to 30% of the initial 
deprotection integral) occurred over the next thirty residues. Transient drops in 
apparent incorporation were observed on refilling the solvent reservoirs on the 
synthesizer. No further large falls in coupling efficiency were observed. The resin 
was dried with ether to give a yellow solid (1.32 g). 
Acidolysis of A 
Many trial cleavages were carried out using small amounts of resin (< 20 mg), 
varying scavenger composition, reaction times, etc. On the basis of these, the 
following protocol was carried out: 
A portion of resin (0.50 g) was stirred for 3 hr. (under nitrogen) in a solution of 4% 
water, 4% EDT, 3% phenol, 2% EMS and 2% anisole in TFA (20 cm 3). This 
solution was then filtered off the resin, which was washed with a little neat TFA, the 
combined filtrates were concentrated in vacuo and a white solid precipitated by the 
addition of excess ether. The solid (not weighed) was collected by filtration. It gave 
a broad band on HPLC [column C, gradient F], eluting between 70-80% CH 3CN. 
This solid was stirred for a further 3 hr. under N 2 in a solution of 4% water, 2% 
EDT, 1% phenol and 1% EMS in TFA (20 cm 3). Treatment as before gave the 
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crude protein as a white solid (0.36 g). A portion of this was cleaved for another 2 
hr. under the latter conditions. Upon the usual work-up, the resultant material (70 
mg) was a dark purple colour (indicative of tryptophan damage) and HPLC showed 
that the main peak had broadened considerably. No further work was carried out on 
this material. 
Sephadex GSO gel filtration 
The rest of the crude synthetic lysozyme (SL) material (0.27 g) was dissolved, with 
sonication, in 30% aqueous acetic acid (30 cm 3) and subjected to gel filtration in 
three runs (3 x 10 cm 3) on a Sephadex 050 column (Superfine, 78 x 2.5 cm), eluting 
at 30 cm 3/hr. with the same solvent. The crude material eluted over tubes 20-40; 
four main peak areas were collected and lyophilised to give (in order of elution), 
compound K (33 mg), compound L (44 mg), compound M (42 mg) and compound 
N (15 mg, collected from first run only). By HPLC (column C, gradient F), 
compounds K and L looked similar to the crude material (wide peaks, elution over 
48-52% CH3CN), compound M was similar also (v. wide peak, 40-52% CH 3CN) but 
compound N consisted of scavengers and other low M.Wt. deletions (many small 
peaks over 35-55%). On analytical C8 columns (A and B), the peaks looked more 
symmetrical and eluted earlier. The void volume, V0, of the column was determined 
by running a Blue Dextran (Pharmacia, M.Wt. > 200 kDal) solution [2 mg/cm 3, in 
30% aqueous acetic acid (10 cm 3)] down the column under the same conditions as 
above. This eluted as a sharp band over tubes 20-22. Finally, natural hen egg white 
lysozyme (HL) [Sigma, Grade IV, 1.25 mg/cm 3, in 30% aqueous acetic acid (30 
cm3)] was passed down the column. The elution volume, Ve, of each peak was 
calculated as the volume of eluent required to elute the compound (estimated to the 
mid-point of each peak on the UV trace at 225 nm). The value of Ye/Vo was 
calculated for each compound. 
Component 1 BD HL K M N Ve/Vo 1.00 1.28 1.02 1 	1.15 1.57 1.81 
Amino acid analysis 
AAA was carried out on the crude SL product before gel filtration : the hydrolysis 
was in HCl for 24 and 45 hr. 
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AA HL Actual K L M N 
Asx 19.8 21.0 23.6 22.5 20.4 18.1 
Thr 7.3 7.0 7.9 6.9 6.4 6.3 
Ser 8.8 10.0 11.0 10.4 10.5 4.6 
Gix 5.6 5.0 5.4 5.1 5.8 5.8 
Pro 1.8 2.0 3.9 5.3 7.0 5.3 
Gly 11.3 12.0 12.6 12.8 11.4 15.2 
Ala 11.2 12.0 12.1 11.9 13.7 12.3 
Cys 6.2 8.0 (0.5) (0.3) N.D. N.D. 
Val 5.1 6.0 4.2 3.9 6.1 6.5 
Met 2.0 2.0 1.5 1.3 2.1 2.3 
Ile 4.6 6.0 5.1 5.4 4.6 4.0 
Leu 7.1 8.0 7.2 7.3 7.2 7.6 
Tyr 2.7 3.0 3.8 4.3 4.6 4.6 
Phe 2.6 3.0 2.4 2.3 2.3 1.8 
His 1.0 1.0 0.9 1.2 1.0 1.2 
Trp 4.8 6.0 1 	4.7 8.2 5.6 6.7 
Lys 5.5 6.0 5.3 5.1 6.8 6.6 
Arg 10.5 11.0 11.5 12.1 10.5 15.3 
Experimental 
AA 24 hr. Actual 45 hr. AA •24 hr. Actual 45 hr. 
Asx 20.1 21.0 19.5 Ile 7.3 6.0 5.0 
Thr 5.3 7.0 4.5 Leu 8.1 8.0 5.5 
Ser 4.2 10.0 3.5 Tyr 2.6 3.0 2.0 
6.3 5.0 3.8 Phe 2.8 3.0 1.8 
EG
ix 
ly 12.9 12.0 11.6 His 1.3 1.0 1.1 
Ala 12.3 12.0 10.6 Lys 6.7 6.0 6.4 
Cys 1 	6.2 8.0 6.1 Arg 1 	12.1 11.0 11.9 
Val 8.5 6.0 7.7 Trp N.D. 6.0 N.D. 
Met 2.4 2.0 1 	2.2 Pro* EN.D. 2.0 1 	N.D. 
* The proline peaks were too small to be integrated. 
AAA was also carried out for the samples of compounds A-D and for HL after 
Mean error 
per residue 10.7% 	0.0% 	11.4% 	11.3% 	9.4% 	21.1% 
The total and mean errors were calculated omitting Cys and Pro values. 
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Preparation of reduced and denatured, natural lysozyme [HL(red.)]. 
After Jaenicke (Ref. 337) 
HL (0.10 g) and DTT (0.11 g) were dissolved in a solution of 8M urea in 0.05m Tris 
buffer (pH 8.7, 10 cm 3), containing 1M EDTA. The solution was stirred for 3 hr. 
under nitrogen, the pH adjusted to around 3 by the addition of glacial acetic acid 
then applied to a Sephadex 025 gel column (Coarse, 45 x 1.5 cm), eluting with 0.1M 
aqueous acetic acid at 30 cm 3lhr. Fractions giving a positive Ehrlich's test were 
examined by HPLC, the purest being combined and lyophilised to give the FIL(red.) 
protein (69 mg) as a fluffy, white solid. This was stored in 5 mg aliquots at -20°C. 
Quantitative Eliman's test : observed 7.6 thiol groups/molecule ; required 8.0. 
HPLC (column C , gradient F) Rt 15.0 mm. 
Gel filtration G75 
The remainder of the resin (0.80 g) was cleaved under the same conditions as before 
to yield a crude product (0.39 g). Most of this (0.30 g) was dissolved in 25% 
aqueous acetic acid (20 cm 3), diluted to 10%, then passed (in three runs) down a 
Sephadex G75 column (Superfine, 150 x 2.5 cm), eluting with 0.1M acetic acid at 20 
cm3/hr. Four areas were collected, combined and lyophilised to give (the earliest 
eluting first); compounds W (31 mg), X (37 mg), Y (55 mg) and Z (0.13 g). Blue 
Dextran (20 mg), HL (20 mg) and HL(red.) (10 mg) were passed in order down the 
column under the same conditions to enable the value of Ve/Vo to be calculated for 
each compound. 
Component 1 BD HL HL(red.) W X Y Z Ve/Vo 1.0 1 	2.7 2.1 1.4 2.0 2.7 3.5 
A second assembly of HL was undertaken. The resin used was as before, except that 
here the resin was first capped with excess benzoyl chloride in DMF (at 0°C for 2 
hr.) then warmed up and allowed to react overnight. The resin was collected by 
filtration and extensively washed with DMF, DCM, DMF and dioxan before use. 
The Fmoc derivatives used were as before except that His(Bum) and Trp(Boc) 
replaced those used in assembly A. The HOBt used here was dried by 
recrystallisation from ethanol before use. The time for each ten-fold excess 
AE/HOBt coupling was extended to 90 min./residue and each a.a. in the sequences 
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Cys76-Cys8° and Ala'°-Cys" 5 was triple-coupled. At residue Thr' (the 87th coupling), 
approx. one quarter of the peptide/resin (1.7 of 6.9 g wet-weight) was removed from 
the reaction vessel to facilitate the washing and vortexing steps. The amount of 
Fmoc present in a sample of this resin was checked by manual UV monitoring giving 
a value of 90% of the initial deprotection (c.f. 86% for the on-line monitoring). 
From this level, the apparent incorporation fell to 55% at the end of the assembly 
(correcting for the resin already removed). The resin was left Fmoc-protected after 
the final coupling and manual UV indicated a value for this of 50% of the initial 
Fmoc deprotection. 3.0 g of yellowish resin was obtained on drying with ether. 
Cleavage 
A sample of resin (0.11 g) had the terminal Fmoc-group removed then was dried 
down in ether and cleaved in a solution of 3% water, 3% phenol, 2% EDT, 1% 
anisole and 1% EMS in TFA (10 cm 3), under nitrogen. Samples (- 1.5 cm3) were 
removed at times t = 3, 4, 6 and 8 hr. and overnight (25 hr.). Each sample was 
concentrated in vacuo, precipitated with ether and collected by filtration. Each 
sample was then examined by HPLC. 
A further 0.48 g of resin was stirred for 6 hr. under nitrogen in a TFA (20 cm 3) 
solution of the same composition as before. The usual work-up gave the crude SL 
product (0.33 g). 
Gel filtration G75 
The crude SL was dissolved in 0.1M acetic acid (30 cm 3) with sonication for 1 hr. 
Addition of some glacial acetic acid (2 cm 3) and resonication was required for 
complete dissolution. This was then, in three runs (1-3), passed down a Sephadex 
075 (Standard, 70 x 3 cm) column, eluting with 0.1M acetic acid at 30 cm 3/hr. 
Three major fractions were collected and combined; fraction A, B and C. 
Column 1+2: Fraction P (tubes 9-12, 19 mg), Q (tubes 13-22, 25 mg) and R (tubes 
23-27, 28 mg). 
Column 3: Fraction P (tubes 10-13, 24 mg), Q (tubes 14-23, 15 mg) and R (tubes 
24-28, 12 mg). 
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Removal of SBut groups 
Fractions P and Q (from columns 1+2) [44 mg] were dissolved in 90% TFE (20 
cm3) with stirring. Excess TBP (0.30 cm 3) was added under nitrogen and stirring 
continued for 3 hr. By HPLC (column C, gradient F), the original wide peak (Rt 
20.3) narrowed and changed to Rt 19.0 minutes. On the same gradient, HL(red.) 
gave a sharp peak with Rt 19.0 mm. The solution was concentrated in vacuo, the 
residue dissolved in 5% aqueous acetic acid (10 cm 3) and extracted three times with 
ether. The aqueous solution was directly applied to the Sephadex 075 column and 
eluted with 0.1M acetic acid at 30 cm 3/hr. Lyophilisation of the appropriate 
fractions recovered the SL(red.) protein (40 mg). Samples of the HL(red.) (32 mg 
columned, 20 mg recovered after lyophilisation) and BD were also passed down the 
column to allow the Ve/Vo values to be calculated as before. Ellman's test on the 
recovered HL(red.) gave only 4.1 SH/molecule whilst that of the SL(red.) was 3.6 
SH/molecule. 
Component BD BL HL(red.) SL(red.) P R 
Ve/Vo 1.0 2.9 2.3 2.4 1.2 2.9 3.9 
Polyacrylamide Molecular Weight Gels 
Samples of HL(red.) and SL(red.) (both from the above G75 column, 0.1 mg of 
each) were dissolved in a 10 mM Tris-Ci buffer (pH 7.2, 0.10 cm 3), containing 
EDTA 0.0 mM), 2.5% sodium dodecyl sulphate (SDS), 2.5% 3—mercaptoethanol 
and 0.01% Bromophenol Blue. The solutions were boiled for 5 mm. These were 
then subjected to SDS-PAGE using the Pharmacia PhastOel system. A pre-cast, 
high-density 20% gel, with SDS added, was used (fractionation range 1-20 kDal). 
M.W. standards (2.6, 6.4, 8.2, 14.6 and 17.2 kDal) were also run. The protein bands 
were stained using Coomassie Blue in accordance with the manufacturer's 
procedures (PhastSystem Separation Technique File N° 111). 
Micrococcus lysodeikticus assay for HL 
[After Jollés (Ref. 252)] 
M. lysodeikticus cells (25 mg) were suspended in 0.067M sodium phosphate buffer, 
pH 6.2, containing 0.1M NaCl. Thorough mixing gave a broth-like suspension, 
which had a transmittance of between 20-22% at 650 nm when water was set at 
100% transmittance. A standard solution of HL was prepared by dissolving 1.25 mg 
in 0.1M Tris-acetate buffer (pH 8.1, 45 cm 3) containing 1mM EDTA with 0.1M 
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acetic acid added (5 cm3) to give a final pH of 7.7. The assay was run at a constant 
37°C, all solutions and the spectrophotometer being maintained at that temperature. 
Assay: A sample of the cell suspension (2.5 cm3) was placed in a quartz cuvette (1 
cm pathlength, 3 cm 3 capacity) and the test solution (0.5 cm3, at various 
concentrations) was squirted into this to aid mixing. The rise in transmittance was 
recorded as a function of time over a three minute period. Using the standard HL 
solution, it was found that a graph of zA 650 against HL concentration gave a straight 
line, passing through the origin, with a gradient (in arbitrary units) of 0.005 
iA650/min./mg HL in 1L buffer. 
Regeneration of activity from inactive HL(red.) 
[After Saxena and Wetlaufer (Ref. 242)] 
All solutions were duplicated and maintained at 37°C. HL(red.) (1.20 mg) was 
dissolved in 0.1M acetic acid (7 cm 3) to give an approx. 10 jiM solution. A sample 
of this (1 cm 3) was added to 0.1 M Tris-acetate buffer (pH 8.1, 9 cm3) containing 1.0 
mM EDTA, 6.0 mM GSH and 0.6 mM GSSG. A control containing only 0.1M 
acetic acid (1cm 3) and the renaturation buffer (9 cm 3) was also set up. These 
solutions were checked for lysozyme activity by assaying samples (0.5 cm3) at 
suitable intervals. A standard native lysozyme solution was also checked each time. 
The results are summarised below: 
Sample Time (mm.) iA65 /min. 
Natural HL 0 1.14x1&' 
HL(red.) in 0.1M acetic acid 0 0 
Control 0 0 
FIL(red.) in regeneration buffer 60 0.43 x 10 
HL(red.) in regeneration buffer 100 0.43 x 10- 
HL(red.) in regeneration buffer 300 0.43 x 10 
HL(red.) in Tris buffer only 60 0.09 x 10-1 
Natural Jjj, A650/min./mg protein = 5.76 
Regenerated }4J(J) AA650/min./mg protein = 3.24 
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Further reduction of SL(red.) under denaturing conditions 
A sample of the previously reduced, synthetic lysozyme [SL(red.), 20 mg] was 
stirred for 3 hr. in a solution containing 6M guanidinium chloride (Gdm.HC1) in 
0.1M Tris-Cl (pH 8.2, 2.5 cm3), propanol (2.3 cm 3) and TBP (0.2 cm 3). The 
solution was concentrated slightly in vacuo then applied to a Sephadex 025 (Coarse, 
25 x 1.5 cm) and eluted with 0.1M acetic acid. The appropriate fractions were 
lyophilised to give the SL(red.) protein (5 mg). Eliman's test on this gave a value of 
3.5 SF/molecule. Under the same conditions, HL(red.) gave only 1.2 SH/molecule. 
Amino acid analysis on HL(red.) and SL(red.). 
Both of the reduced samples were hydrolysed in HCl for 18 hr. then analysed. 
AA HL(red.) Actual SL(red.) AA HL(red.) Actual SL(red.) 
Asx 22.4 21.0 23.4 Ile 5.6 6.0 5.0 
Thr 7.0 7.0 8.4 Leu 8.0 8.0 5.5 
Ser 9.6 10.0 11.5 Tyr 3.1 3.0 .2.0 
Gix 5.8 5.0 5.6 Phe 3.2 3.0 1.8 
Gly 12.2 12.0 11.8 His 1.3 1.0 0.6 
Ala 12.5 12.0 10.7 Lys 5.5 6.0 5.2 
Cys 	1 (2.4) 8.0 (5.5) Arg 9.3 11.0 8.9 
Val 5.6 6.0 1 	5.4 Trp N.D. 6.0 N.D. 
Met 2.3 2.0 1 1.3 	11 Pro (10.0) 1 	2.0 	1 (4.4) 
Attempts at renaturation of SL(red.) 
Fractions P+Q (from 075 column 3, 39 mg) were stirred for 3 hr. in a solution 
containing 6M Gdm.HC1 in Tris buffer (pH 8.0, 3 cm 3), isopropanol (2.5 cm3) and 
TBP (0.5cm 3). After this time, the solution was concentrated slightly in vacuo, 
placed in a dialysis bag (Specirophor, M.Wt. cut-off 2 kDal) then dialysed for 24 hr. 
at 4°C against a solution of 6M Gdm.HC1 in Tris buffer (pH 8.0, 500 cm 3), 
containing 1 mM EDTA and 03M -mercaptoethano1, with two changes of this 
dialysing solution in that time. The protein solution inside the bag was then 
transferred into a larger bag and the volume adjusted to 100 cm 3 with the following 
solution, which also formed the next dialysis solution; 6M Gdm.HC1 in Tris buffer 
(pH 8.0, 1000 cm 3) containing 1mM EDTA. This and subsequent dialysis solutions 
were degassed and purged with nitrogen before use. After 48 hr. and several 
changes of dialysis solution, the bag was dialysed against a similar solution except 
160 
Experimental 
this contained 4M Gdm.HC1. The process was repeated at 2M Gdm.HC1 then at 
0.5M Gdm.HC1. After 24 hr. in this final solution, the contents of the bag became 
cloudy. The solution was increased to 200 cm 3, put into two dialysis bags and 
dialysis continued. No further cloudiness was observed and this final solution was 
used in the following reactivation studies. The solution was estimated to have a 
protein concentration of 10 -5M, ten times more concentrated than that required for 
optimum regeneration. 
Regeneration studies : Many small-scale studies were carried out using the crude, 
'renatured' SL(red.) solution under conditions which had successfully regenerated 
enzymic activity from HL(red.). The resulting solutions were assayed as before. 
None gave any significant activity. More studies were carried to test the effect of 
temperature, denaturant concentration and GSH/GSSG composition. None of these 
tests gave any activity either. It was however observed that the SL(red-) 
concentration in all of the reactivation studies, could not be increased beyond 10M 
without causing precipitation of protein from the solution or its adherence to 
glassware. 
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Resin is suspended in a suitable solvent mixture e.g. DMF, 50% dioxan/DMF, inside 
the cylindrical glass reaction vessel. The mixture is agitated by nitrogen, which is 
introduced through a three-way tap as shown. A glass fit prevents the loss of the 
resin and enables nitrogen to 'bubble' into the solution. Reagents may be added 
through the top of the reaction vessel from wash bottles, automatic pipettes or 
measuring cylinders. Excess reagents and solvents may be drained from the resin 
into the lower reservoir under slight vacuum (via connection to a water pump). It is 
best not to allow the resin to become completely drained of solvent to prevent resin 
aggregation. Resin collecting above the liquid surface can be washed down at each 
reagent addition. Small samples of resin can be removed by Pasteur pipette to 




Levy, E. and Frangione, B. (199 1) Current opinion in Cell Biology, 1,312. 
Selkoe, D.J. (1991) Sci. Am., 265,40. 
Hefti, F. and Weiner, W.J. (1986) Ann. Neurol., 20, 275. 
Tanzi, R.E. (199 1) Current opinion in Neurobiology, 1, 455. 
5 	Farrer, L.A., Myers, R.H., Connor, L., Cupples, A. and Growdon, J.H. (1991) 
Am. J. Hum. Genet., 48, 1026. 
Tanzi, R.E. and Hyman, B.T. (1991) Nature, 350, 564. 
Chartier-Harlin, M-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., 
Fidani, L., Goate, A., Kosser, M., Roques, P., Hardy, J. and Mullan, M. (1991) 
Nature, 353, 844. 
Murrell, J., Farlow, M., Ghetti, B. and Benson, M. (199 1) Science, 253, 97. 
Prusiner, S.B. (1987) N. Eng. J. Med., 317, 1571. 
Mesulam, M.M., Mufson, E.J., Wainer, B.H. and Levey, A.I. (1983) 
Neuroscience, 10, 1185. 
Coyle, J.T., Price, D.L. and DeLong, M.R. (1983) Science, 219, 1184. 
e.g. Deutsch, J.A. (1971) Science, 174, 788. 
Palacios, J.M. and Speigel, R. (1986) Prog. Brain Res., 70,485. 
Levi-Montalcini, R. (1982) Ann. Rev. Neurosci., 5, 341. 
Yankner, B.A. and Shooter, E.M. (1982) Ann. Rev. Biochem., 51, 845. 
Hefti, F. (1983) Ann. Neurol., 13, 109. 
Allen, S.J., Macgowan, S.H., Treanor, J.J.S., Fenney, R., Wilcock, G.K. and 
Dawbarn, D. (1991) Neurosci. Lest., 131,135. 
Gage, F.H., Tuszynski, MB., Chen, K.S., Fagan, A.M. and Higgins, G.A. 
(199 1) in 'Current Topics in Microbiology and Immunology', vol. 165, 
(Bothwell, M.A., ed.), pp.71-94. Springer-Verlag, Berlin Heidelberg. 
e.g. Kromer, L.F. (1987) Science, 235, 214. 
Tuszynski, M.H., Sang, U.H., Amaral, D.G. and Gage, F.H. (1990) J. 
Neurosci., 10, 3604. 
Koliatsos, V.E., Nauta, H.J.W., Clauerbuck, R.E., Holtzman, D.M., Mobley, 
W.C. and Price, D.L. (1990) J. Neurosci., 10, 3801. 
Tuszynski, M.H., Sang, U.H., Yoshida, K. and Gage, F.H. (1991) Ann. 
Neurol., 30, 625. 
'NGF and Alzheimer's Disease . Hopes and Fears' (1990) Science, 247, 408. 
Gage, F.H., Un, J.K. and Fisher, L.J. (1991) Current opinion in Neurobiology, 
1,414. 
Richardson, P.M. (1991) Current opinion in Neurobiology, 1,401. 
Levi-Montalcini, R. and Hamburger, V. (1953) J. Exp. Zool., 123, 233. 
Levi-Montalcini, R. (1987) Bioscience Reports, 7, 681. 
Iwane, M., Kitamura, Y., Kaisho, Y., Yoshimura, K., Shintani, A., Sasada, R., 
Nakagawa, S., Kawahara, K., Nakahama, K. and Kakinuma, A. (1990) 
Biochem. Biophys. Res. Comm., 171, 116. 
Ibáñez, C.F., Hallböök, F., Soderström, S., Ebendal, T. and Persson, H. (1991) 
J. Neurochem., 57, 1033. 
163 
References 
Cohen, S. (1960) Proc. Nat!. Acad. Sci. USA, 46, 302. 
Server, A.C. and Shooter, E.M. (1977) Adv. Prot. Chem., 31, 339. 
Bothwell, M.A. and Shooter, E.M. (1977)1. Biol. Chem., 252, 8458. 
Stech, R.W. and Shooter, E.M. (1980) J. Neurochem., 34, 1499. 
Angeletti, R.H. and Bradshaw, R.A. (1971) Proc. Nail. Acad. Sci. USA., 68, 
2417. 
Ebendal, T., Persson, H., Larhammar, D., LundstrOmer, K. and Olson, L. 
(1989) J. Neurosci. Res., 22, 223. 
Thoenen, H. and Barde, Y-A. (1980) Physiol. Rev., 60, 1284. 
Berger, E.A. and Shooter, E.M. (1977) Proc. Nat!. Acad. Sci. USA., 74, 3647. 
Williams, R., Gaber, B. and Gunning, J. (1982) J. Biol. Chem., 257, 13321. 
Wiodawer, A., Hodgson, K.O. and Shooter, E.M. (1975) Proc. Nat!. Acad. Sci. 
USA., 72,777. 
McDonald, N.Q., Lapatto, R., Murray-Rust, J., Gunning, J., Wlodawer, A. and 
Blundell, T.L. (199 1) Nature, 354, 411. 
Levi, A., Shechter, Y., Neufeld, E.J. and Schiessinger, J. (1980) Proc. Nat!-
Acad. Sci. USA., 77, 3469. 
Johnson, E.M., Andres, R.Y. and Bradshaw, R.A. (1978) Brain Res., 150, 319. 
Layer, P.G. and Shooter, E.M. (1983) J. Biol. Chem., 258, 3012. 
Yankner, B.A. and Shooter, E.M. (1979) Proc. Nat!. Acad. Sci. USA., 76, 
1269. 
Bothwell, M.A., Schechtner, A.L. and Vaughn, K.M. (1980) Cell, 21, 857. 
Halegoua, S., Armstrong, R. C. and Kremer, N.E. (199 1) in 'Current Topics in 
Microbiology and Immunology, vol. 165, (Bothwell, M.A., ed.), pp. 1  19-173. 
Springer-Verlag, Berlin Heidelberg. 
McGuire, J.C. and Greene, L.A. (1979) J. Biol. Chem., 254, 3362. 
Greenberg, M., Greene, L.A. and Ziff, E.B. (1985) J. Biol. Chem., 260, 14101. 
Halegoua, S. and Patrick, J. (1980) Cell, 22, 581. 
Greene, L.A. and Tischler, A.S. (1976) Proc. Nat!. Acad. Sci. USA., 73, 2424. 
Thoenen, H., Angeletti, P.U., Levi-Montalcini, R. and Kettler, R. (197 1) Proc. 
Nat!. Acad. Sci. USA., 68, 1598. 
Whittemore, S.R. and Seiger, A. (1987) Brain Res. Rev., 12,439. 
Johnson, D., Lanahan, A., Buck, C.R., Sehgal, A., Morgan, C., Mercer, E., 
Bothwell, M. and Chao, M. (1986) Cell, 47,545. 
Radeke, M.J., Misko, T.P., Hsu, C., Herzenberg, L.A. and Shooter, E.M. 
(1987) Nature, 325, 593. 
Hempstead, B.L. and Chao, M.V. (1989) in Recent Progress in Hormone 
Research', vol. 45, pp.441-466. Academic Press, New York. 
Smith, C.A., Davis, T., Anderson, D., Solam, L., Beckmann, M.P., Jerzy, R., 
Dower, S.K., Cosman, D. and Goodman, R.G. (1990) Science, 248, 1019. 
Welcher, A.A., Biller, C.M., Radeke, M.J. and Shooter, E.M. (1991) Proc. 
Nat!. Acad. Sci. USA., 88,159. 
Grob, P.M., Ross, A.H., Koprowski, H. and Bothwell, M.A. (1985) J. Biol. 
Chem., 260, 8044. 




Feinstein, D.L. and Larhammar, D. (1990) FEBS Lett., 272, 7. 
Hosang, M. and Shooter, E.M. (1985) J. Biol. Chem., 260, 655. 
Meakih, S.O. and Shooter, E.M. (199 1) Proc. Nat!. Acad. Sci. USA., 88, 5862. 
Kaplan, D.R., Martin-Zanca, D. and Parada, L.F. (199 1) Nature, 350, 158. 
Hempstead, B.L., Martin-Zanca, D., Kaplan, D.R., Parada, L.F. and Chao, 
M.V. (1991) Nature, 350, 678. 
Klein, R., Jing, S., Nanduri, V., O'Rourke, E. and Barbacid, M. (1991) Cell, 
65,189. 
Martin-Zanca, D., Hughes, S.H. and Barbacid, M. (1986) Nature, 319, 743. 
Barker, P.A. and Murphy, R.A. (1992) Mo!. Cell. Biochem., 110, 1. 
Klein, R., Conway, D., Parada, L. and Barbacid, M. (1990) Cell, 61,647. 
Meakin, S.O. and Shooter, E.M. (1992) TINS, 15,323. 
Hohn, A., Leibrock, J., Bailey, K. and Barde, Y-A. (1990) Nature, 344, 339. 
Maisonpierre, P.C., Belluscio, L., Squinto, S., Ip, N.Y., Furth, M.E., Lindsay, 
R.M. and Yancopoulos, G.D. (1990) Science, 247, 1446. 
HailbOOk, F., Ibánez, C.F., and Persson, H. (199 1) Neuron, 6, 845. 
Barde, Y-A. (1990) Prog. Growth Factor Res., 2, 237. 
Rodrigez-Tbar, A., Dachant, G. and Barde, Y-A. (1990) Neuron, 4,487. 
Klein, R., Parada, L.F., Coulier, F. and Barbacid, M. (1989) EMBO. J., 8, 
3701. 
Lamballe, F., Klein, R. and Barbacid, M. (1991) Cell, 66,967. 
Cordon-Cardo, C., Tapley, P., Jing, S., Nanduri, V., O'Rourke, E., Lamballe, 
F., Kovary, K., Klein, R., Jones, K.R., Reichardt, L.F. and Barbacid, M. 
(1991) Cell, 66,173. 
Soppet, D., Escandon, E., Marangos, J., Middlemas, D.S., Reid, S.W., Blair, 
J., Burton, L.E., Stanton, B.R., Kaplan, D.R., Hunter, T., Nikolics, K. and 
Parada, L.F. (199 1) Cell, 65, 895. 
Lynch, D.R. and Snyder, S.H. (1986) Ann. Rev. Biochem., 55, 773. 
Barany, G. and Merrifield, R.B. (1980) in The Peptides', vol.2., (Gross, E. and 
Meienhofer, J., eds.), pp. 1-284. Academic Press, New York. 
'Peptides . Chemistry and Biology' (1992), Proceedings of the 12th American 
Peptide Symposium, (Smith, J.A. and Rivier, J.E., eds.), ESCOM, Leiden [and 
previous Proceedings]. 
'Peptides 1990' (1991), Proceedings of the 21st European Peptide Symposium, 
(Giralt, E. and Andreu, D., eds.), ESCOM, Leiden [and previous Proceedings]. 
'Amino acids, peptides and proteins', Specialist Periodical Reports, (1990), 
vol.20., (Eggeiston, I.M., Elmore, D.T. and Jones, J.H., eds.), pp.65-174. The 
Royal Society of Chemistry, Burlington Ho., London [and other articles in this 
volume and previous Annual Reports].) 
Hofmeister, F. (1902) Ergeb. Physiol. Chem. Pharmacol., 1, 759. 
Fischer, E. (1906) Ber. drsch. Chem. Ges., 39,530. 
Curtius, T. (1881) J. Prakt. Chem., 24,239. 
Fischer, E. (1902) Ber. dtsch. Chem. Ges., 35, 1095. 
Merrifield, R.B. (1963) J. Am. Chem. Soc., 85, 2149. 
Merrifield, R.B. (1964) Biochemistry, 3, 1385. 
Letsinger, R.L. and Kornet, M.J. (1963) J. Am. Chem. Soc., 85, 3045. 
165 
References 
Kent, S.B.H. (1988) Ann. Rev. Biochem., 57, 957. 
Kaiser, E.T. (1989) Acc. Chem. Res., 22, 47. 
Fischer, E. (1902) Ber. dtsch. Chem. Ges., 24, 239. 
Bergmann, M. and Zervas, L. (1932) Ber. dtsch. Chem. Ges., 65, 1192. 
Ben-Ishai, D. and Berger, A. (1952) J. Org. Chem., 17, 1564. 
Yajima, H., Takeyana, M., Kanald, J. and Mitani, K. (1978) J. Chem. Soc. 
Chem. Comm., 482. 
Carpino, L.A. (1959) J. Am. Chem. Soc., 79, 98. 
McKay, F.C. and Albertson, N.F. (1959) J. Am. Chem. Soc., 79, 4686. 
Sieber, P. and Iselin, B. (1968) Helv. Chim. Acta., 51, 614 and 622. 
Kader, A.T. and Stirling, C.M.J. (1964) J. Chem. Soc., 258. 
Tesser, G.I. and Balvaert-Geers, I.C. (1975) mt. J. Peptide Protein Res., 7, 
295. 
Carpino, L.A. and Han, G.Y. (1970) J. Am. Chem. Soc., 92, 5748. 
Carpino, L.A. and Han, G.Y. (1972) J. Org. Chem., 37, 3404. 
Carpino, L.A. (1987) Acc. Chem. Res. , 20,401. 
O'Ferrall, R.A.M. (1970) J. Chem. Soc. (B) , 260, 268 and 274. 
Atherton, E., Dryland, A., Sheppard, R.C. and Wade, J.D. (1983) in 'Peptides; 
Structure and Function', (Hruby, V.J. and Rich, D.H., eds.), pp.45-54. Pierce 
Chemical Co., Rockford, IL. 
Atherton, E., Fox, H., Harkiss, D., Logan, C.J., Sheppard, R.C. and Williams, 
B.J. (1978) J. Chem. Soc. Chem. Comm., 537. 
Atherton, E., Fox, H., Harkiss, D. and Sheppard, R.C. (1978) J. Chem. Soc. 
Chem. Comm., 539. 
Chang, C.-D. and Meienhofer, J. (1978) mt. J. Peptide Protein Res., 11, 246. 
Ramage, R., Blake, A.J., Florence, M.R., Gray, T., Raphy, G. and Roach, P.L. 
(199 1) Tetrahedron, 47, 8001. 
Fischer, E. (1903) Ber. dtsch. Chem. Ges., 36, 2094. 
Leuchs, H. (1906) Ber. dtsch. Chem. Ges., 39, 857. 
Carpino, L.A., Cohen, B.J., Stephens, Jr.K.E., Sadat-Aalaee, S.Y., Tien, J.-H. 
and Langridge, D.C. (1986) J. Org. Chem., 51, 3732. 
Carpino, L.A., Sadat-Aalaee, D., Chao, H.G. and DeSeims, R.H. (1990) J. 
Am. Chem. Soc., 112,9651. 
Curtius, T. (1902) Ber. dtsch. Chem. Ges., 35, 3226. 
Meienhofer, J. (1979) in The Peptides', vol.20., (Gross, E. and Meienhofer, J., 
eds.), pp. 197-239. Academic Press, New York. 
Guttmann, S. and Boissonnas, R.A. (1958) Helv. Chim. Acta., 41, 1852. 
Honzl, J. and Rudinger, J. (1961) Collect. Czech. Chem. Comm., 26, 2333. 
Shiori, T., Ninomiya, K. and Yamada, S. (1972) J. Am. Chem. Soc., 94, 6203. 
Vaughan, Jr.J.R. (195 1) J. Am. Chem. Soc., 73, 3547. 
Wieland, T. and Bernhard, H. (1951) Liebigs. Ann. Chem., 572, 190. 
Ref. 37, pp.263-314. 
Ramage, R., Atrash, B., Hopton, D. and Parrot, M.J. (1985) J. Chem. Soc. 
Perkin Trans. I., 1617. 
Khorana, H.G. (1955) Chem. Ind., 1087. 
Sheehan, J.C. and Hess, G.P. (1955) J. Am. Chem. Soc., 77, 1067. 
References 
Savantakis, D., Teichmann, J., Lien, E.L. and Fenichel, R.L. (1976) Biochem. 
Biophys. Res. Comm., 73, 336. 
Hudson, D., Kain, D. and Ng, D. (1986) in 'Peptide Chemistry 1985', (Kiso, 
Y., ed.), pp.413-418. Protein Research Foundation. Osaka, Japan. 
Konig, W. and Geiger, R. (1970) Chem. Ber., 103, 788. 
Konig, W. and Geiger, R. (1972) in 'Chemistry and Biology of Peptides', 
(Meienhofer, J., ed.), pp.343-350. Ann Arbor Science Publishers, Ann Arbor, 
MI. 
Castro, B., Dormoy, J.R., Evin, G. and Selve, C. (1975) Tet. Lett., 14, 1219. 
Hudson, D. (1988)J. Org. Chem., 53,617. 
Coste, J., Le-Nguyen, D. and Castro, B. (1990) Tet. Lett., 31, 205. 
Dourtoglou, V., Zeigler, J.C. and Gross, B. (1978) Tet. Lett., 15, 1269. 
Knorr, R., Trzeciak, A., Bannwarth, W. and Gillessen, D. (1989) Tet. Left., 30, 
1927. 
Chen, S. and Xu, J. (1992) Tet. Len., 33, 647. 
Bodanszky, A., Bodanszky, M., Chandramouli, N., Kwei, J.Z., Martinez, J. 
and Tolle, J.C. (1980) J. Org. Chem., 45,72. 
Pless, J. and Boissonnas, R.A. (1963) Helv. Chim. Acta., 46, 1609. 
Sivanandaiah, K.M. and Gurusiddappa, S. (1981) Synthesis, 565. 
Kovacs, J., Kisfaludy, L. and Ceprini, M.Q. (1967) J. Am. Chem. Soc., 89, 
183. 
Kisfaludy, L. and Schön, 1(1983) Synthesis, 325. 
Atherton, E. and Sheppard, R.C. (1985) J. Chem. Soc. Chem. Comm., 165. 
Atherton, E., Cameron, L., Meldal, M. and Sheppard, R.C. (1986) J. Chem. 
Soc. Chem. Comm., 1763. 
Atherton, E., Holder, J.L., Meldal, M., Sheppard, R.C. and Valerio, R.M. 
(1988) J. Chem. Soc. Perkin Trans. 1., 2887. 
Sheppard, R.C. (1988) Chem. Britain, 557. 
Hollitzer, 0., Seewald, A. and Steglich, W. (1976) Angew. Chem. mt. Ed. 
Eng., 15,444. 
Kirstgen, R., Sheppard, R.C. and Steglich, W. (1987) J. Chem. Soc. Chem. 
Comm., 1870. 
Hudson, D. (1990) Pept. Res., 3, 51. 
Merrifield, R.B. (1962) Fed. Proc. Amer. Soc. Exper. Biol., 21,412. 
Erickson, B.W. and Merrifield, R.B. (1976) in The Proteins', vol.2., 3rd Edn., 
(Neurath, H. and Hill, R.L., eds.), pp.255-527. Academic Press, New York. 
Merrifield, R.B. (1986) Science, 232, 341. 
Merrifield, R.B. (1964) J. Am. Chem. Soc., 86,304. 
Sakakibara, S. and Shimonishi, Y. (1965) Bull. Chem. Soc. Jpn., 38, 1412. 
Tam, J.P., Heath, W.F. and Merrifield, R .B. (1983) J. Am. Chem. Soc., 105, 
6442. 
Yajima, H., Fujii, N., Ogawa, H. and Kawatani, H. (1974) J. Chem. Soc. 
Chem. Comm., 407. 
e.g. Sheppard, R.C. (1973) in 'Peptides 1971', (Nesvadba, H., ed.), pp.111-
125. North-Holland Publishers, Amsterdam. 
Atherton, E. and Sheppard, R.C. (1987) in The Peptides', vol.9., (Udenfriend, 
S. and Meienhofer, J., eds.), pp. 1-39. Academic Press, New York. 
167 
References 
Atherton, E. and Sheppard, R.C. (1989) in 'Solid-Phase Peptide Synthesis : A 
Practical Approach', IRL Press, Oxford, England. 
Fields, G.B. and Noble, R.L. (1990) mt. J. Peptide Protein Res., 35, 161. 
Chang, C.-D., Waki, M., Ahmad, M., Meienhofer, J., Lundell, E.O. and Haug, 
J.D. (1980) mt. J. Peptide Protein Res., 15, 59. 
Bodanszky, M. and Bodanszky, A. (1984) in The Practice of Peptide 
Synthesis', pp.60-61 and 76-77. Springer-Verlag, Berlin. 
Sigler, G.F., Fuller, W.D., Chaturvedi, N.C., Goodman, M. and Verlander, M. 
(1983) Biopolymers, 22, 2157. 
Paquet, A. (1982) Can. J. Chem., 60,976. 
Schwyer, R. and Rittel, W. (1961) Helv. Chim. Acta., 44,159. 
Kashelikar, D.V. and Ressler, C. (1964) J. Am. Chem. Soc., 86, 4162. 
Mojsov, S., Mitchell, A.R. and Merrifield, R.B. (1980) J. Org. Chem., 45,555. 
Stewart, J.M. and Young, J.D. (1984) in 'Solid-Phase Peptide Chemistry', 2nd 
Edn. Pierce Chemical Co., Rockford, IL. 
Gausepohi, H., Kraft, M. and Frank, R. (1989) mt. J. Peptide Protein Res., 34, 
287. 
Konig, W. and Geiger, R. (1972) Chem. Ber., 105, 2872. 
Sieber, P. and Riniker, B. (1991) Tet. Lett., 32,739. 
Maclean, D. (1991) Ph.D. thesis, University of Edinburgh. 
Li, C.H., Meienhofer, J., Schnabel, E., Chung, D., Lo, T.-B. and 
Ramanchandran, J. (1961) J. Am. Chem. Soc., 83,4449. 
Geiger, R. and Konig, W. (1981) in 'The Peptides', vol.3., (Gross, E. and 
Meienhofer, J., eds.), pp 1-99. Academic Press, New York. 
Rink, H., Sieber, P. and Raschdorf, F. (1984) Tet. Lett., 25, 621. 
Fujino, M., Wakimasu, M. and Kitada, C. (1981) Chem. Pharm. Bull., 29, 
2825. 
Atherton, E., Sheppard, R.C. and Wade, J.D. (1983) J. Chem. Soc. Chem. 
Comm., 1060. 
Ramage, R. and Green, J. (1987) Tet. Lett., 28,2287. 
Ramage, R., Green, J. and Florence, M.R. (1988) in 'Peptides , Chemistry and 
Biology', (Marshall, G.R., ed.), pp. 157-158. Escom, Leiden. 
Green, J., Ogunjobi, O.M., Ramage, R., Stewart, A.S.J., McCurdy,  S. and 
Noble, R. (1988) Tet. Lett., 29, 4341. 
Ramage, R., Green, J. and Blake, A.J. (1991) Tetrahedron, 47, 6353. 
Yamashiro, D., Blake, J. and Li, C.H. (1972) J. Am. Chem. Soc., 94, 2855. 
Jones, J.H., Ramage, W.I. and Witty, M.J. (1980) mt. J. Peptide Protein 
Res., 15, 301. 
Sieber, P. and Riniker, B. (1987) Tet. Lett., 28, 6031. 
Colombo, R., Colombo, F. and Jones, J.H. (1984) J. Chem. Soc. Chem. 
Comm., 292. 
Bodanszky, M. and Martinez, J. (1983) in 'The Peptides', vol.5., (Gross, E. and 
Meienhofer, J., eds.), pp. 111-216. Academic Press, New York. 
Kemp, D. S. (1979) in 'The Peptides', vol.1., (Gross, E. and Meienhofer, J., 
eds.), pp.315. Academic Press, New York. 
Benoiton, N.L. and Chen, F.M.F. (1981) Can. J. Chem., 59, 384. 
168 
References 
Kent, S.B.H., Mitchell, A.R., Barany, G. and Merrifield R.B. (1978) Anal. 
Chem., 50, 155. 
Hofle,G., Steglich, W. and Vorbruggen, H. (1978) Ang. Chem. mt. Ed. Eng., 
17, 569. 
Dryland, A. and Sheppard, R.C. (1986) J. Chem. Soc. Perkin Trans. 1., 125. 
Sieber, P. (1987) Ter. Lett., 28, 6147. 
Atherton, E., Logan, C.J. and Sheppard, R.C. (1981) J. Chem. Soc. Perkin 
Trans. I., 538. 
Pedroso, E., Grandas, A., de las Heras, X., Eritja, R. and Giralt, E. (1986) Tet. 
Lett., 27, 743. 
Bornstein, P. and Balian, G. (1977) Methods Enzymol., 47,132. 
Alder, A.J., Fasman, G.D. and Blout, E.R. (1963) J. Am. Chem. Soc., 85,90. 
Nicolas, E., Pedroso, E. and Giralt, E. (1989) Tet. Lett., 30,497. 
Dimarchi, R.D., Tam, J.P., Kent, S.B.H. and Merrifield R.B. (1982) mt. J. 
Peptide Protein Res., 19, 88. 
Kent, S.B.H. (1983) in 'Peptides . Structure and Function', (Hruby, V.J. and 
Rich, D.H., eds.), pp.99-102. Pierce Chemical Co., Rockford, IL. 
Fontenot, J.D., Ball, J.M., Miller, M.A., David, C.M. and Montelaro, R.C. 
(1991) Pept. Res., 4, 19. 
Piszkiewicz, D., Landon, M. and Smith, M.L. (1970) Biochem. Biophys. Res. 
Comm., 40, 1173. 
Creighton, T.E. (1984) in 'Proteins: Structures and Molecular Principles', 
pp.20-24. Freeman, New York. 
Richardson, J. S. (198 1) Adv. Protein Chem., 34, 167. 
Jocelyn, P.C. (1987) Methods Enzymol., 143, 246. 
Snow, J.T. (1988) 'Peptides . The Drugs for the Future and Derivarised Amino 
Acids for Synthesis', Calbiochem. Corporation, La Jolla, CA. 
Erickson, B.W. and Merrifield, R.B. (1973) J. Am. Chem. Soc., 95, 3750. 
Yamashiro, D. and Li, C.H. (1973) J. Am. Chem. Soc., 95, 1310. 
Stewart, A.S.J. and Drey, C.N.C. (1990) J. Chem. Soc. Perkin Trans. 1., 1753. 
Hiskey, R.G. and Adams, Jr.J.B. (1965) J. Org. Chem., 30, 1340. 
Veber, D.F., Milkowski, T.D., Vargas, S.L., Denkewalter, R.G. and 
Hirschmann, R. (1972) J. Am. Chem. Soc., 94,5456. 
Beyermann, H.C. (1963) in 'Peptides 1962, (Young, G.T., ed.), pp.53. 
Pergamon, Oxford. 
Chimiak, A. (1963) in 'Peptides 1962, (Young, G.T., ed.), pp.37. Pergamon, 
Oxford. 
Wunsch, E. and Spangenber, R. (1971) in 'Peptides 1969, (Scoffone, E., ed.), 
pp.30-34. North-Holland Publishing, Amsterdam. 
McCurdy, S.N. (1989) Pept. Res., 2,147. 
Moroder, L., Gemeiner, M., Goehring, W., Jaeger, E., Thamm, P. and 
Wünsch, E. (1981) Biopolymers, 20, 17. 
Atherton, E., Sheppard, R.C. and Ward, P. (1985) J. Chem. Soc. Perkin Trans. 
1.2065 
Atherton, E., Pinori, M. and Sheppard, R.C. (1985) J. Chem. Soc. Perkin 
Trans. 1. 2057. 
Its,J 
References 
Kamber, B., Hartmann, A., Eisler, K., Riniker, B., Rink, H., Sieber, P. and 
Rittel, W. (1980) Helv. Chim. Acta., 63, 899. 
Nishimura, 0., Kitada, C. and Fujino, M. (1986) Chem. Pharm. Bull., 26, 
1576. 
Matsueda, R. and Walter, R. (1980) mt. J. Peptide Protein Res., 16, 392. 
Ploux, 0., Chassaing, G. and Marquet, A. (1987) mt. J. Peptide Protein Res., 
29,162. 
Koide, T., Otaka, A., Suzuki, H. and Fujii, N. (1991) Synlett., 345. 
Akaji, K., Tatsumi, T., Yoshida, M., Kimura, T., Fujiwara, Y. and Kiso, Y. 
(1991) J. Chem. Soc. Chem. Comm., 167. 
Otaka, A., Koide, T., Shide, A. and Fujii, N. (1991) Tet. Lett., 345. 
Fujii, N., Otaka, A., Watanabe, T., Okamachi, A., Tamamura, H., Yajima, H., 
Inagaki, Y., Nomizu, M. and Asano, K. (1989) J. Chem. Soc. Chem. Comm., 
283. 
Yoshida, M., Tatsumi, T., Fujiwara, Y., Jinuma, S., Kimura, T., Akaji, K. and 
Kiso, Y. (1990) Chem. Pharm. Bull., 38, 1551. 
Fujii, N., Otaka, A., Funakoshi, S., Bessho, K. and Yajima, H. (1987) J. Chem. 
Soc. Chem. Comm., 173. 
Schneider, J. and Kent, S.B.H. (1988) Cell, 54, 363. 
Ramage, R., Green, J. and Ogunjobi, O.M. (1989) Tet. Lett., 30, 2149. 
228 Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana. B.K., Baldwin, E., 
Weber, I.T., SeW, L.M., Clawson, L., Schneider, J. and Kent, S.B.H. (1989) 
Science, 245, 616. 
T. Muir, personal communication. 
e.g. Yajima, H. and Fujii, N. (1980) J. Chem. Soc. Chem. Comm., 115. 
e.g. Fotouhi, N., Galakatos, N.G. and Kemp, D.S. (1989) J. Org. Chem., 54, 
2803. 
Kaiser, E.T., Mihara, H., Laforet, G.A., Kelly, J.W., Walters, L., Findeis, 
M.A. and Sasaki, T. (1989) Science, 243, 187. 
Blake, J., Yamashiro, D., Ramasharma, K. and Li, C.H. (1986) mt. J. Peptide 
Protein Res., 28, 468. 
Clarke-Lewis, I., Hood, L.E. and Kent, S.B.H. (1988) Proc. Nail. Acad. Sd. 
USA., 85,7897. 
Fujii, N. and Yajima, H. (198 1) J. Chem. Soc. Chem. Comm., 789 ; 797; 804; 
811 ; 819; 831. 
Blake, J. (1986) mt. J. Peptide Protein Res., 27, 191. 
Aimoto, S., Mizoguchi, N., Hojo, H. and Yoshimura, S. (1989) Bull. Chem. 
Soc. Jpn., 62, 524. 
Scanlon, D.B., Eefting, M.A., Lloyd, C.J., Burgess, A.W. and Simpson, R.J. 
(1987) J. Chem. Soc. Chem. Comm., 516. 
Wu, C.-R., Stevens, V.C., Tregear, G.W. and Wade, J.D. (1989) J. Chem. Soc. 
Perkin Trans!, 81. 
Valembois, C., Mendre, C., Cavadora, J.C. and Calas, B. (1992) Tet. Lett., 33, 
4005. 
Anfinsen, C.B., Haber, E., Sela, M. and White, Jr.F.H. (1961) Proc. Nail. 
Acad. Sci. USA., 47, 1309. 
Saxena, V.P. and Wetlaufer, D.B. (1970) Biochemistry, 9, 5015. 
170 
References 
Gutte, B. and Merrifield, R.B. (1971) J. Biol. Chem., 246, 1922. 
Sharp,J.J., Robinson, A.B. and Kamen, M.D. (1973) J. Am. Chem. Soc., 95, 
6097. 
Galpin, I.J., Hancock, F.E., Handa, B.K., Jackson, A.G., Kenner, G.W., 
McDowell, P., Noble, P. and Ramage, R. (198 1) Tetrahedron, 37, 3043. 
Blake, C.C.F., Koenig, D.F., Mair, G.A., North, A.C.T., Phillips, D.C. and 
Sarnia, V.R. (1965) Nature, 206, 757. 
Blake, C.C.F., Johnson, L.N., Mair, G.A., North, A.C.T., Phillips, D.C. and 
Sarnia, V.R. (1967) Proc. Roy. Soc. (London) Ser. B., 167, 378. 
e.g. Stryer, L. (1988) in 'Biochemistry' 3rd Edn., pp.207-211. Freeman, New 
York. 
Canfield, R.E. (1963) J. Biol. Chem., 238, 2698. 
Ristow, S.S. and Wetlaufer, D.B. (1973) Biochem. Biophys. Res. Comm., SO, 
544. 
Acharya, A.S. and Taniuchi, H. (1976) J. Biol. Chem., 251, 6934. 
Jollès, P. (1962) Methods Enzymol., 5, 137. 
James, R. and Bradshaw, R. (1984) Ann. Rev. Biochem., 53, 259 
Levi-Montalcini, R. (1987) Science, 237, 1154. 
Misko, T.P., Radeke, M.J. and Shooter, E.M. (1987) J. Exp. Biol., 132, 177. 
Yankner, B.A., Caceres, A. and Duffy, L.K. (1990) Proc. Nat!. Acad. Sci. 
USA., 87, 9020. 
Pulliam, M.W., Boyd, L.F., Beglan, N.C. and Bradshaw, R.A. (1975) 
Biochem. Biophys. Res. Comm., 67, 1281. 
Bradshaw, R.A., Jeng, I. Andres, R.Y., Pulliam, M.W., Silverman, R.E., 
Rubin, J. and Jacobs, J.W. (1977) in 'Endocrinology', vol.2., (James, H.V.T., 
ed.), pp.206-212. Excerpta Medica, Amsterdam. 
Frazier, W.A., Angeletti, R.A., Sherman, R. and Bradshaw, R.A. (1973) 
Biochemistry, 12, 3281. 
Merrell, R., Pulliam, M.W., Randono, L., Boyd, L.F., Bradshaw, R.A. and 
Glaser, L. (1975) Proc. Nat!. Acad. Sci. USA., 72,4270. 
Greene, L.A. and Shooter, E.M. (1980) Ann. Rev. Neurosci., 3, 353. 
Knowles, J.R. (1987) Science, 236, 1252. 
Pierschbacher, M.D. and Ruoslahti, E. (1984) Nature, 309, 30. 
Baird, A., Schubert, D., Ling, M. and Guillemin, R. (1988) Proc. Nat!. Acad, 
Sci. USA., 85, 2324. 
Longo, F.M., Vu, T-K.H. and Mobley, W.C. (1990) Cell Regulation, 1, 189. 
Mercanti, D., Butler, R. and Revoltella, R. (1977) Biochim. Biophys. Acta., 
496, 412. 
Butler, R.H. and Revoltella, R.P. (1982) Mo!. Immunol., 19, 323. 
Romani, S., Moroder, L., Gohring, W., Scharf, R., Wünsch, E., Barde, Y.-A. 
and Thoenen, H. (1987) mt. J. Peptide Protein Res., 29, 107. 
Springer, C.J. and Vernon, C.A. (1987) Biochim. Biophys. Acta., 916, 251. 
Hopp, T.P. and Woods, K.R. (198 1) Proc. Nat!. Acad. Sci. USA., 78, 3824. 




Mobley, W.C., Schenker, A. and Shooter, E.M. (1976) Biochemisuy, 15, 
5543. 
Ullrich, A., Gray, A., Berman, C. and Dull, T.J. (1983) Nature, 303, 821. 
Meier, R., Becker-André, M., Gotz, R. and Heumann, R. (1986) EMBO. J., 5, 
1489. 
Scott, J., Selby, M., Urdea, M., Quiroga, M., Bell, G.I. and Rutter, W. (1983) 
Nature, 302, 538. 
Ebendal, T., Larhammar, D. and Persson, H. (1986) EMBO. J., 5, 1483. 
Dutta, A.S. (1988) Drugs of the Future, 13,43 and 761. 
Bickel, M. (1986) Drugs of Today, 22, 265. 
Geysen, H.M., Rodda, S.J., Mason, T.J., Tribbick, G. and Schoofs, P.O. 
(1987) J. Immunol. Methods, 102, 259. 
Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J., Kazmierski, W.M. and 
Knapp, R.J. (199 1) Nature, 354, 82. 
Fodor, S.P.A., Read, J.L., Pirrung, M.C., Stryer, L., Lu, A.T. and Solas, D. 
(1991) Science, 251, 767. 
Scott, J.K. and Smith, G.P. (1990) Science, 249, 386. 
Shoemaker, K.R., Kim, P.S., York, E.J., Stewart, J.M. and Baldwin, R.L. 
(1987) Nature, 326, 563. 
Veber, D.F. (1992) in Ref.3, pp.3-14. 
Hruby, V.J. (1985) Peptides, 7, 6. 
Wang, S.S. (1973) J. Am. Chem. Soc., 95, 1328. 
Lu, 0., Mojsov, S., Tam, J.P. and Merrifield, R.B. (1981) J. Org. Chem., 46, 
3433. 
McInnes, C. (1990) Ph.D. thesis, University of Edinburgh. 
S. Irving, personal communication. 
Weingarten, H., Chupp, J.P. and White, W.A. (1983) J. Org. Chem., 48,661. 
Holden, R. (1989) Ph.D. thesis, University of Edinburgh. 
Kaiser, E., Colescott, R.L., Bossinger, C.D. and Cook, P.I. (1970) Anal. 
Biochem., 34, 595. 
Hancock, W.S. and Battersby, J.E. (1976) Anal. Biochem., 71, 260. 
Sarin, V.K., Kent, S.B.H., Tam, J.P. and Merrifield, R.B. (1981) Anal. 
Biochem., 117, 147. 
Wade, J.D., Bedford, J., Sheppard, R.C. and Tregear, G.W. (1991) Pept. Res., 
4,194. 
Sarin, V.K., Kent, S.B.H., Mitchell, A.R. and Merrifield, R.B. (1984) J. Am. 
Chem. Soc., 106, 7845. 
Narita, M., Ogura, T., Sato, K. and Honda, S. (1986) Bull. Chem. Soc. Jpn., 
59, 2433. 
Milton, R.C.deL., Milton, S.C.F. and Adams, P.A. (1990) J. Am. Chem. Soc., 
112,6039. 
Narita, M., Umeyama, H. and Yoshida, T. (1989) Bull. Chem. Soc. Jpn., 62, 
3582. 
Lundt, B.F., Johansen, N.L., Voland, A. and Markussen, J. (1978) mt. J. 
Peptide Protein Res., 12, 258. 
172 
References 
Tam, J.P. and Merrifield, R.B. in The Peptides', vol.9., (Udenfriend, S. and 
Meienhofer, J., eds.), pp. 185-248. Academic Press, New York. 
'Introduction to Cleavage Procedures' (1989), Applied Biosystems Inc., Foster 
City, CA. 
King, D.S., Fields, C.G. and Fields, G.B. (1990) mt. J. Peptide Protein Res., 
36,255. 
Eritja, R., Ziehler-Martin, J.P., Walker, P.A., Lee, T.D., Legesse, K., 
Albericio, F. and Kaplan, B.E. (1987) Tetrahedron, 43, 2675. 
White, P. (1992) in Ref. 3., pp.537-538. 
The Handbook of Analysis and Purification of Peptides and Proteins by 
Reverse-Phase HPLC' (1991), Vydac Separations Group, Hesperia, CA. 
Mant, C.T. and Hodges, R.S. (1989) J. Liq. C/zr., 12,139. 
Ball, H., Grecian, C., Mascagni, P. and Kent, S.B.H. (1989) in 'Peptides: 
Synthesis, Structure and Function', (Rivier, J. and Marshall, G.R., eds.), 
pp.435-436. ESCOM, Leiden. 
Ramage, R. and Raphy, G. (1992) Tet. Lett., 33, 385. 
Tam, J.P., Wu, C.-R., Liu, W. and Zhang, J.-W. (1991) J. Am. Chem. Soc., 
113, 6657. 
Sweetman, B.J. and Maclaren, J.A. (1966) Aust. J. Chem., 19, 2347. 
Akaji, K., Fujino, K., Tatsumi, T. and Kiso, Y. (199 1) Tet. Lett., 33, 1073. 
A. Cuthbertson, personal communication. 
Chiron report to Parke-Davis, June 1990. 
Tam, J.P., Sheihk, M.A., Solomon, D.S. and Ossowski, L. (1986) Proc. Nat!. 
Acad. Sci. USA., 83, 8082. 
Eliman, G.L. (1959) Arch. Biochem. Biophys., 82,70. 
Fujii, N., Watanabe, T., Otaka, A., Bessho, K., Yamamoto, I., Noda, T. and 
Yajima, H. (1987) Chem. Pharm Bull., 35, 4769. 
Bematowicz, M.S., Matsueda, R. and Matsueda, G.R. (1986) liii. J. Peptide 
Protein Res., 28, 107. 
Bosch, R., Jung, 0., Schmitt, H., Sheldrick, G.M. and Winter, W. (1984) 
Angew. Chem. mt. Ed. Engl., 23,450. 
Ramachandran, G.N., Ramakrishman, C. and Sasisekharan, V. (1963) J. Mo!. 
Biol., 7, 95. 
Degrado, W.F. (1988) Adv. Protein Chem., 39,51. 
Rose, G.D., Gierasch, L.M. and Smith, J.A. (1985) Adv. Protein Chem., 37, 1. 
Kishore, R. and Balaram, P. (1985) Biopolymers, 24, 2041. 
Prorok, M. and Lawrence, D.S. (1990) J. Am. Chem. Soc., 112, 8626. 
Smith, J.A. and Pease, L.G. (1980) CRC Crit. Rev. Biochem., 8, 315. 
Kishore, R., Ragothama, S. and Balaram, P. (1988) Biochemistry, 27, 2462. 
Falcomer, C.M., Meinwald, Y.C., Choudhary, I., Talluri, S., Milburn, P.J., 
Clardy, J. and Scheraga, H.A. (1992) J. Am. Chem. Soc., 114, 4036. 
GarcIa-Echeverria, C., Albericio, F., Pons, M., Barany, G. and Giralt, E. 
(1989) Tet. Lett., 30, 2441. 
Veber, D.F., Holly, F.W., Paleveth, W.J., Nutt, R.F., Bergstrand, S.J., 
Tochiana, M., Glitzer, M.S. and Saperstein, R. (1979) Nature, 280, 512. 
173 
References 
Knittel, J.J., Sawyer, T.K., Hruby, V.J. and Hadley, M.E. (1983) J. Med. 
Chem., 26, 125. 
Samann J., Au, F.E., Romoff, T., Calvo, R., Sorenson, E., Vasko, J., Storer, 
B., Berry, D., Bennett, D., Kostler, P., Powers, D., Stadel, J. and Nichols, A. 
(199 1) J. Med. Chem., 34, 3114. 
Hoffmann, E., Beck-Sickinger, A.G. and Jung, G. (1991) Liebigs. Ann. 
Chem., 585. 
Brady, S.F, Varga, S.L., Freidinger, R.M., Schwenk, D.A., Mendlowski, 
M.M., Holly, F.W. and Veber, D.F. (1979) J. Org. Chem. , 44, 3101. 
WUthnch, K. (1986) in 'NMR of Proteins and Nucleic Acids', J. Wiley and 
Sons, New York. 
K. Shaw, personal communication. 
e.g. Beavis, R.C. and Chait, B.T. (1990) Proc. Nail. Acad. Sci. USA, 87, 6873. 
Jaenicke, R. and Rudolph, R. (19 89) in 'Protein Structure . a practical 
approach', (Creighton, T.E., ed.), pp. 191-224. IRL Press, Oxford. 
Kaplan, D.R., Hempstead, B.L., Martin-Zanca, D., Chao, M.V. and Parada, 
L.F. (1991) Science, 252, 554. 
Ibáflez, C.F., Ebendal, T., Barbany, G., Murray-Rust, J., Blundell, T.L. and 
Persson, H. (1992) Cell, 69, 329. 
Vroegop, S., Decker, D., Hinzmann, J., Poorman, R. and Buxser, S. (1992) J. 
Protein Chem., 11, 71. 
A. Kelly, personal communication. 
174 
COURSES ATFENDED 
Organic Research Seminars (various speakers) University of Edinburgh, 1989-92. 
Recent Advances in Organic Chemistry (various speakers) University of Edinburgh, 
1989-92. 
Current Topics in Organic Chemistry (various speakers) University of Edinburgh, 
1989-92. 
Scottish Protein Group (various speakers) University of Edinburgh, 1992. 
Medicinal Chemistry (Prof. R. Baker and colleagues, Merck, Sharp and Dohme) 
1990, 1992. 
Medicinal Chemistry (Members of IC! Pharmaceuticals, various speakers) 1992. 
N.M.R. Spectroscopy (Dr. I.H. Sadler) University of Edinburgh, 1990-92. 
Scottish Perkin Meeting (various speakers) University of Strathclyde, 1989. 
12th American Peptide Symposium (various speakers) M.I.T., Boston, 1991. 
